---
document_datetime: 2023-09-21 20:47:11
document_pages: 82
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/ultomiris-h-c-004954-ii-0010-epar-assessment-report-variation_en.pdf
document_name: ultomiris-h-c-004954-ii-0010-epar-assessment-report-variation_en.pdf
version: success
processing_time: 238.656477
conversion_datetime: 2025-12-21 18:30:50.304129
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

22 July 2021 EMA/552844/2021 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Ultomiris

International non-proprietary name: ravulizumab

ProcedureNo.EMEA/H/C/004954/II/0010

## Note

VariationassessmentreportasadoptedbytheCHMPwithallinformationofacommercially confidentialnaturedeleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure .                                |                                                                             |
|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| 1.1. Type II variation ...                                                  |                                                                             |
| 1.2. Steps taken for the assessment of the product.                         |                                                                             |
| 2. Scientific discussion .                                                  |                                                                             |
| 2.1.Introduction..                                                          | .6                                                                          |
| 2.1.1.Problem statement                                                     | 6                                                                           |
| 2.1.2.About the product.                                                    | .8                                                                          |
| 2.1.3. The development programme/compliance with CHMP guidance...           | .8                                                                          |
| 2.1.4.General commentson compliance withGCP..                               | 8                                                                           |
| 2.2. Non-clinical aspects....                                               | 9                                                                           |
| 2.2.1.Ecotoxicity/environmentalriskassessment                               | 9                                                                           |
| 2.3. Clinical aspects ...                                                   | 9                                                                           |
| 2.3.1.Introduction..                                                        | 9                                                                           |
| 2.3.2. Pharmacokinetics..                                                   | .9                                                                          |
| 2.3.3. Pharmacodynamics..                                                   | 16                                                                          |
| 2.3.3. PK/PD modelling..                                                    | 19                                                                          |
| 2.3.4. Discussion on clinical pharmacology...                               | .20                                                                         |
| 2.3.5. Conclusions on clinical pharmacology ..                              | .21                                                                         |
| 2.4. Clinical efficacy ....                                                 | 21                                                                          |
| 2.4.1. Dose response study(ies)                                             | 21                                                                          |
| 2.4.2. Main study(ies) .....                                                | 22                                                                          |
| 2.4.3. Discussion on clinical efficacy....                                  | ..47                                                                        |
| 2.4.4.Conclusions on the clinical efficacy....                              | ..50                                                                        |
| 2.5. Clinical safety ...                                                    | 51                                                                          |
| Adverse Events in Eculizumab Studies in Patients with PNH and aHUS ..... 64 | Adverse Events in Eculizumab Studies in Patients with PNH and aHUS ..... 64 |
| 2.5.1. Discussion on clinical safety.....                                   | ...67                                                                       |
| 2.5.2. Conclusions on clinical safety ....                                  | .69                                                                         |
| 2.5.3. PSUR cycle ....                                                      | .69                                                                         |
| 2.6. Risk management plan..                                                 | 70                                                                          |
| 2.7. Update of the Product information.                                     | 74                                                                          |
| 2.7.1. User consultation...                                                 | .74                                                                         |
| 3. Benefit-Risk Balance.                                                    | .74                                                                         |
| 3.1.Therapeutic Context.                                                    | 74                                                                          |
| 3.1.1. Disease or condition....                                             | ..74                                                                        |
| 3.1.2.Available therapiesandunmetmedicalneed                                | ..75                                                                        |
| 3.1.3. Main clinical studies...                                             | .75                                                                         |
| 3.2.Favourable effects..                                                    | 75                                                                          |
| 3.3.Uncertainties andlimitations aboutfavourableeffects.                    | 76                                                                          |
| 3.4. Unfavourable effects....                                               | ..76                                                                        |
| 3.5. Uncertainties and limitations about unfavourable effects               | .76                                                                         |
| 3.6.Effects Table...                                                        | 77                                                                          |
| 3.7.Benefit-riskassessmentanddiscussion.                                    | 78                                                                          |

<div style=\"page-break-after: always\"></div>

| 3.7.1. Importance of favourable and unfavourable effects.. .78   |
|------------------------------------------------------------------|
| 3.7.2.Balanceofbenefitsand risks.... .78                         |
| 3.7.3.Additionalconsiderationsonthebenefit-riskbalance .78       |
| 3.8.Conclusions.. 78                                             |
| 4.Recommendations.. .78                                          |
| 5.EPARchanges .82                                                |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

Abbreviation

Definition

ADA

antidrug antibody

ADR

adverse drug reaction

AE

adverseevent

aHUS

atypicalhaemolyticuremicsyndrome

BTH

breakthroughhaemolysis

C5

complementcomponent5

CHMP

Cmax

maximumobservedserumravulizumabconcentration

CRBC

chicken red blood cell

CSR

clinical study report

Ctrough

serumravulizumabconcentrationattheendofthedosinginterval

DBL

database lock

FACIT

Functional Assessment of ChronicIllness Therapy

FDA

FoodandDrugAdministration International Council forHarmonisationof Technical Requirementsfor PharmaceuticalsforHumanUse

ICH

IV

intravenous(ly)

LDH

lactate dehydrogenase

mAb

monoclonal antibody

MAVE

major adverse vascular event

NAb

neutralizing antibody

PD

pharmacodynamic(s)

PDCO

PaediatricCommittee

PIP

PaediatricInvestigationPlan

PK

pharmacokinetic(s)

PNH

paroxysmal nocturnal hemoglobinuria

Pop-PK

population PK

q2w/q3w/q4w/q8wevery2/3/4/8weeks

QoL

quality of life

REMS

risk evaluation and mitigation strategy

RMP

risk management plan

SAE

seriousadverseevents

SD

standarddeviation

TA

transfusion avoidance

ULN

upper limit of normal

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1.TypeIIvariation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Alexion Europe SAS submitted to theEuropeanMedicinesAgencyon17December2020anapplicationforavariation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                   | Type    | Annexes affected   |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.1.6.a               | C.1.6.a - Change(s) to therapeutic indication(s) - Addition ofanewtherapeuticindicationormodificationofan approvedone | Type II | 1, II and IIIB     |

Extension of indication to include treatment of paediatric patients with paroxysmal nocturnal haemoglobinuria (PNH) for Ultomiris; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, and 5.2 of the reflectthe additionof aPNHParentguide.Version2.1 oftheRMPhas alsobeen submitted,inorderto include the new indication.

The requested variation proposed amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP).

## Informationonpaediatricrequirements

At the time of submission of the application, the PIP P/0399/2020 was not yet completed as some measuresweredeferred.

## Informationrelatingtoorphanmarketexclusivity

## Similarity

PursuanttoArticle8ofRegulation(EC)No.141/2000andArticle3ofCommissionRegulation(EC)No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphanmedicinalproductsbecausethereisnoauthorisedorphanmedicinalproductforacondition related to the proposed indication.

## Scientific advice

TheMAHdidnotseekscientificadvicefromtheCHMP.

## 1.2.Steps takenfor the assessmentoftheproduct

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Agnes Gyurasics

Rapporteur:Blanca Garcia-Ochoa

Co-Rapporteur:

<div style=\"page-break-after: always\"></div>

| Timetable                                            | Actual dates    |
|------------------------------------------------------|-----------------|
| Submission date                                      | 17December2020  |
| Start ofprocedure:                                   | 23 January 2021 |
| CHMP Co-Rapporteur Assessment Report                 | 19 March2021    |
| CHMPRapporteurAssessmentReport                       | 30March2021     |
| PRACRapporteur Assessment Report                     | 25March2021     |
| PRACmemberscomments                                  | 29March2021     |
| PRACOutcome                                          | 9March2021      |
| CHMP members comments                                | 12March2021     |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 18April2021     |
| Request for supplementary information (RsI)          | 22April2021     |
| CHMP RapporteurAssessmentReport                      | 25 June 2021    |
| CHMP memberscomments                                 | 12 July2021     |
| Updated CHMPRapporteurAssessmentReport               | 15 July 2021    |
| Opinion                                              | 22July2021      |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Thepurpose of the currentsubmission is to extend theindicationforravulizumab to paediatricpatients with paroxysmal nocturnal haemoglobinuria (PNH). The proposed updated indication is as follows:

ULTOMIRISisindicatedinthetreatmentofadultandpaediatricpatientswithabodyweightof10kgor abovewithparoxysmalnocturnalhaemoglobinuria(PNH):

- inpatientswithhaemolysiswithclinicalsymptom(s)indicativeofhighdiseaseactivity.
- inpatientswhoareclinicallystableafterhavingbeentreatedwitheculizumabforatleastthe past 6 months.

<div style=\"page-break-after: always\"></div>

## Epidemiology

TheoverallprevalenceofPNHisestimatedat15.9casespermillionindividualsworldwideandoccurs morefrequentlyinAsia than inwesterncountries(Hill,2017;Hill,2006).Paroxysmalnocturnal onsetofPNHistypicallyinadulthood,withpaediatriccasesaccountingfor5%to10%ofreported

aligning with the median survival rate of 10 years seen in adults (Hillmen,1995). While it is well established thatmortalityriskinadultswithPNH ismostoftenattributed to thromboticevents,this is less clear in paediatric patients. Mortality rates in paediatric patients are often difficult to establish due tothechallengesinidentifying thethrombosisleadingtodeathas aconsequenceofPNH.

## Clinical presentation, diagnosis

Paroxysmal nocturnal haemoglobinuria (ICD-10 classification: D59.5) is an ultra-rare, progressive, destructive,andlife-threateningdiseaseinwhichuncontrolledcomplementactivationleadstosystemic complications, principally through intravascular haemolysis and thrombophilia (Brodsky, 2014; Brodsky,2015).

In adults, the clinical manifestations of PNH include haemoglobinuria, chronic renal insufficiency, erectile dysfunction,thrombosis,abdominalpain,dyspnoea,and dysphagia(Parker,2005).

In contrast, children with PNH usually present with nonspecific symptoms related to the underlying 1991).Clinicalevaluationinpaediatricpatientsalsorevealsmorefrequentbonemarrowfailure the bone marrow disorder is resolved in paediatric patients or the PNH clone expands (the cause of whichisstillunknown),thediseaseeventuallyevolvesintoonemoretypicallyseenin adults at presentation.Thus,paediatricpatientscanbeexpected tosuffer substantial morbidityrelated to haemolysis,as seen in adultPNHpatients(Parker,2005).

## Management

s benefit,ratherthan substantive diseaseimprovement.Additionally,anti-coagulanttherapyincreases the risk of bleeding and haemorrhage. Overall, there is inadequate evidence supporting a positive benefit-riskprofileduetothelackofcontrolledstudieswiththesetherapies.

Since PNH in the paediatric population frequently presents with bone marrow failure, patients are commonlyreferred tobonemarrowtransplantation(Urbano-Ispizua,2017).However,thisprocedure isrestrictedtoalimitednumberofpatientsduetotheavailabilityofmatcheddonorsandcarriesa

<div style=\"page-break-after: always\"></div>

EculizumabwasthefirstC5inhibitor tobeevaluated astreatmentoptioninpaediatricpatientswith PNH.Patients achieved importantclinicalbenefitsas demonstratedby theimpactofeculizumab treatmenttoeffectivelyinhibitterminalcomplementactivationinalltreatedpatientsandreduce paediatric patients with PNH was generally favourable.

analysisincludedpatientswhowereenrolled atanactivePNHRegistrysiteandwerenotdiscontinued inhibitor,of whom only1was aged&lt; 12years.

## 2.1.2. About the product

complementcomponent5(C5).

Ravulizumab is administered every 8 weeks (q8w) in patients weighing ≥ 20 kg or every 4 weeks abovewithatypicalhaemolyticuremicsyndrome(aHus).

Ravulizumab is marketed in 2 different strengths, ravulizumab 10 mg/mL and 100 mg/mL.

## 2.1.3. The development programme/compliance with CHMP guidance

[Week26])ofthepaediatricStudyALXN1210-PNH-304.

PNH-302) and 2 studies in paediatric and adult patients with aHUS (ALXN1210-aHUS-311 and theoutcomeoftreatmentislikelytobesimilarinpaediatricsubsetsbyweightcompared toadults. withPNHoraHuSarealsoincludedasbothravulizumabandeculizumabhavethesamemechanismof action.

## 2.1.4. General comments on compliance with GCP

TheMAHconfirmed thattheCSRsubmittedisincompliancewiththeguidanceICHTopicE3Structure andContentof ClinicalStudyReports aswell as theNotefor guidanceon theinclusionof appendices inspectionshavetakenplacetodate,andnoinspectionsareplannedatthistime

<div style=\"page-break-after: always\"></div>

## 2.2. Non-clinical aspects

Nonewclinicaldatahavebeensubmittedinthisapplication,whichwasconsideredacceptablebythe CHMP.

## 2.2.1.Ecotoxicity/environmental risk assessment

Theactivesubstance,ravulizumab,isaproteinandthereforenoenvironmentalriskassessment studieshavebeen submitted,inlinewith theguidelines\"Guideline on theEnvironmental Risk AssessmentofMedicinalProductsforHumanUse\"(EMEA/CHMP/S/4447/00).

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

TheClinicaltrialswereperformedinaccordancewithGCPasclaimedbytheMAH

TheMAHhasprovidedastatementtotheeffectthatclinicaltrialsconductedoutsidethecommunity werecarriedoutinaccordancewiththeethicalstandardsofDirective2001/20/EC.

- Tabularoverviewofclinicalstudies

## Table 1RavulizumabClinical TrialsinPaediatricPatientswithParoxysmalNocturnal Haemoglobinuria

| Type of Study              | Study Identifier           | Location ofStudy Report    | Objective(s) of theStudy                                                     | Study Design,Type of Control,and Subjeet Type                                                                                                                                   | Test Product(s), Dosage Regimen, Route of Administration                                                         | Number of Subjects (Planned/ Treated)   | Duration of Treatment                                                         | Study Status, Type of Report                                                                    |
|----------------------------|----------------------------|----------------------------|------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|-----------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| UncontrolledClinicalSmdies | UncontrolledClinicalSmdies | UncontrolledClinicalSmdies | UncontrolledClinicalSmdies                                                   | UncontrolledClinicalSmdies                                                                                                                                                      | UncontrolledClinicalSmdies                                                                                       | UncontrolledClinicalSmdies              | UncontrolledClinicalSmdies                                                    | UncontrolledClinicalSmdies                                                                      |
| Efficacy and Safety        | ALXN1210-PNH-304           | M5.3.5.2                   | Assess PK, PD, safety，and efficacy in pediatric patients (<18 years)with PNH | Phase 3, open-label, uncontrolled,multicenter, single treatment arm study in pediatric patients with PNH who are complement inhibitor treatment-naive or eculizumab-experienced | RavulizumabIV Weight-based loading* dose on Day 1 and maintenancedose on Day 15 and q8w (q4w for patients <20kg) | 13/13 (enrollment ongoing)              | 26-week Primary Evaluation Period followed by Extension Periodofup to 4 years | Primary Evaluation Period (Primary Endpoint) complete, Extension Period ongoing: interim report |

patients weighing ≥30 to &lt;40 kg.2400 mg for patients weighing≥40 to&lt;60 kg.2700 mg for patients weighing ≥60 to &lt;100 kg,3000 mg for patients weighing ≥100 kg.

≥100 kg

Abbreviations: CSR = clinical study report, IV = intravenous;PD = pharmacodynamics;PK = pharmacokinetics; q4w = every 4 weeks; q8w = every S weeks; PNH = paroxysmal nocturnal hemoglobinuria.

The interim CSR for this study includes results from the first 12 patients treated in the study,8 patients in the eculizumab-experienced cohort and 4 patients in the complement inhibitor treatment-naive cohort.

## 2.3.2. Pharmacokinetics

## AnalyticalMethods

<div style=\"page-break-after: always\"></div>

AllPK,PD,andADAassaymethodsused insupportofStudyALXN1210-PNH-304inpaediatricpatients withPNHarethesameastheassaymethodsusedinsupportofthepreviousPhase3studiesinadult patientswithPNHandpaediatricpatientswithatypicalhaemolyticuremicsyndrome.

TheestablishedLTSdoescoverthemaximumstudysamplestorageperiodforallPKandPDsamples.

ForPK andPDsamples analysis,theindividualandglobalcalibrationstandardsandQCsof theinstudyvalidationwereacceptable.ThereasonsforPKandPDsamplesre-analysisareacceptable.

TheISRwasperformedforravulizumabandtheresultsshowanacceptablereproducibility.NoISRws performed for Total C5 and Haemolysis and the ISR is ongoing for Free C5. This is considered acceptableastheISRhasonlytobeperformedinthefirstclinicaltrialinsubjects.

## Pharmacokineticsinthetargetpopulation

ComparisonofAdolescent(12to&lt;18years)andadultpatientswithPNH

final PNHPop-PKmodel(Table2)inFigure 2.Becauseravulizumab dosingregimensarebodyweightbased,the adultsimulations areshownfor the≥40kg to&lt;60kgand the≥60kg to&lt;100kgbody weightgroups.

Figure 2: ObservedPKDataFromAdolescentPatientsWithPNHOverlaidonVPC SimulationsofMedianSerumRavulizumabConcentration-TimeProfile (95%PI) forAdultPatientsWithPNHFromPhase3StudiesBasedonUsing theFinalPNHPopulationPKModel

<!-- image -->

Study Day

Note:Datafor adolescentpatientsfromStudyALXN1210-PNH-304PrimaryEvaluationPeriodare overlaid on PK simulations (N=500) of Phase3data from adult patients withPNHusing the final PNHpopulationPK model (PNH Adult Module 2.7.2Section 3.2.1.2).The lower dashed horizontal line indicates serum concentration of maximum serum concentrationobserved in the ravulizumab clinical development program. Observed adolescent ravulizumabserumconcentrationdatafromEnd of Infusion andPredose are displayedusingtriangles and circles. respectively.Black lines represent mean observed data from adult patients withPNH and grey lines represent the simulateddata(median and95%PI) for adult patients withPNH.Ravulizumabserum concentrations for

'adolescentPatient whoreceived multiple packed red blood cell transfusions during the 26-weekPrimary EvaluationPeriodofStudyALXN1210-PNH-304arehighlightedinblue.

Abbreviations:PI =prediction interval;PK=pharmacokinetic;PNH =paroxysmal nocturnal hemoglobinuria; VPC=virtual predictivecheck

Source:vpc\\_overlay\\_pnh\\_20200806.R(PNH model)

<div style=\"page-break-after: always\"></div>

Table 2: Mean ± SD (%CV) PK Parameters of Ravulizumab Following the First IV Loading Dose and the Last IV Maintenance Dose During the Primary EvaluationPeriodforAdolescent andAdultPatientsWithPNH

| PK Para- meter   | Dosing Period   | AdolescentPatientsWithPNHa                  | AdolescentPatientsWithPNHa      | Adult Patients With PNHb                       | Adult Patients With PNHb          |
|------------------|-----------------|---------------------------------------------|---------------------------------|------------------------------------------------|-----------------------------------|
| PK Para- meter   | Dosing Period   | Complement Inhibitor Treatment-naive (N=39) | Eculizumab- experienced (N = 7) | Complement Inhibitor Treatment-naive (N = 125) | Eculizumab- experienced (N = 97d) |
| Cmax (μg/mL)     | LD              | 764.5±NA (NA)                               | 923.7±140.68 (15.2)             | 771.4±165.89 (21.5)                            | 842.9±203.47 (24.1)               |
| Cmax (μg/mL)     | Last MD         | 1475.0±NA (NA)                              | 1680.0± 160.73 (9.6)            | 1378.5 ± 275.94 (20.0)                         | 1386.3 ± 268.42 (19.4)f           |
| Ctrough (μg/mL)  | LD              | 397.0±NA (NA)                               | 469.7± 50.97 (6:01)             | 391.2±136.77 (35.0)                            | 405.4± 121.24 (29.9)              |
| Ctrough (μg/mL)  | Last MD         | 448.5±NA (NA)                               | 573.1± 70.88 (12.4)             | 472.7± 157.94 (33.4)e                          | 500.8 ± 143.17 (28.6)g            |

b Data for complement inhibitor treatment-naive adult patients with PNH are from Study ALXN1210-PNH-301 and datafor eculizumab-experienced adult patientswithPNHarefromStudyALXN1210-PNH-302,Primary Evaluation Periods.

a Data for adolescent patients with PNH are from Study ALXN1210-PNH-304 Primary Evaluation Period.

- c Serum ravulizumab concentrations from adolescent Patient (complement inhibitor treatment-naive) were excluded due to administration of packed red blood cell transfusions during the study. Because n = 2, SD and %CV are not applicable.
- e Data for Patient were excluded from the summary statistics for the last MD dosing period due to missing Day 127 dosing information; thus, n = 124.
- d Data for Patient were not included due to missing concentration records; thus, n = 96.
- f In addition to data for Patient not included (footnote d above), data for Patient are not included because the Day 127 end of infusion sample was missing; thus, n = 95.
- g In addition to data for Patient not included (footnote d above), data for Patient are not included because the Day 183 predose sample was missing; thus,n = 95.
- Abbreviations: Cmax = maximum observed serum concentration; Ctrough = serum concentration at the end of the dosing interval; CV = coefficient of variation; IV =intravenous; LD =loading dose; MD =maintenance dose; NA =not applicable; PK =pharmacokinetic; PNH =paroxysmal nocturnalhemoglobinuria; SD = standard deviation

Source: Module 5.3.5.3 Extrapolation Report Table 14.2.1.1.4.3.s; ALXN1210-PNH-301 CSR Table 14.2.5.1.1 and Table14.2.5.2.1;ALXN1210-PNH-302CSR Table 14.2.6.1.1 and Table14.2.6.2.1

## ComparisonofChildren(Birthto&lt;12years)andadultpatientswithPNH

ObservedserumravulizumabconcentrationsforthechildrenwithPNHareoverlaidonsimulationsof thePKforadultpatientswithPNHfromPhase3studiesusingthefinalPNHPop-PKmodel-asbelow.

<div style=\"page-break-after: always\"></div>

Figure 3: ObservedPKDataFromChildrenWithPNHOverlaidonVPCSimulations ofMedianSerumRavulizumabConcentration-TimeProfile(95%Pl)for AdultPatientsWithPNHFromPhase3StudiesUsingtheFinalPNH PopulationPKModel

Sampling time at:Ernd dtitusion Prdo续

<!-- image -->

Study.Day

Note:DataforchildrenwithPNHfromStudyALXN1210-PNH-304PrimaryEvaluationPeriod(Patients and areoverlaidonPKsimulationsofPhase3datafrom adult patientswithPNHusing thefinalPNH populationPKmodel(PNH AdultModule 2.7.2 Section 3.2.1.2).The 1ower dashed horizontal line indicates serum concentrationof175ug/mL,thetherapeuticPKthreshold forravulizumab.and theupperdashedhorizontal line indicatesthemaximumserumconcentrationobservedintheravulizumabclinicaldevelopmentprogram:Black linesrepresentmedianobserved data from adult patientswithPNHandgrey linesrepresentthe simulated data （medianand95%P1)for adultpatientswithPNH.Observedravulizumabserumconcentrationdataforchildren fromEndof Infusion andPredose are displayed using triangles and circles,respectively.

VPC=virtualpredictive.check

Abbreviations:PI=prediction interval;PK=pharmacokinetic;PNH=paroxysmalnocturnal hemoglobinuria;

Source:vpcoverlaypnh20200806.R(PNHmodel)

Table 3:PKParameters of RavulizumabFollowing the FirstIV Loading Dose and the Last IV MaintenanceDoseDuring thePrimaryEvaluationPeriodforChildren andAdultPatients With PNH

| PK Parameter    | Dosing Period   | Statistic                | Children With PNHa                          | Children With PNHa             | AdultPatientsWithPNHb                         | AdultPatientsWithPNHb           |
|-----------------|-----------------|--------------------------|---------------------------------------------|--------------------------------|-----------------------------------------------|---------------------------------|
|                 |                 |                          | Complement Inhibitor Treatment-naive (N =1) | Eculizumab- experienced (N =1) | Complement lnhibitor Treatment-naive (N =125) | Eculizumab- experienced (N=97%) |
| Cmax (μg/mL)    | LD              | Mean±SD (%CV) Min, max   | 589                                         | 611                            | 771.4± 165.89 (21.5) 403,1310                 | 842.9±203.47 (24.1) 511,1750    |
| Cmax (μg/mL)    | Last MD         | Mean±SD (%CV) Min, max   | 1990                                        | 1880                           | 1378.5 ± 275.94 (20.0)d 780,2100              | 1386.3±268.42 (19.4)e 902,2320  |
| Ctrough (μg/mL) | LD              | Mean ± SD (%CV) Min, max | 292                                         | 330                            | 391.2±136.77 (35.0) 199,1500                  | 405.4 ± 121.24 (29.9) 197,1040  |
| Ctrough (μg/mL) | Last MD         | Mean ± SD (%CV) Min, max | 630                                         | 513                            | 472.7 ± 157.94 (33.4)d 135,1000               | 500.8 ±143.17 (28.6)f 232,854   |

<div style=\"page-break-after: always\"></div>

- a Datafor children with PNH arefrom StudyALXN1210-PNH-304
- c Data for Patient were not included due to missing concentration records; thus, n = 96.
- b Data for complement inhibitor treatment-naive adult patients with PNH are from Study ALXN1210-PNH-301 and data for eculizumab-experiencedadultpatientswithPNHarefromStudyALXN1210-PNH-302.
- d Data for Patient were excluded from the summary statistics for the last MD dosing period due to missing Day 127 dosing information;thus,n =124.
- f In addition to data for Patient not included (footnote °above), data for Patient are not included because the Day 183 predose samplewas missing;thus,n=95.
- e In addition to data for Patient not included (footnote above), data forPatient are not included because the Day 127 end of infusion sample was missing; thus, n = 95.
- Abbreviations: Cmax =maximum observed serum concentration; Ctrough = serum concentration at the end of the dosing interval; CV = coefficient of variation;IV =intravenous;LD = loading dose; max = maximum; MD = maintenance dose; Min = minimum; PK = pharmacokinetic; PNH = paroxysmal nocturnal hemoglobinuria; SD = standard deviation

Source:ALXN1210-PNH-304 CSR Listing16.2.5.2.3;ALXN1210-PNH-301 CSR Table14.2.5.1.1 and Table14.2.5.2.1; ALXN1210-PNH-302CSRTable14.2.6.1.1andTable14.2.6.2.1

ComparisonofAdolescentwithPNH(12to&lt;18years)andpatientswithaHUStreatedwith ravulizumab

ObservedserumravulizumabconcentrationsfortheadolescentpatientswithPNHareoverlaidon simulationsofthePKforpatientswithaHUSfromPhase3studiesusing thefinalaHUSPop-PKmodel.

Figure 4: ObservedPKDataFromAdolescentPatientsWithPNHOverlaidonVPC SimulationsofMedianSerumRavulizunabConcentration-TimeProfile (95%PI)forPatientsWithaHUSFromPhase3StudiesUsingtheFinal aHUSPopulationPKModel

<!-- image -->

Study Day

Note:DataforadolescentpatientswithPNHfromStudyALXN1210-PNH-304PrimaryEvaluationPeriod are overlaidonPK simulations of Phase3 datafrompatientswith aHUS using thefinal aHUS populationPKmodel (aHUS Module 2.7.2 Section 3.3.2).The lower dashed horizontalline indicates serum concentration of 175μg/mL, the therapeuticPK thresholdfor ravulizumab,and the upper dashed horizontal line indicates the maximum serum concentration observed in the ravulizumab clinical development program.Black lines represent median observed datafrom adult patientswithPNH andgrey lines represent thesimulated data(median and 95%PI)for adult patientswithPNH.Observed adolescent ravulizumabserumconcentration datafromEnd of Infusion and Predose are displayed using triangles and circles,respectively.Ravulizumab serum concentrationsfor adolescentPatient whoreceivedmultiplepackedred bloodcell transfusionsduringthe26-weekPrimary EvaluationPeriodofStudyALXN1210-PNH-304arehighlightedinbhue.

Abbreviations:aHUs=atypical hemolytic uremic syndrome;PI=prediction interval;PK=pharmacokinetic; PNH=paroxysmalnocturnal hemoglobinuria;VPC=virtual predictivecheck

Source:vpc\\_overlay\\_ahus\\_20200807.R(aHUS m0del)

<div style=\"page-break-after: always\"></div>

Table 4:PKParametersofRavulizumabFollowing theFirstIV LoadingDoseand the Last IV MaintenanceDose During thePrimaryEvaluationPeriod forAdolescentPatientsWith PNHandPatientsWithaHUs

| PK Paramet      | Dosi ng Perio   | Statist ic        | AdolescentPatients WithPNHa            | AdolescentPatients WithPNHa   | PatientsWithaHUS                       | PatientsWithaHUS                       | PatientsWithaHUS          | PatientsWithaHUS                       | PatientsWithaHUS          |
|-----------------|-----------------|-------------------|----------------------------------------|-------------------------------|----------------------------------------|----------------------------------------|---------------------------|----------------------------------------|---------------------------|
| er              | d               |                   | Study ALXN1210- PNH-304                | Study ALXN1210- PNH-304       | Study ALXN1210 -aHUS-311               | StudyALXN1210-aHUS-312                 | StudyALXN1210-aHUS-312    | StudyALXN1210-aHUS-312                 | StudyALXN1210-aHUS-312    |
|                 |                 |                   |                                        |                               | Adults                                 | Childrena                              | Childrena                 | AdolescentPatients                     | AdolescentPatients        |
|                 |                 |                   | Complem ent Inhibitor Treatmen t-naive | Eculizum ab- experienc ed     | Compleme nt Inhibitor Treatment -naive | Complem ent Inhibitor Treatmen t-naive | Eculizum ab- experienc ed | Complem ent Inhibitor Treatmen t-naive | Eculizum ab- experienc ed |
| Cmax (μg/mL)    | LD              | Mean ±SD (%CV )；n | 764.5± NA (NA);2b                      | 923.7± 140.68 (15.2); 7       | 754.3±265 .31 (35.2); 52               | 584.0± 72.66 (12.4); 4                 | 550c                      | 987.0± NA (NA); 2b                     | 929.3± 136.58 (14.7); 7   |
| Cmax (μg/mL)    | Last MD         | Mean ±SD (%CV );n | 1475.0± NA (NA); 2b                    | 1680.0± 160.73 (9.6); 7       | 1458.4± 256.19 (17.6); 46              | 1856.7± 280.62 (15.1); 6               | 2060c                     | 2020b                                  | 1655.7± 296.02 (17.9); 7  |
| Ctrough (μg/mL) | LD              | Mean ±SD (%CV )；n | 397.0± NA (NA); 2b                     | 469.7± 50.97 (10.9); 7        | 313.2± 106.16 (33.9); 55               | 202.8± 23.39 (11.5); 5                 | 315c                      | 288.5± NA (NA); 2b                     | 458.7± 83.32 (18.2); 7    |
| Ctrough (μg/mL) | Last MD         | Mean ±SD (%CV )；n | 448.5 ± NA (NA); 2b                    | 573.1± 70.88 (12.4); 7        | 506.9± 215.51 (42.5); 46               | 532.3± 184.42 (34.6); 6                | 639c                      | 531.5± NA (NA); 2b                     | 456.7± 77.98 (17.1); 7    |

bBecausen=2,SD and %CVarenot applicable.

aDataforchildrenwhoreceivedravulizumabonce every4weeks arenotincluded.

c Observed value only presented as n = 1.

Abbreviations: aHUS = atypical haemolytic uremic syndrome; Cmax =maximum observed serum concentration; Ctrough = serum concentration at the end of the dosing interval; CV = coefficient of variation; IV = intravenous; LD = loading dose; MD = maintenance dose;NA =not applicable;PK =pharmacokinetic;PNH =paroxysmal nocturnal hemoglobinuria; SD = standarddeviation

Source: Module 5.3.5.3 Extrapolation ReportTable 14.2.1.1.4.3.s;ALXN1210-aHUS-311 CSR Table 14.2.5.1.1 and Table 14.2.5.2.1; and Module 5.3.5.3 Extrapolation ReportTables 14.2.5.1.1.4.AGE.312.c1 and 14.2.5.1.1.4.AGE.312.c2

Comparison of ChildrenwithPNH (Birth to&lt;12years) andpatients with aHUStreatedwith ravulizumab

Observedserumravulizumabconcentrationsfor thechildrenwithPNHareoverlaidonsimulationsof thePKforpatientswithaHUSfromPhase3studiesusing thefinalaHUSPop-PKmodel.

<div style=\"page-break-after: always\"></div>

Figure 5: ObservedPKDataFromChildrenWithPNHOverlaidonVPCSimulations ofMedianSerumRavulizumabConcentration-TimeProfile(95%PI)for PatientsWithaHUSFromPhase3StudiesUsingtheFinalaHUSPopulation PK Model

<!-- image -->

Study Day

Note:DataforchildrenwithPNHfromStudyALXN1210-PNH-304PrimaryEvaluationPeriod(Patients and are overlaid onPKsimulations ofPhase3datafrom patientswith aHUSusing thefinal aHUS population PK model (aHUS Module 2.7.2 Section 3.3.2).The lower dashed horizontal line indicates serum concentrationof175μg/mL,thetherapeuticPKthresholdforravulizumab,and the upperdashedhorizontalline indicates themaximumserumconcentration observedin theravulizumabclinicaldevelopmentprogram.Black linesrepresentmedianobserveddatafrom adultpatientswithPNH andgrey linesrepresent thesimulated data （medianand95%PI)foradultpatientswithPNH.Observedravulizumabserumconcentrationdataforchildren from End of Infusion andPredose are displayed using triangles and circles,respectively.

Abbreviations:aHUS=atypicalhemolyticuremicsyndrome;PI=predictioninterval;PK=pharmacokinetic;

PNH=paroxysmal nocturnal hemoglobinuria;VPC=virtual predictive check Source:vpc\\_overlay\\_ahus\\_20200807.R(aHUSmodel)

Table5:PKParameters of RavulizumabFollowing the FirstIV Loading Dose and the Last IV MaintenanceDose During thePrimaryEvaluationPeriod for ChildrenWithPNH and PatientsWithaHus

| PK Parame ter   | Dosi Peri ng   | Statis tic        | Children With PNH                      | Children With PNH         | PatientsWithaHUS                       | PatientsWithaHUS                       | PatientsWithaHUS          | PatientsWithaHUS                       | PatientsWithaHUS          |
|-----------------|----------------|-------------------|----------------------------------------|---------------------------|----------------------------------------|----------------------------------------|---------------------------|----------------------------------------|---------------------------|
| PK Parame ter   | po             |                   | StudyALXN1210-PNH- 304                 | StudyALXN1210-PNH- 304    | Study ALXN1210- aHUS-311               | StudyALXN1210-aHUS-312                 | StudyALXN1210-aHUS-312    | StudyALXN1210-aHUS-312                 | StudyALXN1210-aHUS-312    |
| PK Parame ter   |                |                   |                                        |                           | Adults                                 | Childrena                              | Childrena                 | Adolescent Patients                    | Adolescent Patients       |
|                 |                |                   | Complemen t Inhibitor Treatment- naive | Eculizu mab- experien ced | Complemen t Inhibitor Treatment- naive | Complemen t Inhibitor Treatment- naive | Eculizu mab- experien ced | Comple ment Inhibitor Treatme nt-naive | Eculizu mab- experien ced |
| Cmax (μg/mL     | LD             | Mean ±SD (%CV );n | 589b                                   | 611b                      | 754.3±265. 31 (35.2); 52               | 584.0± 72.66 (12.4); 4                 | 550b                      | 987.0± NA (NA); 2c                     | 929.3± 136.58 (14.7); 7   |
| Cmax (μg/mL     | Last MD        | Mean ±SD (%CV );n | 1990b                                  | 1880b                     | 1458.4± 256.19 (17.6); 46              | 1856.7± 280.62 (15.1); 6               | 2060b                     | 2020b                                  | 1655.7± 296.02 (17.9); 7  |
| Ctrough (μg/mL  | LD             | Mean ±SD (%CV );n | 292b                                   | 330b                      | 313.2± 106.16 (33.9); 55               | 202.8± 23.39 (11.5); 5                 | 315b                      | 288.5± NA (NA); 2c                     | 458.7± 83.32 (18.2); 7    |

<div style=\"page-break-after: always\"></div>

| Last MD   | Mean ±SD (%CV );n   | 630b   | 513b   | 506.9± 215.51 (42.5); 46   | 532.3± 184.42 (34.6); 6   | 639b   | 531.5 ± NA (NA); 2c   | 456.7± 77.98 (17.1); 7   |
|-----------|---------------------|--------|--------|----------------------------|---------------------------|--------|-----------------------|--------------------------|

aDataforchildrenwhoreceivedravulizumabonceevery4weeks arenotincluded.

cBecause n = 2, SD and %CV are not applicable.

b Observed value only presented as n = 1.

Abbreviations:aHUS=atypical haemolyticuremic syndrome;Cmax=maximum observed serum concentration;Ctrough=serum concentration at the end of the dosing interval; CV =coefficient of variation;IV=intravenous;LD =loading dose;MD= maintenance dose; NA = not applicable; PK = pharmacokinetic; PNH = paroxysmal nocturnal hemoglobinuria; SD = standard deviation

## Immunogenicity

InStudyALXN1210-PNH-304,nopaediatricpatientshadADAstoravulizumabatbaseline (pretreatment)ordevelopedADAsatanytimeduringthePrimaryEvaluationPeriod.

Ravulizumabexhibiteda lowincidenceofimmunogenicity(&lt;0.5%)inadultpatientswithPNH(both ALXN1210-PNH-301)observedwithalowtiter,noevidenceofneutralization,andnoapparentimpact of immunogenicity onPK,PD,safety,or efficacy.

Similarly, ravulizumab exhibited a low incidence of immunogenicity in adult patients with aHus in the Phase3studies(StudyALXN1210-aHUS-311andStudyALXN1210-aHUS-312),withonly 1 treatment-emergent ADA positive result(complement inhibitor-naive adult patient with aHuS in StudyALxN1210-aHUS-311)observedwithalowtiter,onlytransientlypositivenoevidenceof

NoimmunogenicitywasobservedinthepaediatricStudyALXN1210-PNH-304and,overall, studies.Thus,there is alowlikelihood of ADAs occurringinpaediatricpatientswithPNHweighing &lt; 30 kg.

## 2.3.3.Pharmacodynamics

## Primaryandsecondarypharmacology

serumtotalC5concentration.

## Free C5

Mean(95%confidenceinterval[CI])serumfreeC5concentrationispresentedovertimeinFigure1 plotsofserumfreeC5concentrationsversustimeprofilesfollowingtreatmentwithravulizumabfor dataforPatientwereexcludedduetopRBCtransfusionsduring thestudy.Theexclusionswere corroboratedwithpairedPKdata.

As expected, the eculizumab-experienced patients had complete terminal complement inhibition at baseline,whichwasmaintainedthroughouttreatmentwithravulizumab.Followinginitiationof treatmentwithravulizumab,complementinhibitortreatment-naivepatientshadimmediate(afterthe endofinfusionofthefirstdoseonDay1)andcompleteterminalcomplementinhibitionthatwas maintainedthroughoutthetreatmentperiod.

<div style=\"page-break-after: always\"></div>

Figure 1: Mean(95%oCI)SerumFreeC5ConcentrationOverTime (Study ALXN1210-PNH-304 Pharmacodynamic Set)

<!-- image -->

Note:Baseline was defined as the last nonmissingvalue priortofirstdose of ravulizumab.Forthefree C5BLoQvalues, LLOQ/2=0.00915μg/mLwasutilized.The dashedhorizontallineindicatesserumfreeC5concentrationof0.5μg/mL,the levelatwhichcompleteterminalcomplementinhibitionoccurs.TheDay71samplefromPatientintheeculizumabexperiencedcohortwasprocessedincorrectly(predoseandpostdosesampleswerecombinedinthesamecryovial)and, therefore,itwasnotshippedtothecentral laboratory.SerumfreeC5valuesfromPatient(complementinhibitortreatmentnaive)were excluded due to administration of packed red blood cell transfusions during the study Abbreviations:BL=baseline;BLoQ=below thelimitofquantification;C5=complementcomponent5;LLoQ=lowerlimit ofquantification

Figure 2: Box Plots of Serum Free C5 Concentration Over Time (Study ALXN1210-PNH-304PharmacodynamicSet)

<!-- image -->

Note:Baselineisdefinedasthelastvaluepriortothefirstdoseofravulizumab.Thehorizontallineinthemiddleofeach 25thpercentiles,respectively.Thewhiskersrepresenttheminimumandmaximumwithin1.5IQR,andoutliers are dashedhorizontallineindicatesserumfreeC5concentrationof0.5μg/mL,thelevelatwhichcompleteterminal incorrectly(predoseandpostdosesampleswerecombinedinthesamecryovial)(ALxN1210-PNH-304CSR Listing 16.2.2.1.2);therefore,itwasnotshipped to thecentral laboratory.SerumfreeC5valuesfromPatient(complement inhibitortreatment-naive)wereexcludedduetoadministrationofpackedredbloodcell transfusionsduringthestudy. Abbreviations:BL=baseline;C5=complementcomponent5;IQR=interquartilerange

<div style=\"page-break-after: always\"></div>

Noneof theeculizumab-experiencedpatientshadaserumfreeC5concentration≥0.5μg/mLat inhibitortreatment-naivepatientshadserumfreeC5concentrations≥0.5μg/mLatbaselineandnone hadsuchaconcentrationoncetreatmentwithravulizumabwasinitiated.Thus,ravulizumabprovided treatment-naivepatients.

## ChickenRedBloodCell HaemolyticActivity

Mean(95%CI)%cRBChaemolysisispresentedforcomplementinhibitor treatment-naive and was&lt;20%,indicatingmeancompleteinhibitionof terminal complementthatwasindistinguishable betweenthe2cohortsofpatients.

Figure3: Mean(95%oCI) %ocRBC Haemolysis Over Time(Study ALXN1210-PNH-304 Pharmacodynamic Set)

<!-- image -->

Note:Baselinewasdefinedasthelastnonmissingvaluepriortofirstdoseofravulizumab.ThecRBCassaywasvalidated asasemiquantitativeassay.Theassayyieldsacontinuousquantitativeresult(%haemolysis)withadiscrete(qualitative) samplefromPatientintheeculizumab-experiencedcohortwasprocessed incorrectly(predoseandpostdosesampleswere combinedinthesamecryovial)and,therefore,itwasnotshipped tothecentrallaboratory.

Source:ALXN1210-PNH-304 CSR Figure 14.2.4.2.1.4

Abbreviation:BL=baseline;CI=confidence interval;cRBC=chickenredblood cell

## Total C5

TotalC5levelwasnotconsideredaprimaryendpointforthisstudy.

Mean(95%CI)serumtotalC5concentrationispresentedovertimeinFigure4forcomplement inhibitortreatment-naiveandeculizumab-experiencedpatients.TheserumtotalC5valueswere 2cohortsbytheendofthePrimaryEvaluationPeriod.

Figure 4: Mean(95% CI) Total C5 Over Time(Study ALXN1210-PNH-304 PharmacodynamicSet)

<div style=\"page-break-after: always\"></div>

Note:Baselinewasdefinedasthelastnonmissingvaluepriortofirstdoseofravulizumab.TheDay71samplefromPatient samecryovial)and,therefore,itwasnotshippedtothecentral laboratory.

<!-- image -->

## 2.3.3.PK/PDmodelling

AplotvisualizingtherelationshipbetweenserumfreeC5concentrationversusserumravulizumab concentrationswithserumfreeC5concentrationsstratifiedbyageanddiseasewascreatedtoreveal similaritiesanddifferencesamongthestratificationfactors(Figure6).Allpostbaselineindividualserum freeC5concentrationswere&lt;0.5μg/mL,thethresholddefinedasachievingcompleteterminal experiencedadolescentpatientsandchildrenwithPNHtreatedwithravulizumab(StudyALXN1210PNH-304),adultpatientswithPNH treated withravulizumab(StudyALXN1210-PNH-301),and nearly all(&gt;99.5%ofanalyzedsamples)adultandpaediatricpatientswithaHuStreatedwithravulizumab (StudiesALXN1210-aHUS-311andALXN1210-aHUS-312).Generally,aconsistentandnearlyidentical correlationisseenbetweenserumravulizumabconcentrationandserumfreeC5concentrationamong wellaspaediatricandadultpatientswithaHus.

<div style=\"page-break-after: always\"></div>

Figure 6: SerumRavulizumabConcentrationVersusTimeMatchedSerumFreeC5 PediatricPatientsWithaHUS,andAdultPatientsWithaHUs

<!-- image -->

Note:The dashed horizontal line indicates serum free C5 concentration of 0.5pg/mL.the level at which complete terminal complement inhibition occurs.Thedashedvertical lineindicatesserumravulizumab concentration of 175μg/mL,the therapeuticPK threshold for ravulizumab.

Abbreviations:aHUS= atypical hemolyticuremic syndrome;C5=complement component5;peds=pediatric patients;PK=pharmacokinetic;PNH=paroxysmal nocturnalhemoglobinuria Source:\\_001\\_PKfC5\\_PedsAdult\\_PNHaHUS\\_24AUG2020(Splusscript)

## 2.3.4. Discussion on clinical pharmacology

patients with PNH are the same as the assays used in support of the Phase 3 studies and were previouslyassessed.

ForPK andPDsamples analysis,theindividualandglobalcalibrationstandards andQCsof theinstudyvalidationwereacceptable.ThereasonsforPKandPDsamplesre-analysisareconsidered acceptable. The ISR was performed for ravulizumab and the results show an acceptable reproducibility.

The clinical pharmacology properties of ravulizumab in paediatric patients (children and adolescent) ALXN1210-PNH-304)togetherwithsupplementarydatafromstudiesofravulizumabinadultpatients withPNH andinpaediatricand adultpatientswithatypicalhaemolyticuremicsyndrome(aHUS). pharmacodynamicendpoints.

Themajorlimitationofthecurrentapproachisthelimitedexperimentalevidenceofpaediatricpatients naiveand1eculizumab-experienced)wereconsideredasexternalvalidationformodelpredictions.The adequacyofabodyweight-basedravulizumabdosingregimenforpaediatricpatientshasbeen

<div style=\"page-break-after: always\"></div>

12paediatricpatientswith the model-predicted exposure in adultsderived from apreviously developedpopulationPKmodel inadults.Theconcordancebetween theexposureachieved in efforts would be expected to support the use of ravulizumab in paediatric patients below 2 years of age since PK differences in absorption, distribution and metabolism occur, which may reduce the prediction similar exposure ranges across the differentsubgroups ofpatients and schedules(naive and eculizumab-treated), which indicates that PK characteristics in paediatric patients with PNH treated withravulizumabwerecomparabletothatobservedinadultswithPNHandadultsandpaediatric patientswithaHUS(seeSmPCsection5.2).

Thepharmacodynamicevaluationof free-C5,ChickenRed BloodCellHaemolyticActivity,and total C5 showed that thecurrentdosingregimenofravulizumabinpaediatricpatientswithPNH allowed to achieve(i)complete terminalcomplementinhibitionby theendof thefirstravulizumabinfusion and sustained throughout the evaluation period,(ii) complete haemolysis inhibition, and(i) a slight increasebutcomparabletotalC5valuesamongbothcohortsofpatients.Moreover,theexposure-free C5 concentration relationship confirmed the observed trend in adult patients, since paediatric observationslaidovertheobservedvaluesintheadultpopulationandsimilartrendwasobserved

## 2.3.5. Conclusions on clinical pharmacology

predictionsfrom apopulationPK model ofravulizumabinadults.Themodellingstrategyis endorsed andshowstheadequacyof thebodyweight-baseddosingregimenof ravulizumabinadolescents.

## 2.4.Clinicalefficacy

## 2.4.1. Dose response study(ies)

Nodoseresponsestudiesweresubmitted.

Theweight-baseddosagesofravulizumabinthisstudywerepremisedonPK/PDdatafromearly developmentstudiesinhealthyadultvolunteersaswellastheavailabledatafrompatientswithPNH in conceptstudy(ALXN1210-PNH-201).Ravulizumabpaediatric dosing waspredicted tonotexceed Analysis)itwasdecided toamend theprotocol(ProtocolAmendment2dated23Aug2018)toincrease theloadingdoseforpatientsintheweightrange≥5 to&lt;10kgfrom300mg to600mg(or300mg divided in 2 infusions administered within a 24-hour window).

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study(ies)

## StudyALXN1210-PNH-304

This is an ongoing Phase 3, open-label, single-arm multicentre study to evaluate the PK, PD, safety, andefficacyofravulizumabincomplementinhibitortreatment-naiveandeculizumab-experienced

Thestudyconsistsofa 4-weekScreeningPeriod,a26-weekPrimaryEvaluationPeriod,and an ExtensionPerioduntil theproductisregisteredorapproved(inaccordancewithcountry-specific regulations) or for of up to 4 years (with the exception of any country specific mandates), whichever

## Methods

## Study participants

## Inclusion criteria

Patientswereeligibleforenrolmentinthestudyonlyiftheymetallofthefollowingcriteria:

- 1.Maleandfemalepatients&lt;18yearsofageandweighing≥5kgatthetimeofconsent.
2. Documented diagnosis of PNH, confirmed by high-sensitivity flow cytometry evaluation (Borowitz, 2010)of RBCs and whitebloodcells(WBCs),withgranulocyte or monocyte clone size of≥5%.
- 3.For patients not currently treated with eculizumab, presence of 1 or more of the following PNHrelated signs or symptoms within 3 months of Screening: fatigue, haemoglobinuria, abdominal pain,shortness ofbreath(dyspnoea),anaemia,historyofa majoradversevascularevent (including thrombosis), dysphagia, or erectile dysfunction; or history of packed red blood cell (pRBC)transfusionduetoPNH.
- 4.Lactate dehydrogenasevalues at Screening as follows:
- a.For patients not currently treated witheculizumab,LDH level ≥ 1.5× ULN
- obtained on a scheduled eculizumab-dosing day prior to dose administration [ie, at trough eculizumablevel]andanalysedbythecentral laboratory)
- receiving ameningococcalvaccinemustreceive treatmentwithappropriateprophylactic antibiotics until2weeksaftervaccination.Patientswhocannotbevaccinatedmustreceiveantibiotic prophylaxisfortheentiretreatmentperiodandfor8monthsfollowinglastdose.
6. Patients must have been vaccinated against Haemophilus influenzae type b (Hib) and guidelines, as appropriate.
7. Female patients of childbearing potential (i.e. had achieved menarche) and male patients with guidance for avoiding pregnancy while on treatment and for 8 months after last dose of study drug.
- 8.Patient's legal guardian must have been willing and able to give written informed consent and the patient must have been willing to give written informed assent(if applicable as determined by the centralorlocalIRB/IECandcomplywiththestudyvisitschedule.

<div style=\"page-break-after: always\"></div>

Exclusioncriteria

- 1.Platelet count &lt; 30,000/mm3 (30 × 109 /L) at Screening
2. Absolute neutrophil count &lt; 500/uL (0.5 × 109 /L) at Screening
- 3.History of bone marrow transplantation
4. History of N meningitidis infection
- 5.History of unexplained, recurrent infection
6. Active systemic bacterial, viral, or fungal infection within 14 days prior to study drug administration on Day 1
7. History of malignancy within 5 years of Screening with the exception of adequately treated nonmelanomaskincancerorcarcinomainsituofthecervix
8. History of or ongoing major cardiac, pulmonary, renal, endocrine, or hepatic disease (eg, active hepatitis)that,inthe opinionof theInvestigator orAlexion,precludes thepatient'sparticipation in an investigational clinical study
9. Unstable medical conditions(eg,myocardial ischemia,active gastrointestinal bleed,severe congestive heart failure, anticipated need for major surgery within 6 months of Screening, coexistingchronicanaemiaunrelatedtoPNH)thatwouldhavemadethemunlikelytotoleratethe requirementsoftheprotocol
10. Concomitant use of anticoagulants was prohibited if not on a stable regimen for at least 2 weeks prior to Day 1
11. History of hypersensitivity to any ingredient contained in the study drug, including hypersensitivity to murine proteins
12. Females who planned to become pregnant or were currently pregnant or breastfeeding
13. Females of childbearing potential who had a positive pregnancy test result at Screening or on Day 1
- 30daysbeforeinitiationofstudydrugonDay1inthisstudyorwithin5half-livesofthat investigationalproduct,whicheverwasgreater
- 15.Known or suspected history of drug or alcohol abuse or dependencewithin1year prior to the start of Screening
16. Known medical or psychological condition(s) or risk factor that, in the opinion of the Investigator or Alexion,mighthaveinterferedwiththepatient'sfullparticipationinthestudy,posed any

<div style=\"page-break-after: always\"></div>

additionalriskforthepatient,orconfoundedtheassessmentofthepatientoroutcomeofthe study

## Treatments

Patientsreceived aweight-based loading dose onDay 1followed by aweight-basedmaintenance treatmentonDay15and thenonceevery 4weeks(q4w)forpatientsweighing&lt;20kgandonce every8weeks(q8w)forpatientsweighing≥20kg.Forpatientsentering thestudyoneculizumab therapy,Day1of study treatmentwastobe2weeks afterthepatient'slast doseof eculizumab.

Table6:LoadingandMaintenanceTreatmentRegimens

| BodyWeightRange (kg)a   |   Loading Dose (mg) |   Maintenance Doses (mg) | MaintenanceDosing Frequency   |
|-------------------------|---------------------|--------------------------|-------------------------------|
| ≥5to<10                 |                 600 |                      300 | q4w                           |
| ≥10to<20                |                 600 |                      600 | q4w                           |
| ≥20 to<30               |                 900 |                     2100 | q8w                           |
| ≥30to<40                |                1200 |                     2700 | q8w                           |
| ≥40to<60                |                2400 |                     3000 | q8w                           |
| ≥60to<100               |                2700 |                     3300 | q8w                           |
| ≥100                    |                3000 |                     3600 | q8w                           |

bWith the agreement of theAlexionMedical Monitor,the 600mg loading dose could have been given to patients weighing ≥5 to&lt;10 kg as 2 separate infusions administered no more than 24 hours apart.

Doseregimenwasbasedonbodyweightobtained atthe studyvisit.If the studydrugneeded tobepreparedthe day prior to thevisit,theweight from theprevious visit would be used.

Abbreviations: q4w= once every 4weeks;q8w= once every8weeks.

## Objectives

The objectives of this study were to assess the pharmacokinetics(PK),pharmacodynamics(PD), safety, and efficacy of ravulizumab in paediatric patients with paroxysmal nocturnal haemoglobinuria (PNH).

## Outcomes/endpoints

## Primary endpoints

PK/PD parameters (trough and peak) at baseline and Weeks 2, 10, 18, and 26

- PK:maximum serum concentration (Cmax), trough serum concentration(measured at end ofdosinginterval atsteadystate;Ctrough),accumulationratio.
- PD:change in free C5concentrations and in chickenred blood cell(cRBC)haemolytic activityover time8.2.

## Secondaryendpoints

- Percentage change inLDH frombaseline toDay 183(Week26)
- Transfusion avoidance (TA), defined as the proportion of patients who remained transfusionfreeanddonotrequireatransfusionthroughDay183(Week26)
- (FACIT)Fatigue questionnaire(patients≥ 5 years of age),frombaseline to Day 183 (Week26)
- decreaseinhaemoglobinlevelfrombaselineintheabsenceoftransfusionthroughDay183 (Week26)
- Percentagechangeinfreehaemoglobinfrombaseline toDay183(Week26)
- worsening symptom or sign of intravascular haemolysis (fatigue, haemoglobinuria, abdominal pain, shortness of breath [dyspnoea], anaemia, major adverse vascular event [MAvE, including thrombosis], dysphagia, or erectile dysfunction) in the presence of elevated LDH as follows:
- -For patients who entered the study naive to complement inhibitor treatment, elevated LDH ≥ 2 × the upper limit of normal (ULN) after prior LDH reduction to &lt; 1.5 x ULN on therapy.
- Forpatientswhoentered thestudystabilizedoneculizumabtreatment,elevatedLDH ≥2 ×ULN

<div style=\"page-break-after: always\"></div>

## Sample size

toensure atleast10evaluablepatientswouldcomplete thePrimaryEvaluationPeriod.Asamplesize of10wasexpectedtobesufficienttoadequatelydescribePK/PDinpaediatricpatientswithPNH.

## Randomisation

ravulizumabtoeachpatient.

## Blinding (masking)

Thiswas anopenlabelstudy.

## Statisticalmethods

## Analysispopulation

- PharmacokineticAnalysisSet:ThePKAnalysisSetincluded allpatientswhoreceived atleast1 doseofravulizumabandwhohadevaluablePKdata.ThePKAnalysisSetwasusedforallPK analyses.
- PharmacodynamicAnalysisSet:ThePDAnalysisSetincludedallpatientswhoreceivedatleast 1 doseofravulizumabandwhohadevaluablePDdata.ThePDAnalysisSetwasusedforall PD analyses.
- ravulizumab and had at least 1 efficacy assessment after the first infusion of ravulizumab. The FASwasthepopulationusedforallefficacyanalyses.
- SafetySet:TheSafetySetincludedallpatientswhoreceivedatleast1doseofravulizumab. TheSafetySet was used for all safety and immunogenicity analyses.

<div style=\"page-break-after: always\"></div>

## Efficacyanalyses

All analyses were performed through the end of the Primary Evaluation Period (Day 183 [Week 26]).

The efficacy analyses were performed on the Full Analysis Set (FAS), which included all patients who receivedatleast1doseofravulizumabandhad atleast1postbaselineassessment.Continuous variables were summarized using descriptive statistics, including number of observations and mean, standard deviation(SD),median,minimum,and maximum values.Categorical variables were summarized by frequency counts and percentage of patients. Analyses were conducted separately for complementinhibitortreatment-naiveandeculizumab-experiencedpatients.

visitsuptoDay183(Week26)bybothobservedcase(OC)andlastobservationcarriedforward (LocF).Baselinewasdefinedastheaverageofallassessmentsanalysedbythecentral laboratory priortofirststudydrugadministration.

Thenumber(%)ofpatients achievingLDH levels atorbelow1.0xULNand levels at orbelow1.5x ULN were displayed.Mean(±95%confidence interval[CI])of absolute LDH levels,and the change and percentchangefrombaselinewereplottedover time,bycomplementinhibitortreatment-naiveand eculizumab-experiencedpatients.

- oTransfusionavoidance

Pointestimates and2-sided95%exactCIswerecomputed.Patientswhowithdrewfrom thestudydue were to be counted in the group needing transfusion.For patients who withdrewfrom the study for any other reason during the Primary Evaluation Period, their data up to the time of withdrawal will be usedtoassessTA.

A summary of the number of pRBC transfusion requirements up to Day 183 study were presented includingnumberoftransfusionepisodesandunitstransfused.

Change in QoL, as measured by Paediatric Functional Assessment of Chronic Illness Therapy (FACIT)Fatigue questionnaire from baseline to Day 183 (Week 26):

- The scoring guidelinefor thePaediatricFACIT-Fatigueinstrumentwas used to calculate a FACIT-Fatigue score.
- Absolutescores,changefrombaseline,andpercentchangefrombaselineinFACIT-Fatigue scoresweresummarizedbybothOCandLocFatbaselineandatthestudyvisitswhere this assessmentwascollected uptoDay183(Week26).
- Ateachstudyvisit,theproportionofpatientswhoshowedanimprovementofatleast3 sided 95% exact CIs.
- oStabilizedhaemoglobin

Stabilizedhaemoglobinwasdefinedasavoidanceof≥20g/Ldecreaseinhaemoglobinfrombaseline in the absence of transfusion through Day 183. Point estimates and 2-sided 95% exact CIs were computed.Patientswhowithdrewfromthestudyduetolackofefficacyduring thePrimaryEvaluation meetthestabilizedhaemoglobindefinition.Forpatientswhowithdrewfromthestudyforanyother reason during the Primary Evaluation Period, their data up to the time of withdrawal were to be used toassessstabilizedhaemoglobin.

<div style=\"page-break-after: always\"></div>

- 0Percentage change in free haemoglobin from baseline to Day 183 (Week 26)
- Absolutefreehaemoglobinvalues,and thechangeandpercentchangefrombaseline,were summarizedbybothOCandLOCFatallstudyvisitsuptoDay183(Week26).Baseline was defined as the last non-missing assessment value prior to the first study drug infusion.
- Mean (±95% Cl) of free haemoglobin, and the change and percent change from baseline experienced patients.
- oBreakthroughhaemolysis

Pointestimatesand2-sided95%exactCIswerecomputed.Patientswhowithdrewfrom thestudydue were tobecounted inthegroupwithBTH.Forpatientswhowithdrewfromthestudyfor anyother reason during the Primary Evaluation Period, their data up to the time of withdrawal were to be used to assess BTH.

The number of any treatment-emergent MAvEs (n) and number of patients with events (n, %) were displayed.EachoftheMAVEcategorieswassimilarlysummarized.PatientshavingmultipleMAVEs within a category was be counted once in that category.

## Results

## Participant flow

Twelvepatients,4ofwhomwerenaivetocomplementinhibitortreatmentand8ofwhomwere failures).All 12 patients completed the Primary EvaluationPeriod and entered the ExtensionPeriod of the study.

## Recruitment

Patients were enrolled at 9 sites in 6 countries (United States, United Kingdom, France, Netherlands,

## Conduct of the study

## Protocolamendments

Since theoriginalprotocol(dated05Sep2017),2globaland 3country-specificprotocolamendments weremade.Theseamendmentsaresummarizedinthetablebelow.

Table7:SummaryofProtocol Changes

<div style=\"page-break-after: always\"></div>

| Amendment Number                          | SummaryofSignificant Changes to theStudyProtocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 1 (France) Dated: 19 Dcc 2017   | Additional pregnancy assessments have been added during the Extension Period to cnsure testing prior to cach q8w dose,per request by theFrench Ethics Committcc.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Amendment 2 (Global) Dated: 23 Aug 2018   | Increascd loading dose for patients who are ≥5 to <10 kg in body weight based on analysis of interim PK/PD data from an ongoing aHUS pediatric study. Allowed loading dose to be administered as 2 infusions (no more than approximately 24 hours apart) for patients who are ≥5 to <10 kg in body weight at study entry; predose PK/PD sample collected before the first infusion and EOl sample collected after the second infusion. Allowed supplemental dosc of ravulizumab upon agrecment of the Alexion Medical Monitor. Follow-up phone call 8 weeks after patient's last dose of study drug was added for monitoring of concomitant medications,procedures, and adverse events.                                                                                    |
| Amendment 2.1 (France) Dated: 13 Sep 2018 | Increased loading dose for patients who are ≥ 5 to < 10 kg in body weight bascd on Allowed loading dose to be administered as 2 infusions (no more than approximately 24 hours apart) for patients who are ≥ 5 to <10 kg in body weight at study entry; predose PK/PD sample collected before the first infusion and EOI sample collected after the second infusion. Allowed supplemental dose of ravulizumab upon agreement of the Alexion Medical Monitor. Follow-up phone call 8 wecks after patient's last dose was added for monitoring of concomitant medications,procedures,and adverse events.                                                                                                                                                                     |
| Amendment 2.2 (Norway) Dated: 06 Jun 2019 | The tem'primary'was deleted from the overall statement on study objectives in the synopsis to maintain consistency with Section 6.1 of the Protocol. The statement on the duration of the Extension Period was modified to specify a fixcd duration of 2 years. The SUSAR reporting procedures were clarified in Section 11.7.5.                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Amendment 3 (Global) Dated: 22 Apr 2020   | ·Extension Period was prolonged from 2 years to 4 years and the Schcdules of Assessments were revised accordingly. ·Number of patients to be enrolled was increased to allow for the enrollment of patients currently identified and to comply with EMA PIP requisites. ·Urine pregnancy tests were to be performed prior to each q&w study drug administration for patients who have reached menarche. ·Transfusions were tobe recorded at everyvisit To cnsure patient safety and trcatment continuity during the COVID-19 pandemic, the option for patients to receive ravulizumab administration remotely at a medical facility that was located near the patient's home or at the patient's home was added. ·Timcpoints for interim analyses and CSRs were clarificd. |

Abbreviations: aHUS = atypical hemolytic uremic syndrome; COVID-19 = coronavirus discase 2019; EMA=European Medicincs Agcncy;EOl =cnd of infusion;PD=pharmacodynamics;PIP=pediatric investigation plan;PK=pharmacokinctics: q8w= cvery 8wceks;SUSAR=suspccted unexpected serious adverse reaction.

## Changesinplannedanalyses

The SAP (version 2.0) was finalized on 08 May 2020, prior to database lock for the Primary Evaluation Period.

Aninterimanalysisofdata，includingravulizumabPK,freeC5levels,andsafety,wasplannedtobe purpose of the interim analysis was to ensure that ravulizumab treatment was well tolerated and was interimanalysisconductedandreportedinStudyALxN1210-aHUS-312.Basedontheinterimanalysis resultsintheALXN1210-aHUS-312Study,theprotocolwasamended(ProtocolAmendment2dated23 Aug2018)toadjusttheloadingdoseforpatientsintheweightrange≥5to&lt;10kgfrom300mg to

<div style=\"page-break-after: always\"></div>

600mg(or300 mg divided in 2 infusions administered within a24-hourwindow),followed by a maintenancedoseof300mgonDay15andq4wthereafter

Samplesfromthecentral laboratorywereconsidered tohaveundergonetable-tophaemolysis(TTH)if theserumpotassiumvaluewas≥6mmol/L and theLDHvaluewas≥2×ULN.Central laboratory samplesthatmettheseTTHcriteriawereidentified,andallpotassium,alanineaminotransferase wereexcludedfromanalysisofallefficacyandsafetyendpoints,withtheexceptionthattheLDH level,wasnotavailableforsomepatients atthetimeoftheinterimCSR,andnosampleswere excluded for TTH from the analyses included intheCSR.Instead,a haemolyticindex(HI)value is provided for LDH values that were haemolysed. According to the central laboratory, an HI value &gt; 15 causestestinterferenceandmayresultinfalselyelevatedLDHlevels.

## Protocoldeviations

werethosethatcouldpotentiallyimpacttherights,welfare,orsafetyof thepatientand/orthe integrityofthestudydata;allotherswereconsiderednotimportant.Atotalof8patientshad important protocol deviations in the Primary Evaluation Period.

Table8:ImportantProtocol Deviations (Full AnalysisSet)

| Categories of Deviation                                | Complement Inhibitor Treatment-naive Patients (N=4)   | Eculizumab- experienced Patients (N=8)   | AllPatients (N=12)   |
|--------------------------------------------------------|-------------------------------------------------------|------------------------------------------|----------------------|
| Patientswithimportantdeviations,n(%)                   | 3 (75.0)                                              | 5 (62.5)                                 | 8 (66.7)             |
| Type of important deviations,n(%) Laboratoryassessment | 1 (25.0)                                              | 4 (50.0)                                 | 5 (41.7)             |
| Source document                                        | 0                                                     | 2 (25.0)                                 | 2 (16.7)             |
| Visit schedule                                         | 2 (50.0)                                              | 0                                        | 2 (16.7)             |
| Informed consent                                       | 0                                                     | 1 (12.5)                                 | 1(8.3)               |
| Safety reporting                                       | 0                                                     | 1 (12.5)                                 | 1 (8.3)              |
| Studyprocedures/test                                   | 0                                                     | 1 (12.5)                                 | 1 (8.3)              |

Note:Some patientshadmore than I important protocol deviation.Percentageswere based on the total number of patients in each cohort or overall.

patient had theDay71PDsamples forfreeC5and cRBClostdue to shipping issues; 1 patient did not resultsduetoclottedsamples;and 1patientdidnothaveADAserumsamplescollectedatDay183 duetoinsufficientamountofblood.

Twopatientshadimportantdeviationsrelatedtosourcedocumentduetothesitefailingtoremindthe patientsateachsitevisittocarrytheirsafetycardwiththematalltimes.

Importantdeviationstothevisitschedulewerereportedfor2patientsduetocancellationoftheDay 99VisitasperInvestigator'sdecisionandpatient'spersonalreasons.

Onepatienthad2importantdeviationsrelated toinformedconsentprocedureswherethewrong versions of theICF,aswellasthe assentform,were signed.

Importantprotocoldeviationsrelatingtosafetyreportingprocedureswerenotedfor1patientwhohad delayedreportingofasingleSAE.

<div style=\"page-break-after: always\"></div>

Onepatienthad 1importantdeviationrelated tostudyprocedures/tests:screeningLDHwasnot collectedwithin24hoursoflasteculizumabdose.

## Baselinedata

## Demographiccharacteristics

Eightof the 12patientswerefemale,and the mean age atthe time of firststudy druginfusion was 14.4years.Twopatients were under 12years of age at the time offirst study drug infusion:Patient in thecomplementinhibitortreatment-naivecohortwas11yearsoldandPatientintheeculizumabdruginfusion.

Table9:DemographicsandBaselineCharacteristics(FullAnalysisSet)

<div style=\"page-break-after: always\"></div>

| Variable                                      | Treatment Naive (N = 5) n (%)   | Eculizumab Experienced (N = 8) (%) u   | Total (N = 13) (%) u   |
|-----------------------------------------------|---------------------------------|----------------------------------------|------------------------|
| Sex, n (%)                                    |                                 |                                        |                        |
| Male                                          | 4 (80.0)                        | 1 (12.5)                               | 5 (38.5)               |
| Female                                        | 1 (20.0)                        | 7 (87.5)                               | 8 (61.5)               |
| Ethnicity, n (%)                              |                                 |                                        |                        |
| Not Hispanic or Latino                        | 5 (100)                         | 6 (75.0)                               | 11 (84.6)              |
| Not Reported                                  | 0 (0.0)                         | 2 (25.0)                               | 2 (15.4)               |
| Hispanic or Latino                            | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Missing/Unknown                               | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Race, n (%)                                   |                                 |                                        |                        |
| White                                         | 5 (100)                         | 3 (37.5)                               | 8 (61.5)               |
| BlackorAfricanAmerican                        | 0 (0.0)                         | 2 (25.0)                               | 2 (15.4)               |
| Not Reported                                  | 0 (0.0)                         | 2 (25.0)                               | 2 (15.4)               |
| Other                                         | 0 (0.0)                         | 1 (12.5)                               | 1 (7.7)                |
| AmericanIndian or Alaska Native               | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Asian                                         | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Multiple                                      | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Native Hawaiianor OtherPacific Islander       | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Age at First Infusion (years)                 |                                 |                                        |                        |
| Mean (SD)                                     | 14.4 (2.19)                     | 14.4 (3.07)                            | 14.4 (2.66)            |
| Median                                        | 15.0                            | 15.0                                   | 15.0                   |
| Min, Max                                      | 11, 17                          | 9,17                                   | 9,17                   |
| Age at First Infusion (years) Category, n (%) |                                 |                                        |                        |
| < 12 years                                    | 1 (20.0)                        | 1 (12.5)                               | 2 (15.4)               |
| ≥ 12 years                                    | 4 (80.0)                        | 7 (87.5)                               | 11 (84.6)              |
| Baseline Weight (kg)                          |                                 |                                        |                        |
| Mean (SD)                                     | 56.26 (11.594)                  | 56.25 (12.247)                         | 56.25 (11.502)         |
| Median                                        | 55.60                           | 55.50                                  | 55.60                  |
| Min, Max                                      | 39.5, 72.0                      | 36.7, 69.0                             | 36.7, 72.0             |
| Baseline Weight (kg) Category, n (%)          |                                 |                                        |                        |
| ≥5to<10 kg                                    | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| ≥10 to < 20 kg                                | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| ≥20 to<30kg                                   | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| ≥30to<40kg                                    | 1 (20.0)                        | 1 (12.5)                               | 2 (15.4)               |
| ≥ 40 to<60 kg                                 | 3 (60.0)                        | 4 (50.0)                               | 7 (53.8)               |
| ≥ 60 to <100 kg                               | 1 (20.0)                        | 3 (37.5)                               | 4 (30.8)               |
| ≥ 100 kg                                      | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Baseline Height (cm)                          |                                 |                                        |                        |
| Mean (SD)                                     | 163.40 (11.760)                 | 160.99 (9.369)                         | 161.92 (9.940)         |
| Median                                        | 168.00                          | 158.95                                 | 164.00                 |
| Min, Max                                      | 143.0, 171.0                    | 146.0, 176.2                           | 143.0, 176.2           |
| Baseline Body Mass Index (BMI) (kg/m2)        |                                 |                                        |                        |

<div style=\"page-break-after: always\"></div>

| Variable                                      | Treatment Naive (N = 5) n (%)   | Eculizumab Experienced (N = 8) (%) u   | Total (N = 13) (%) u   |
|-----------------------------------------------|---------------------------------|----------------------------------------|------------------------|
| Sex, n (%)                                    |                                 |                                        |                        |
| Male                                          | 4 (80.0)                        | 1 (12.5)                               | 5 (38.5)               |
| Female                                        | 1 (20.0)                        | 7 (87.5)                               | 8 (61.5)               |
| Ethnicity, n (%)                              |                                 |                                        |                        |
| Not Hispanic or Latino                        | 5 (100)                         | 6 (75.0)                               | 11 (84.6)              |
| Not Reported                                  | 0 (0.0)                         | 2 (25.0)                               | 2 (15.4)               |
| Hispanic or Latino                            | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Missing/Unknown                               | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Race, n (%)                                   |                                 |                                        |                        |
| White                                         | 5 (100)                         | 3 (37.5)                               | 8 (61.5)               |
| BlackorAfricanAmerican                        | 0 (0.0)                         | 2 (25.0)                               | 2 (15.4)               |
| Not Reported                                  | 0 (0.0)                         | 2 (25.0)                               | 2 (15.4)               |
| Other                                         | 0 (0.0)                         | 1 (12.5)                               | 1 (7.7)                |
| AmericanIndianorAlaska Native                 | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Asian                                         | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Multiple                                      | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Native Hawaiian or OtherPacific Islander      | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Age at First Infusion (years)                 |                                 |                                        |                        |
| Mean (SD)                                     | 14.4 (2.19)                     | 14.4 (3.07)                            | 14.4 (2.66)            |
| Median                                        | 15.0                            | 15.0                                   | 15.0                   |
| Min, Max                                      | 11, 17                          | 9,17                                   | 9,17                   |
| Age at First Infusion (years) Category, n (%) |                                 |                                        |                        |
| < 12 years                                    | 1 (20.0)                        | 1 (12.5)                               | 2 (15.4)               |
| ≥ 12 years                                    | 4 (80.0)                        | 7 (87.5)                               | 11 (84.6)              |
| Baseline Weight (kg)                          |                                 |                                        |                        |
| Mean (SD)                                     | 56.26 (11.594)                  | 56.25 (12.247)                         | 56.25 (11.502)         |
| Median                                        | 55.60                           | 55.50                                  | 55.60                  |
| Min, Max                                      | 39.5, 72.0                      | 36.7, 69.0                             | 36.7, 72.0             |
| Baseline Weight (kg) Category, n (%)          |                                 |                                        |                        |
| ≥5to<10 kg                                    | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| ≥10 to < 20 kg                                | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| ≥20 to<30kg                                   | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| ≥30to<40kg                                    | 1 (20.0)                        | 1 (12.5)                               | 2 (15.4)               |
| ≥ 40 to<60 kg                                 | 3 (60.0)                        | 4 (50.0)                               | 7 (53.8)               |
| ≥60to<100kg                                   | 1 (20.0)                        | 3 (37.5)                               | 4 (30.8)               |
| ≥ 100 kg                                      | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Mean (SD)                                     | 20.92 (2.657)                   | 21.45 (2.756)                          | 21.25 (2.618)          |
| Median                                        | 20.20                           | 21.60                                  | 20.70                  |
| Min, Max                                      | 18.9, 25.5                      | 17.2, 24.8                             | 17.2, 25.5             |

Abbreviation:SD=standarddeviation

Diseasehistoryandcharacteristics

<div style=\"page-break-after: always\"></div>

MeanageatPNHdiagnosiswas13.8yearsforthecomplementinhibitortreatment-naivecohortand cytometry at Screening to quantify the percentage of PNH cells (clone size) in the peripheral blood. cohort and 82.91% in the eculizumab-experienced cohort.

Table 10: Disease Characteristics (Full Analysis Set)

| Variable Category                                     | Treatment Naive (N = 5) (%) u   | Eculizumab Experienced (N = 8) (%) u   |
|-------------------------------------------------------|---------------------------------|----------------------------------------|
| Age (years) at PNH Diagnosis                          |                                 |                                        |
| Mean (SD)                                             | 13.8 (2.39)                     | 12.3 (3.11)                            |
| Median                                                | 14.0                            | 12.5                                   |
| Min, Max                                              | 11, 17                          | 7,16                                   |
| MethodofInitialPNHDiagnosis,n(%)                      |                                 |                                        |
| Flow Cytometry                                        | 5 (100)                         | 7 (87.5)                               |
| Ham's Test                                            | 0 (0.0)                         | 0 (0.0)                                |
| Sucrose Hemolysis Test                                | 0 (0.0)                         | 0 (0.0)                                |
| Other                                                 | 0 (0.0)                         | 1 (12.5)                               |
| YearsfromDiagnosistoInformed Consent                  |                                 |                                        |
| Mean (SD)                                             | 0.74 (1.433)                    | 2.01 (0.999)                           |
| Median                                                | 0.10                            | 1.65                                   |
| Min, Max                                              | 0.0, 3.3                        | 1.1, 3.8                               |
| PNHCloneSizeatBaseline PNH RBC Type II Clone Size (%) |                                 |                                        |
| n                                                     | 4                               | 6                                      |
| Mean (SD)                                             | 18.65 (19.467)                  | 10.57 (16.408)                         |
| Median                                                | 16.25                           | 3.05                                   |
| Min, Max                                              | 0.7,41.4                        | 0.6, 42.6                              |
| PNH RBC Type III Clone Size (%)                       |                                 |                                        |
| Mean (SD)                                             | 19.18 (12.922)                  | 54.51 (22.192)                         |
| Median                                                | 15.40                           | 62.40                                  |
| Min, Max                                              | 6.2, 39.9                       | 20.6, 80.8                             |
| Total PNH RBC Clone Size(%)                           |                                 |                                        |
| n                                                     | 4                               | 6                                      |
| Mean (SD)                                             | 38.78 (31.512)                  | 65.65 (22.714)                         |
| Median                                                | 40.05                           | 71.15                                  |
| Min, Max                                              | 6.9, 68.1                       | 21.2,85.4                              |
| TotalPNHGranulocyteCloneSize(%)                       |                                 |                                        |
| Mean (SD)                                             | 68.10 (26.391)                  | 82.91 (26.043)                         |
| Median                                                | 78.30                           | 91.60                                  |
| Min, Max                                              | 36.8, 99.0                      | 20.3, 97.6                             |
| Total PNH Monocyte Clone Size (%)                     |                                 |                                        |
| Mean (SD)                                             | 75.18 (24.012)                  | 91.94 (5.457)                          |
| Median                                                | 79.90                           | 93.60                                  |
| Min, Max                                              | 34.9, 98.9                      | 81.3, 97.7                             |

Notes:Percentages are based on the total number of patients in each group.

<div style=\"page-break-after: always\"></div>

Total RBC, Granulocyte, Monocyte Clone Size = Sum Type II and Type III RBC, Granulocyte, Monocyte clone size, respectively.

Baselineisdefinedasthelastnon-missingvaluepriortofirstdoseofALxN1210.

Abbreviations:PNH=paroxysmal nocturnal hemoglobinuria;RBC=red blood cell;SD= standard deviation

Duringthe12monthspriortofirstdoseofravulizumab,2patientsinthecomplementinhibitor treatment-naivecohortand2patientsintheeculizumab-experiencedcohorthadreceived atleast1 pRBCtransfusionwithatotalof10and2transfusions,respectively.

Table11:PackedRedBloodCell/WholeBloodTransfusionsWithin12MonthsPriortoFirst Dose (Full AnalysisSet)

| Variable Category                                                                     | Treatment Naive (N = 5) (%) u   | Eculizumab Experienced (N = 8) (%) u   |
|---------------------------------------------------------------------------------------|---------------------------------|----------------------------------------|
| NumberofPatientswithpRBC/WholeBloodTransfusionsWithin 12 MonthsPrior toFirstDose,n(%) | 2 (40.0)                        | 2 (25.0)                               |
| pRBC/WholeBloodTransfusionsWithin12 MonthsPrior toFirst Dose                          |                                 |                                        |
| Total                                                                                 | 10                              | 2                                      |
| Mean (SD)                                                                             | 5.0 (1.41)                      | 1.0 (0.00)                             |
| Median                                                                                | 5.0                             | 1.0                                    |
| Min, Max                                                                              | 4,6                             | 1, 1                                   |
| UnitsofpRBC/WholeBloodTransfusedWithin12MonthsPrior to First Dose                     |                                 |                                        |
| Total                                                                                 | 14                              | 2                                      |
| Mean (SD)                                                                             | 7.0 (5.66)                      | 2.0                                    |
| Median                                                                                | 7.0                             | 2.0                                    |
| Min, Max                                                                              | 3,11                            | 2,2                                    |

Notes:Percentagesarebasedonthetotal numberofpatientsineachgroup.

Twelve of the 13 patients had at least 1 PNH-associated sign or symptom at any time prior to informed asthenia(generalizedweakness);abdominalpain;redordarkurine;CNS-related symptomssuchas headache, dizziness, or difficulty concentrating; jaundice (yellowing of skin or eyes); back or flank pain; and chest pain.

All 13 patients had at least 1 PNH-associated condition diagnosed at any time prior to informed consent.

Table 12: PNH Medical History: PNH-Associated Conditions Diagnosed at Any Time Prior to Informed Consent (Full Analysis Set)

| PNH-associated Conditions, n (%o)                    | Treatment Naive (N = 5) (%)u   | Eculizumab Experienced (N = 8) (%) u   | Total (N = 13) (%) u   |
|------------------------------------------------------|--------------------------------|----------------------------------------|------------------------|
| PatientswithanyPNHConditionsPriorto Informed Consent | 5 (100)                        | 8 (100)                                | 13 (100)               |
| Anemia                                               | 2 (40.0)                       | 5 (62.5)                               | 7 (53.8)               |
| Hematuria or Hemoglobinuria                          | 2 (40.0)                       | 5 (62.5)                               | 7 (53.8)               |

<div style=\"page-break-after: always\"></div>

| PNH-associated Conditions, n (%o)   | Treatment Naive (N = 5) n (%)   | Eculizumab Experienced (N = 8) n (%)   | Total (N = 13) n (%)   |
|-------------------------------------|---------------------------------|----------------------------------------|------------------------|
| AplasticAnemia                      | 3 (60.0)                        | 1 (12.5)                               | 4 (30.8)               |
| Renal Failure                       | 2 (40.0)                        | 2 (25.0)                               | 4 (30.8)               |
| Other                               | 0 (0.0)                         | 1 (12.5)                               | 1 (7.7)                |

Notes:Percentagesarebasedonthe total number of patientsineachgroup,oroverall.

Patients can be counted in more than one category.

CodedusingMedDRAVersion24.0.

Abbreviation:PNH =paroxysmal nocturnal hemoglobinuria

## Priormedicationsandtreatments

All13patientshad ahistoryofprior medicationuse.Themostcommonlyreported(≥2patients) groups of prior medications included bacterial vaccines (13/13); immunosuppressants (11/13); vitamin B12and folic acid(7/13);bacterialand viral vaccines,combined (6/13);beta-lactam antibacterials, penicillins (5/13); other analgesics and antipyretics; and other vitamin products, combinations (3/13, each);and corticosteroidsfor systemic use,plain;othervitaminproducts,combinations; antiseptics anddisinfectants;antithromboticagents;bile therapy;opioids;quinoloneantibacterials;andvitaminK andotherhaemostatics(2/13each).

## Concomitantmedicationsandtreatments

All13patients tookatleast1concomitantmedication.Themostcommonlyreported(≥3patients) groupsofconcomitantmedicationswereotheranalgesics and antipyretics;vitaminB12andfolic acid (9/13);beta-lactamantibacterials,penicillins(8/13);otherbeta-lactamantibacterials(7/13each); anaesthetics,local;anti-inflammatoryandantirheumaticproducts,non-sterioids; immunosuppressants; opioids;quinolone antibacterials; antipruritics(4/13);anaesthetics,general;

(3/13 each).

## Numbers analysed

All12 patients initially treated with ravulizumab were included in all of the analysis sets: FAS, Safety Set,PKAnalysisSet,andPDAnalysisSet.Datafroma 13thpatient(ongoingin thePrimaryEvaluation Period as of the cut-off date)was provided during theprocedure and was not included in the initial analysis.

## Outcomes and estimation

## Secondaryendpoints

- ·Percent change in lactate dehydrogenase

In the complement inhibitortreatment-naive cohort, themeanLDH atbaseline was957.00 U/L,and all whichwasgenerallysustained throughout thePrimaryEvaluationPeriod.

On Day 183, the mean (SD) percent reduction from baseline in LDH was -47.91 % (52.716 %). Two patients had LDH≤ 1 x ULN and a third had≤ 1.5× ULN.The fourthpatienthad an LDH value of 637 U/L onDay 183,which maybe attributable toTTHof the sample,as thelaboratoryreported anHI of

<div style=\"page-break-after: always\"></div>

195.NoAE,SAE,orsignsorsymptomsofPNHwereassociatedwiththeincreaseinLDH.Notethaton Day99,datafrom2ofthe4patientsweremissing.

In theeculizumab-experiencedcohort,themeanLDHatbaselinewas262.75U/L.MeanLDHvalues weregenerallystablethroughout thePrimaryEvaluationPeriod,withpercentchangefrombaseline ranging between -7.27% and +11.5%. At Day 183, the mean (SD) percent change from baseline in LDH was +4.65% (44.702%), and 4 patients had LDH ≤ 1 × ULN; 2 patients had LDH ≤ 1.5 × ULN; 1 patienthad theDay183samplemissingbuthadLDH≤ 1.5xULNatallothertimepoints;1patient 1.5 × ULN on all other timepoints. No AE, SAE, or signs or symptoms of PNH were reported in connectionwiththeincreaseofLDHinthispatient.

Figure5:Mean(95%CI)LactateDehydrogenaseOver Time(FullAnalysisSet)

<!-- image -->

Notes:BaselineforLDHisdefinedastheaverageofallavailablevaluespriortofirstALxN1210infusion. MultipleLDHnormalranges arepresent depending onpediatricage andgendergroup:100-220,100-242,100-275, 120-290,and140-280U/L.

Dashedhorizontallinesindicatelowernormalvalue.Dottedhorizontallinesindicateuppernormalvalue. Abbreviations:BL=baseline;CI=confidenceinterval;LDH=lactatedehydrogenase

Figure6:Mean(95%CI)PercentageChangeFromBaselineinLactateDehydrogenaseOver Time(Full AnalysisSet)

<!-- image -->

Notes:BaselineforLDHisdefinedastheaverageofallavailablevaluespriortofirstALxN1210infusion. Abbreviations: BL = baseline; CI = confidence interval; LDH = lactate dehydrogenase

<div style=\"page-break-after: always\"></div>

On Day 351, the mean (SD) percent reduction from baseline in LDH was -54.46% (33.456%) in the cohort.

In4outof5complementinhibitortreatment-naivepatientswhohadLDH&gt;1.5×ULNatbaseline, LDH improvedby52-weeks of treatment andremained≤ 1.5x ULN.Day351 LDHvalue was not availablefor1patientbecauseofinsufficientsample.However,allotherLDHvaluesuptoDay295for thispatientwerewithinnormalrange.All8patientsintheeculizumab-experiencedcohortmaintained LDH≤1.5xULNafter52weeksofravulizumabtreatment.

Figure7.Mean(95%CI) changefrombaselinein LDH over time-Full Analysis Set

<!-- image -->

Notes:BaselineforLDHisdefinedastheaverageofallavailablevaluespriortofirstALxN1210infusion. Abbreviations:BL=baseline;CI=confidence interval;LDH=lactate dehydrogenase

## Transfusionavoidance

DuringthePrimaryEvaluationPeriod,3ofthe5complementinhibitortreatment-naivepatientsandall 8 eculizumab-experienced patients remained transfusion free.

Patientreceived 3 blood transfusions,each1unit of pRBCs,on Days 44,46,and 58;these transfusionsweregiven during treatmentformultipleSAEsincluding device-related thrombosisand septicshock.Patienthad a transfusionof 2unitsof pRBCsonDay1.

Table13:Number(%)ofPatientsAchievingTransfusionAvoidanceThroughDay183(Week 26), (Full Analysis Set)

| Variable                                                                             | Treatment Naive (N = 5) (%) u   | Eculizumab Experienced (N = 8) (%) u   |
|--------------------------------------------------------------------------------------|---------------------------------|----------------------------------------|
| AchievingpRBC/WholeBloodTransfusion AvoidanceAfterFirstDoseofALxN1210Through Day 183 |                                 |                                        |
| NumberofPatients(n)                                                                  | 3                               | 8                                      |
| Percentage (%)                                                                       | 60.0                            | 100.0                                  |
| 95% Exact CI                                                                         | (14.66, 94.73)                  | (63.06,100.00)                         |

<div style=\"page-break-after: always\"></div>

through Day 183 (Week 26).

Percentages arebased onthetotal number ofpatientsin eachgroup.

Patientswhowithdrawfromthestudyduringprimaryevaluationperiodduetolackofefficacywillbeconsidered as non-responders and will be counted in the group requiring transfusions.

ExactunconditionalapproachwasusedforcalculatingtheCIs.

Abbreviations:CI=confidence interval;pRBC=packed red blood cells remained transfusionfreeduring theExtensionPeriod throughthedatacut-offdate;theonly receiveabonemarrowtransplant.Nevertheless thepatientremainedtransfusionfreeuntilwithdrawal.

## Quality of life

QualityoflifewasassessedusingthePaediatricFACIT-FatigueQuestionnaire.ThePaediatricFACITFatigueScaleisa13-itemquestionnairethatassessesfatigueanditsimpactupondailyactivitiesand function over the preceding 7 days. Each item is scored on a 5-point scale, and total scores range from were≥8yearsofageatthetimeofenrollmentandreportedbycaregiversforpatientswhowere&gt;5 to&lt;8yearsofageatthetimeofenrollment.Patients&lt;5yearsofagewerenottobeassessed.

OnDay183,thecomplementinhibitortreatment-naivecohorthadamean(SD)improvementin Paediatric FACIT-fatigue score of 3.00 (6.976) compared to baseline, and the eculizumab-experienced cohorthad a mean(SD)improvementof 1.28(5.235)compared tobaseline.

Figure8:Mean(95%CI)ChangefromBaselineinPaediatricFACIT-FatigueOverTime(Full AnalysisSet)

<!-- image -->

Notes:FACITscorerangesfrom 0-52,withahigherscore indicatinglessfatigue.

Baselineisdefinedasthelastnon-missingassessmentvaluepriortofirstALxN1210infusion.

Dashedhorizontal lineindicatesthreshold thatdelineatesclinicallymeaningfulimprovement(&gt;3points).

Abbreviations:BL=baseline;CI= confidence interval;FACIT=Functional Assessment of ChronicIllness Therapy

improvement(Cella,2002;Webster,2003),wasobserved atDay15in2(40%)patientsinthe complementinhibitortreatment-naivecohort，whichwassustainedthroughDay183.

<div style=\"page-break-after: always\"></div>

Through52-weeks,thecomplementinhibitortreatment-naivecohorthadamean(SD)improvementin Paediatric FACIT fatigue score of 4.00(4.690) compared to baseline, and the eculizumab-experienced cohort had a mean (SD) change of -0.85 (8.509) compared to baseline.

Table 14. Number (%) of patients who showed an improvement of at least 3 points in Paediatric FACIT-FatigueScore-FullAnalysisSet

| Visit Statistics       | Treatment Naive (N = 5) (%) u   | Eculizumab Experienced (N = 8) (%) u   |
|------------------------|---------------------------------|----------------------------------------|
| Day 15                 |                                 |                                        |
| Number of Patients (n) | 2                               | 3                                      |
| Percentage (%)         | 40.0                            | 42.9                                   |
| 95% Exact CI           | (5.27, 85.34)                   | (9.90, 81.59)                          |
| Day 71                 |                                 |                                        |
| Number ofPatients (n)  | 3                               | 1                                      |
| Percentage (%)         | 60.0                            | 12.5                                   |
| 95% Exact CI           | (14.66, 94.73)                  | (0.32, 52.65)                          |
| Day 127                |                                 |                                        |
| Number ofPatients(n)   | 3                               | 2                                      |
| Percentage (%)         | 60.0                            | 25.0                                   |
| 95% Exact CI           | (14.66, 94.73)                  | (3.19, 65.09)                          |
| Day 183                |                                 |                                        |
| Number of Patients (n) | 3                               | 2                                      |
| Percentage (%)         | 60.0                            | 25.0                                   |
| 95% Exact CI           | (14.66, 94.73)                  | (3.19, 65.09)                          |
| Day351                 |                                 |                                        |
| NumberofPatients(n)    | 4                               | 2                                      |
| Percentage (%)         | 80.0                            | 25.0                                   |
| 95% Exact CI           | (28.36, 99.49)                  | (3.19, 65.09)                          |

Notes:Percentagesarebasedonthetotal number ofpatientsineachgroupatavisit.

ExactunconditionalapproachwasusedforcalculatingtheCIs.

Abbreviations: CI = confidence interval;FACIT =Functional Assessment of Chronic Illness Therapy

## Stabilized haemoglobin

Haemoglobin stabilization, defined as avoidance of a 2 g/dL (or greater) decrease in haemoglobin level frombaseline inthe absenceof transfusion throughDay183,was achievedby3of 5complement inhibitor treatment-naive patients and 6 of 8 eculizumab-experienced patients.

Table 15: Number (%) of patients with stabilized haemoglobin through Day 183 (Week 26) (Full Analysis Set)

| Variable                                           | Treatment Naive (N = 5) (%)u   | Eculizumab Experienced (N = 8) (%) u   |
|----------------------------------------------------|--------------------------------|----------------------------------------|
| AchievedStabilizedHemoglobinThroughDay183 (Week26) |                                |                                        |
| Number of Patients (n)                             | 3                              | 6                                      |
| Percentage (%)                                     | 60.0                           | 75.0                                   |
| 95% Exact CI                                       | (14.66, 94.73)                 | (34.91, 96.81)                         |

<div style=\"page-break-after: always\"></div>

the absence of transfusion throughDay 183(Week26). Percentages arebasedonthetotal numberofpatientsineachgroup. Abbreviation:CI=confidenceinterval achievedhaemoglobinstabilizationduringtheExtensionPeriodthroughthedatacut-offdate.Theonly eculizumab-experiencedpatientconsideredasnon-responderduringtheExtensionPeriodiwithdrew fromthestudyonD341toreceiveabonemarrowtransplant;thepatientachievedhaemoglobin stabilizationuntilwithdrawal.

## ·Percent change in free haemoglobin

In thecomplementinhibitor treatment-naive cohort,themean(SD)freehaemoglobinatbaselinewas 15, 43,71, 99, 127, and 155, but on Day 183, free haemoglobin increased to 30.23 mg/dL (108.74% changefrombaseline)duetovaluesabove450mg/dLfor2patients.Thesedataarebasedonthefirst 12 patientsenrolled in the study.Noupdated datawereprovided.

In the eculizumab-experienced cohort, the mean (SD) free haemoglobin at baseline was 20.35 (14.775)mg/dL.Meanfreehaemoglobinlevelsweregenerallystable overtime,withavalue of14.30 mg/dL at Day 183 (-15.29% change from baseline).

## ·Breakthrough haemolysis

Breakthrough haemolysis is defined as at least 1 new or worsening symptom or sign of intravascular haemolysis(fatigue,haemoglobinuria，abdominalpain，shortnessofbreath[dyspnoea],anaemia, follows:

- For patients who entered the study naive to complement inhibitor treatment, elevated LDH ≥ 2 X the ULN after prior LDH reduction to &lt; 1.5 × ULN on therapy.
- Forpatientswhoentered the studystabilized oneculizumabtreatment,elevatedLDH≥2 x ULN.

TherewerenoeventsofBTH during thePrimaryEvaluationPeriod.

DuringtheExtensionPeriod throughthedatacut-offdate,oneeculizumab-experiencedpatienthad BTHonDay666.

## LDH normalisation (post-hoc analysis)

A post-hoc analysis for LDH normalization (defined as the proportion of patients who achieved LDH levels≤ 1 x upper limit of normal [ULN])wasperformed on theFull AnalysisSet.Results are age and gender group, as detailed in Table 16 below.

OnDay1,noneofthepatientsinthecomplementinhibitortreatment-naivecohortand3of8patients in the eculizumab-experienced cohort had LDH levels≤ 1 x ULN.Atthe end of thePrimaryEvaluation normalized LDH; 1 patient achieved LDH normalizationin addition to the 3patients withLDH levels ≤ 1 x ULN on Day 1.

<div style=\"page-break-after: always\"></div>

| LDHnormal range (U/L)   | Age range (years)   | Sex   | Patient ID   |
|-------------------------|---------------------|-------|--------------|
| 180-430                 | 0-2                 | M/F   | N/A          |
| 155-345                 | 3-6                 | M     | N/A          |
| 135-395                 | 3-6                 | F     | N/A          |
| 145-325                 | 7-12                | M     | N/A          |
| 140-280                 | 7-12                | F     |              |
| 120-290                 | 13-15               | M     |              |
| 100-275                 | 13-15               | F     |              |
| 100-242                 | >16                 | M     |              |
| 100-220                 | >16                 | F     |              |

bPatient 1003-502 normal rangewas120-290U/Lfrom screening toD239,and100-242U/LfromD295 untilD351

Patient0199-502normalrangewas140-280U/Lfromscreening toD183,and100-275U/LfromD239untilD351

Table 17: Number (%) of Patients Achieving LDH Normalization byVisit (Full Analysis Set)

| Visit          | TreatmentNaive (N = 5) n (%)   | EculizumabExperienced (N = 8) (%) u   |
|----------------|--------------------------------|---------------------------------------|
| Day 1, n (%)   | 0 (0.0)                        | 3 (37.5)                              |
| Day 15, n (%)  | 2 (40.0)                       | 3 (37.5)                              |
| Day 43, n (%)  | 2 (40.0)                       | 4 (50.0)                              |
| Day 71, n (%)  | 1 (20.0)                       | 4 (50.0)                              |
| Day 99,n (%)   | 1 (20.0)                       | 5 (62.5)                              |
| Day 127,n (%)  | 2 (40.0)                       | 4 (50.0)                              |
| Day 155, n (%) | 2 (40.0)                       | 4 (50.0)                              |
| Day 183, n (%) | 3 (60.0)                       | 4 (50.0)                              |

Notes:Stabilizedhemoglobinisdefinedasavoidanceofa≥2g/dLdecreaseinhemoglobinlevelfrombaselinein the absenceof transfusion throughDay 183(Week26).

Percentagesarebasedonthetotalnumberofpatientsineachgroup.

Abbreviation:CI=confidenceinterval

## Summaryofefficacyresults

Table18.Summary ofefficacy resultsinpaediatricpatientswithPNHinStudyALXN1210-PNH304 throughPrimary EvaluationPeriod (Full AnalysisSet)

<div style=\"page-break-after: always\"></div>

| Key Efficacy Endpoints                                                            | Complement Inhibitor Treatment-naive Patients (N = 5)   | Eculizumab-experienced Patients (N = 8)   |
|-----------------------------------------------------------------------------------|---------------------------------------------------------|-------------------------------------------|
| LDH%changefrombaselinetoend ofPrimaryEvaluationPerioda, Mean (SD)                 | -47.91 (52.716)                                         | 4.65 (44.702)                             |
| Transfusion avoidanceb n                                                          | 3                                                       | 8                                         |
| Percentage of patients(%)                                                         | 60.0                                                    | 100.0                                     |
| FACIT-Fatigue,change from baseline to end of Primary Evaluation Perioda Mean (SD) | 3.40 (6.107)                                            | 1.28 (5.235)                              |
| Achievedhaemoglobinstabilizationc n                                               | 3                                                       | 6                                         |
| Percentage of patients(%)                                                         | 60.0                                                    | 75.0                                      |

aEndofPrimaryEvaluationPeriodwas defined asDay183forStudyALXN1210-PNH-304.

bTransfusion avoidance was defined as patients who remained transfusion free and did not require a transfusion

absence of transfusionthroughDay183(Week 26).Percentages werebased onthe total numberof patients in each cohort.

Abbreviations:FACIT-Fatigue=FunctionalAssessment of ChronicIllness Therapy-Fatigue;LDH=lactate dehydrogenase;min =minimum;max=maximum;PNH=paroxysmal nocturnal haemoglobinuria

Table19:EfficacyresponseinadolescentswithPNHinstudyALXN1210-PNH-304through PrimaryEvaluationPeriod,Full Analysis Set

|                                           | LDH(U/L)                                  | LDH(U/L)                                  | TA                                        | FACIT-Fatigue                             | FACIT-Fatigue                             | Achieved                                  |
|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Patient ID                                | Baseline                                  | Week26                                    | (Y/N)                                     | Baseline                                  | Week26                                    | Hemoglobin Stabilization (Y/N)            |
| Cohort:Complementinhibitortreatment-naive | Cohort:Complementinhibitortreatment-naive | Cohort:Complementinhibitortreatment-naive | Cohort:Complementinhibitortreatment-naive | Cohort:Complementinhibitortreatment-naive | Cohort:Complementinhibitortreatment-naive | Cohort:Complementinhibitortreatment-naive |
| ALXN1210-PNH-304                          | 543.3                                     | 195a                                      | N                                         | 40                                        | 51                                        | N                                         |
| ALXN1210-PNH-304                          | 588.5                                     | 257*                                      | Y                                         | 47                                        | 47                                        | Y                                         |
| ALXN1210-PNH-304                          | 2269.7                                    | 195a                                      | N                                         | 51                                        | 46                                        | N                                         |
| Cohort:Eculizumab-experienced             | Cohort:Eculizumab-experienced             | Cohort:Eculizumab-experienced             | Cohort:Eculizumab-experienced             | Cohort:Eculizumab-experienced             | Cohort:Eculizumab-experienced             | Cohort:Eculizumab-experienced             |
| ALXN1210-PNH-304                          | 250                                       | Missing                                   | Y                                         | 36.8                                      | 39                                        | Y                                         |
| ALXN1210-PNH-304                          | 230.5                                     | 221                                       | Y                                         | 50                                        | 51                                        | Y                                         |
| ALXN1210-PNH-304-                         | 275                                       | 235                                       | Y                                         | 46                                        | 42                                        | Y                                         |
| ALXN1210-PNH-304-                         | 487                                       | 286                                       | Y                                         | 42                                        | 40                                        | Y                                         |
| ALXN1210-PNH-304-                         | 304.5                                     | 611a                                      | Y                                         | 31                                        | 43                                        | N                                         |
| ALXN1210-PNH-304                          | 161.5                                     | 154                                       | Y                                         | 42                                        | 39                                        | Y                                         |
| ALXN1210-PNH-304                          | 140.5                                     | 145                                       | Y                                         | 28                                        | 33                                        | Y                                         |

Abbreviations:FACIT-Fatigue =Functional Assessment of Chronic Illness Therapy-Fatigue; ID=Identity; LDH =lactate dehydrogenase;N=no;NA=not applicable,PNH=paroxysmal nocturnal hemoglobinuria; TA=transfusion avoidance;Y=yes

Samplehemolyzedwithoutanyassociatedsignsandsymptoms.

Table20:EfficacyresponseinchildrenwithPNHin studyALXN1210-PNH-304 through PrimaryEvaluationPeriod,Full AnalysisSet

<div style=\"page-break-after: always\"></div>

|                                           | LDH (U/L)                                 | LDH (U/L)                                 | TA (Y/N ）                                 | FACIT-Fatigue                             | FACIT-Fatigue                             | Achieved Hemoglobin Stabilization (Y/N)   |
|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| PatientID                                 | Baseline                                  | Week26                                    | TA (Y/N ）                                 | Baseline                                  | Week 26                                   | Achieved Hemoglobin Stabilization (Y/N)   |
| Cohort:Complementinhibitortreatment-naive | Cohort:Complementinhibitortreatment-naive | Cohort:Complementinhibitortreatment-naive | Cohort:Complementinhibitortreatment-naive | Cohort:Complementinhibitortreatment-naive | Cohort:Complementinhibitortreatment-naive | Cohort:Complementinhibitortreatment-naive |
| ALXN1210-PNH-                             | 444                                       | 637#                                      | Y                                         | 38                                        | 44                                        | Y                                         |
| Cohort:Eculizumab-experienced             | Cohort:Eculizumab-experienced             | Cohort:Eculizumab-experienced             | Cohort:Eculizumab-experienced             | Cohort:Eculizumab-experienced             | Cohort:Eculizumab-experienced             | Cohort:Eculizumab-experienced             |
| ALXN1210-PNH                              | 253                                       | 236                                       | Y                                         | 50                                        | 49                                        | N                                         |

Samplehemolyzedwithoutanyassociatedsignsandsymptoms. Abbreviations:FACIT-Fatigue=Functional Assessment of Chronic Illness Therapy-Fatigue;ID=Identity, LDH =lactate dehydrogenase;N=no;NA =not applicable;PNH = paroxysmal nocturnal hemoglobinuria; TA=transfusion avoidance;Y=yes

## Ancillaryanalyses

N/A

<div style=\"page-break-after: always\"></div>

## Summaryofmainstudy

Thefollowingtablessummarisetheefficacyresultsfromthemainstudiessupportingthepresent application.Thesesummariesshouldbereadinconjunctionwiththediscussiononclinicalefficacyas wellasthebenefitriskassessment(seelatersections).

Table1.SummaryofEfficacyfortrialALXN1210-PNH-304

| Title: A phase 3, open-label study of ALxN1210 in children and adolescents with paroxysmal nocturnalhaemoglobinuria(PNH)   | Title: A phase 3, open-label study of ALxN1210 in children and adolescents with paroxysmal nocturnalhaemoglobinuria(PNH)                                                                                                                                                                                      | Title: A phase 3, open-label study of ALxN1210 in children and adolescents with paroxysmal nocturnalhaemoglobinuria(PNH)                                                                                                                                                                                      | Title: A phase 3, open-label study of ALxN1210 in children and adolescents with paroxysmal nocturnalhaemoglobinuria(PNH)                                                                                                                                                                                      | Title: A phase 3, open-label study of ALxN1210 in children and adolescents with paroxysmal nocturnalhaemoglobinuria(PNH)                                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                           | Prot0colNo:ALXN1210-PNH-304 EudraCTNumber:2017-002820-26r                                                                                                                                                                                                                                                     | Prot0colNo:ALXN1210-PNH-304 EudraCTNumber:2017-002820-26r                                                                                                                                                                                                                                                     | Prot0colNo:ALXN1210-PNH-304 EudraCTNumber:2017-002820-26r                                                                                                                                                                                                                                                     | Prot0colNo:ALXN1210-PNH-304 EudraCTNumber:2017-002820-26r                                                                                                                                                                                                                                                     |
| Design                                                                                                                     | OngoingPhase3,open-label,single-armmulticentrestudytoevaluatethe PK/PD,safety,andefficacyofravulizumabadministeredbyintravenous(IV) infusion to paediatric patients (< 18 years of age) with PNH. Thestudyconsistsofa4-weekScreeningPeriod,a26-weekPrimary EvaluationPeriod,andanExtensionPeriodofupto4years. | OngoingPhase3,open-label,single-armmulticentrestudytoevaluatethe PK/PD,safety,andefficacyofravulizumabadministeredbyintravenous(IV) infusion to paediatric patients (< 18 years of age) with PNH. Thestudyconsistsofa4-weekScreeningPeriod,a26-weekPrimary EvaluationPeriod,andanExtensionPeriodofupto4years. | OngoingPhase3,open-label,single-armmulticentrestudytoevaluatethe PK/PD,safety,andefficacyofravulizumabadministeredbyintravenous(IV) infusion to paediatric patients (< 18 years of age) with PNH. Thestudyconsistsofa4-weekScreeningPeriod,a26-weekPrimary EvaluationPeriod,andanExtensionPeriodofupto4years. | OngoingPhase3,open-label,single-armmulticentrestudytoevaluatethe PK/PD,safety,andefficacyofravulizumabadministeredbyintravenous(IV) infusion to paediatric patients (< 18 years of age) with PNH. Thestudyconsistsofa4-weekScreeningPeriod,a26-weekPrimary EvaluationPeriod,andanExtensionPeriodofupto4years. |
|                                                                                                                            | Duration of main phase:                                                                                                                                                                                                                                                                                       | Duration of main phase:                                                                                                                                                                                                                                                                                       | Datefirstpatienttreated:22Feb2018 Datelastanalysedpatientcompleted PrimaryEvaluationPeriod:25Mar2020 (12thpatient's Day183Visit)* *Updated data including 13th patient were provided based on a data cut-off of 4 May 2021andarepresentedbelow                                                                | Datefirstpatienttreated:22Feb2018 Datelastanalysedpatientcompleted PrimaryEvaluationPeriod:25Mar2020 (12thpatient's Day183Visit)* *Updated data including 13th patient were provided based on a data cut-off of 4 May 2021andarepresentedbelow                                                                |
|                                                                                                                            | Hypothesis N/A                                                                                                                                                                                                                                                                                                | Hypothesis N/A                                                                                                                                                                                                                                                                                                | Hypothesis N/A                                                                                                                                                                                                                                                                                                | Hypothesis N/A                                                                                                                                                                                                                                                                                                |
| Treatments groups                                                                                                          | Ravulizumab(10mg/mL solution) IV infusion. n=13                                                                                                                                                                                                                                                               | Ravulizumab(10mg/mL solution) IV infusion. n=13                                                                                                                                                                                                                                                               | Loading dose onDay1 and maintenance DosesonDay15andq8w thereafterfor patientsweighing≥20kg,orq4wfor patients weighing < 20 kg. Posologybased onpatient's body weight.                                                                                                                                         | Loading dose onDay1 and maintenance DosesonDay15andq8w thereafterfor patientsweighing≥20kg,orq4wfor patients weighing < 20 kg. Posologybased onpatient's body weight.                                                                                                                                         |
|                                                                                                                            | ComplementInhibitor Treatment-naivePatients                                                                                                                                                                                                                                                                   | ComplementInhibitor Treatment-naivePatients                                                                                                                                                                                                                                                                   | n =5                                                                                                                                                                                                                                                                                                          | n =5                                                                                                                                                                                                                                                                                                          |
|                                                                                                                            | Eculizumab-experienced Patients                                                                                                                                                                                                                                                                               | Eculizumab-experienced Patients                                                                                                                                                                                                                                                                               | n=8                                                                                                                                                                                                                                                                                                           | n=8                                                                                                                                                                                                                                                                                                           |
| Endpoints and definitions                                                                                                  | Efficacy %LDH                                                                                                                                                                                                                                                                                                 | Efficacy %LDH                                                                                                                                                                                                                                                                                                 | PercentagechangeinLDHfrombaselineto Day183(Week26)                                                                                                                                                                                                                                                            | PercentagechangeinLDHfrombaselineto Day183(Week26)                                                                                                                                                                                                                                                            |
|                                                                                                                            | endpoint change Efficacy Transfusion endpoint avoidance                                                                                                                                                                                                                                                       | endpoint change Efficacy Transfusion endpoint avoidance                                                                                                                                                                                                                                                       | Proportionofpatientswhoremained transfusion-free and donotrequire a transfusionthroughDay183(Week26)                                                                                                                                                                                                          | Proportionofpatientswhoremained transfusion-free and donotrequire a transfusionthroughDay183(Week26)                                                                                                                                                                                                          |
|                                                                                                                            | Efficacy QoL endpoint                                                                                                                                                                                                                                                                                         | Efficacy QoL endpoint                                                                                                                                                                                                                                                                                         | Change inqualityof life,asmeasured by PaediatricFACIT-Fatiguequestionnaire (patients ≥ 5 years of age), from baseline to Day183(Week26)                                                                                                                                                                       | Change inqualityof life,asmeasured by PaediatricFACIT-Fatiguequestionnaire (patients ≥ 5 years of age), from baseline to Day183(Week26)                                                                                                                                                                       |
|                                                                                                                            | Efficacy Hb endpoint stabilization                                                                                                                                                                                                                                                                            | Efficacy Hb endpoint stabilization                                                                                                                                                                                                                                                                            | Proportionofpatientswith stabilized haemoglobin,defined as avoidance of a ≥ 2 g/dLdecreaseinhaemoglobinlevelfrom baselineintheabsenceoftransfusion                                                                                                                                                            | Proportionofpatientswith stabilized haemoglobin,defined as avoidance of a ≥ 2 g/dLdecreaseinhaemoglobinlevelfrom baselineintheabsenceoftransfusion                                                                                                                                                            |
| Database lock                                                                                                              | throughDay183(Week26) 27May2020                                                                                                                                                                                                                                                                               | throughDay183(Week26) 27May2020                                                                                                                                                                                                                                                                               | throughDay183(Week26) 27May2020                                                                                                                                                                                                                                                                               | throughDay183(Week26) 27May2020                                                                                                                                                                                                                                                                               |
| Results and Analysis                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                                          | Results and Analysis                                                                                                                                                                                                                                                                                          | Results and Analysis                                                                                                                                                                                                                                                                                          | Results and Analysis                                                                                                                                                                                                                                                                                          |
| Analysis description                                                                                                       | Primary Analysis                                                                                                                                                                                                                                                                                              | Primary Analysis                                                                                                                                                                                                                                                                                              | Primary Analysis                                                                                                                                                                                                                                                                                              | Primary Analysis                                                                                                                                                                                                                                                                                              |
| Analysis population and time point description                                                                             | Intenttotreat                                                                                                                                                                                                                                                                                                 | Intenttotreat                                                                                                                                                                                                                                                                                                 | Intenttotreat                                                                                                                                                                                                                                                                                                 | Intenttotreat                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimatevariability                                                                             | Descriptive statistics and estimatevariability                                                                                                                                                                                                                                                                | Treatment group Complement inhibitor naive                                                                                                                                                                                                                                                                    | Treatment group Complement inhibitor naive                                                                                                                                                                                                                                                                    | Eculizumabexperienced                                                                                                                                                                                                                                                                                         |
|                                                                                                                            |                                                                                                                                                                                                                                                                                                               | Numberofsubject                                                                                                                                                                                                                                                                                               | Numberofsubject                                                                                                                                                                                                                                                                                               | n=8                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

## Notes

| LDH%change(Mean)        | -47.91   | 4.65     |
|-------------------------|----------|----------|
| (SD)                    | (52.716) | (44.702) |
| Transf avoidance (n)    | 3        | 8        |
| (%)                     | 60       | 100      |
| QoL-FACITT(mean)        | 3.40     | 1.28     |
| (SD)                    | (6.107)  | (5.235)  |
| AchievedHb stabiliz (p) | 3        | 6        |
| (%)                     | 60.0     | 75.0     |

EndofPrimaryEvaluationPeriodwasdefinedasDay183forStudyALXN1210-PNH304.

Transfusionavoidancewasdefined aspatientswhoremainedtransfusionfreeand on the total number ofpatientsineachcohort.

Stabilizedhaemoglobinwasdefinedasavoidanceofa≥2g/dLdecreasein haemoglobinlevelfrombaselineintheabsenceoftransfusionthroughDay183 (Week 26). Percentages were based on the total number of patients in each cohort. Fatigue;LDH=lactate dehydrogenase;min=minimum;max=maximum;PNH=

paroxysmalnocturnalhaemoglobinuria

## Analysisperformed across trials(pooledanalyses andmeta-analysis)

Not applicable

## Clinicalstudiesin special populations

Not applicable

## Supportivestudies

TosupplementefficacydatageneratedinStudyALXN1210-PNH-304,theMAHhasconductedan extrapolationexercisetobridgedatafromthePrimaryEvaluationPeriodoftheStudyALxN1210-PNH304comparedwiththedatafrom adult and/orpaediatricpatients treated inongoingstudies of ravulizumab(PNH and aHUS)andwithdatafromadultsandpaediatricpatientsfromeculizumab studies.

RavulizumabefficacyinadultpatientswithPNH

Asummaryof theefficacyresultsforthePhase1b,Phase2andPhase3studiesinadultpatientswith PNHareprovidedbelow.

Table21:Overview ofPopulationCharacteristics andEfficacyResultsforPhase1b/2andPhase 3RavulizumabStudiesinAdultPatientsWithPNH

<div style=\"page-break-after: always\"></div>

|                                                                                                                  | Complement Inhibitor Treatment-naive Patients   | Complement Inhibitor Treatment-naive Patients   | Complement Inhibitor Treatment-naive Patients     | Eeulizumab- experienced Patients              |
|------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|---------------------------------------------------|-----------------------------------------------|
| Study                                                                                                            | ALXN1210- PNH-103 (N=13)                        | ALXN1210- PNH-201 (N=26)                        | ALXN1210- PNH-301 (N=125)                         | ALXN1210- PNH-302 (N=97)                      |
| Population Characteristics                                                                                       |                                                 |                                                 |                                                   |                                               |
| Sex, n (%) Male Female                                                                                           | 6 (46.2) 7 (53.8)                               | 20 (76.9) 6 (23.1)                              | 65 (52.0) 60 (48.0)                               | 50 (51.5) 47 (48.5)                           |
| Race, n (%)                                                                                                      |                                                 |                                                 |                                                   |                                               |
| Asian                                                                                                            | 12 (92.3) 1 (7.7) 0                             | 7 (26.9) 15 (57.7)                              | 72 (57.6) 43 (34.4) 2 (1.6)                       | 23 (23.7)                                     |
| White                                                                                                            |                                                 |                                                 |                                                   | 50 (51.5)                                     |
| Black or African American                                                                                        |                                                 | 0                                               |                                                   | 5 (5.2)                                       |
| American Indian or Alaska Native                                                                                 | 0                                               | 0                                               | 1 (0.8)                                           | 0                                             |
| Other                                                                                                            | 0                                               | 1 (3.8)                                         | 4 (3.2)                                           | 2 (2.1)                                       |
| Not reported                                                                                                     | 0                                               | 3 (11.5)                                        | 3 (2.4)                                           | 13 (13.4)                                     |
| Unknown                                                                                                          | 0                                               | 0                                               | 0                                                 | 3(3.1)                                        |
| Body weight (kg) category, n (%)                                                                                 | NA.                                             | NA                                              | 41 (32.8) 79 (63.2)                               | 27 (27.8) 62 (63.9)                           |
| ≥ 40 to < 60 ≥60 to <100 ≥100                                                                                    |                                                 |                                                 | 5 (4.0)                                           | 8 (8.2)                                       |
| Body weight (kg)mean (SD) Baseline LDH (U/L) Mean (SD)                                                           | 67.7 (10.51) 1614.52                            | 77.8 (14.62) 1668.90                            | 68.2 (15.58)                                      | 72.4 (16.84)                                  |
| Median Min,max Number of patients with pRBC/whole blood transfusions within 12 months prior to first dose, n (%) | 5 (38.5)                                        | 7 (26.9)                                        | 1633.53 (778.752) 1513.50 378.0,3759.5 103 (82.4) | 228.01 (48.712) 224.00 135.00,383.5 13 (13.4) |
| Efficacy results                                                                                                 |                                                 |                                                 |                                                   |                                               |
| LDH % change from baseline to end ofPrimaryEvaluationPeriod* n Mean (SD)                                         | 13 -85.297 (3.4289)                             | 26 81.23 (9.422)                                | 124 -77.90 (17.395)                               | 95 -0.81 (13.845)                             |
| Transfusion avoidanceb n (%)                                                                                     | NA.                                             | NA                                              | 92 (73.6)                                         | 85 (87.6)                                     |
| FACIT-Fatigue, change from baseline to end of Primary Evaluation Period* n                                       | 13 10.4 (11.11)                                 | 23 10.6 (11.22)                                 | 125 7.48 (10.709)                                 | 96 1.59 (6.433)                               |
| Mean (SD)                                                                                                        | NA.                                             | NA                                              | 85 (68.0)                                         | 74 (76.3)                                     |
| Achieved hemoglobin stabilization n (%)                                                                          |                                                 |                                                 |                                                   |                                               |

End of Primary Evaluation Period was defined as Day 169 for Study ALXN1210-PNH-103, Day 253 (Cohorts 1 through 3) or Day 281(Cohort 4) forStudy ALXN1210-PNH-201, and Day 183 for Studies ALXN1210-PNH-301 and ALXN1210-PNH-302.

EfficacydatafromeculizumabstudiesinadultandpaediatricpatientswithPNH

Table22:OverviewofPopulationCharacteristics andEfficacyResultsforEculizumabStudiesin PaediatricandAdultPatientsWithPNH

<div style=\"page-break-after: always\"></div>

|                                                                                                                   | Pediatrie and Adolescent Patients    | Adult Patients                      | Adult Patients                      |
|-------------------------------------------------------------------------------------------------------------------|--------------------------------------|-------------------------------------|-------------------------------------|
| Study                                                                                                             | M07-005 (N=7)                        | 100-10 (N=43)                       | (N=97)                              |
| Population characteristies                                                                                        |                                      |                                     |                                     |
| Sex,n (%) Male Female                                                                                             | 3 (43) 4(57)                         | 20 (46.5) 23 (53.5)                 | 48 (49.5) 49 (50.5)                 |
| Race,n (%) Asian White Black or African American Other Not required                                               | 0 5 (71) 2(29) 0 0                   | 1 (2.3) 37 (86.0) 4 (9.3) 0 1 (2.3) | 3 (3.1) 88 (90.7) 3 (3.1) 3 (3.1) 0 |
| Weight(kg) Mean (SD)                                                                                              | 59.19 (6.874)                        |                                     | 73.59 (14.18)                       |
| Mean (SE)                                                                                                         |                                      |                                     | 2200.7 (104.90)                     |
| Number of patients with pRBC/whole blood transfusions within 12 months prior to first dose,n (%) Efficacy results | 1019.6 (967.34) 651.0 (308.0,3144.0) | 2199.7 (157.66) 43 (100.0)          | 97 (100.0)                          |
| Median (min,max)                                                                                                  | 6 (85.7)                             | 74.9 (11.69)                        |                                     |
| Baseline LDH (U/L)                                                                                                |                                      | 2032.0 (499.0, 5962.0)              | 2051.0 (537.0, 5245.0)              |
| Change from baseline in LDH at Week26                                                                             | -771.1 (914.19)                      | -1850 (127.69)                      |                                     |
| Mean (SE)                                                                                                         |                                      |                                     | -1869.4 (109.33)                    |
| Transfusion avoidance n (%)                                                                                       | 6(85.7)                              | 22 (51.2)                           | NA                                  |
| FACIT-Fatigue,change from baseline to Week 26 Mean (SE)                                                           | NA                                   |                                     | 11.8 (1.20)                         |
| Achieved hemoglobin stabilization                                                                                 |                                      | 6.4 (1.19)                          |                                     |
| n (%)                                                                                                             | NA                                   | 21 (48.8)                           | NA                                  |

Mean (standard deviation).

* Local law did not allow the collection of race data at sites in France.

Mean (standard deviation) change from baseline in LDH at Week 12.

Abbreviations: FACIT=Functional Assessment of Chronic Illness Therapy fatigue;LDH= lactate dehydrogenase;

Based on results of number of patients with at least I transfusion episode post dosing.

NA = not applicable; PNH = paroxysmal nocturnal hemoglobinuria; SE = standard error

## 2.4.3. Discussion on clinical efficacy

RavulizumabiscurrentlyauthorisedintheEUforthetreatmentofadultpatientswithparoxysmal nocturnalhaemoglobinuria(PNH)andfor thetreatmentofpatientswithabodyweightof10kg or theMAHisseekinganextensionoftheindicationforravulizumabtopaediatricpatientswithPNH.

In support of this application, results from the study ALXN1210-PNH-304 have been submitted.

## Design and conduct of clinical studies

StudyALxN1210-PNH-304isaPhase3,open-label,single-armstudyinpaediatricpatients(&lt;18 years and weighing ≥5kg)withPNH.

wasdiscussedinthecontextoftheagreedravulizumabPIPinPNHwiththeEMA(EMEA-002077PIP01-16).

<div style=\"page-break-after: always\"></div>

confirmedbyhigh-sensitivityflowcytometryevaluation(Borowitz,2010)ofRBCsandwhitebloodcells (WBCs), with granulocyte or monocyte clone size of ≥ 5%. Both eculizumab-experienced and complementinhibitortreatment-naivepatientswereincluded.Complementinhibitor-naivepatients should present 1 or more PNH signs or symptoms within 3 months of screening (e.g. fatigue, and LDHlevel ≥ 1.5× ULN.For eculizumab-experienced patientsLDH levels should be LDH≤ 1.5x ULN.Overall, inclusion and exclusion criteria seem acceptable.

period of up to 4 years. Through the initial submission, results from the Primary Evaluation Period of the first12patients treatedwereprovided,withadatacut-offof27May2020.Updatedefficacydataup to 52weeks)wereprovidedduringtheprocedureandaredescribedbelow.

The primary objective of the study was to assess PK and PD of ravulizumab in paediatric patients with Questionnaire), stabilised haemoglobin, percent change in free haemoglobin and breakthrough haemolysis.All analyseswereperformed through the endof thePrimaryEvaluationPeriod(i.e.day adultpatients and are considered acceptable.Whilenormalisation of LDHwasnotaplannedendpoint, apost-hoc analysis of LDH normalisationhasbeenprovided,which iswelcomed,since thiswas a coprimaryendpointintheravulizumabstudyALXN1210-PNH-301incomplementinhibitortreatmentnaiveadultpatients.

The proposed posology is the same currently authorised for ravulizumab in adults (PNH and aHUS) and pharmacology).The loading dose inpatients weighting≥5 to&lt;10kgwas modified (Protocol amendment 2, dated 23 Aug 2018) from 300 mg to 600 mg based on the ALXN1210-aHUS-312 study weighting&lt;10kg;see additional commentsinthisrespectbelow.

24 hours of last eculizumab dose) and relating to safety reporting (delayed reporting of a single SAE). Protocoldeviationsassigned asnon-importantones occurred atallsites enrollingpatient(s).All protocoldeviations.NonimportantprotocoldeviationsincludedhaemolysedPNHcloneand/or haematologysamples,clottedblood samples andpre-dosePK/PDsample collectionperformed more than30minutesprior theinfusion(30minuteswas thepre-dosesamplecollection timewindowprechemistryhaemolysedsamplesofPatient (eculizumab-experiencedcohort)werenot availablebecausethesamplesweretoooldfor analysis.Inotherwords,aremarkablepartofbaseline data is missingfor thispatient.

<div style=\"page-break-after: always\"></div>

## Efficacydataandadditionalanalyses

The Full Analysis Set(FAS), which included patients who received at least 1 dose of ravulizumab and allefficacyanalyses. A totalof13patientswere enrolled inthestudy.However,onlydata fromthefirst 12patientsenrolled were initially provided.All these 12 patients completed the Primary Evaluation Period and entered the Extension Period of the study. According to the MAH the 13th patient was ongoing in the Primary EvaluationPeriod and was notinitiallyincluded in the analyses.Of the 13patients, 5patientswere paediatricpatients,treatmentdurationofprioreculizumabranged from89daysto1324days.All patientsexceptonereceivedeculizumabformorethan4oodaysbeforeenrolmentinthestudy. Oneof themainlimitationsofthisstudyis thelackofcontrolarmandthelimitedsamplesize,which hindertheappropriateinterpretationof theresults.However,duetotherarityofthediseasein children,thisdesignisacknowledged.Besides,thisstudywaspartof theagreedPIP(P/0199/2017; EMEA-002077-PIP01-16).According tothePIPatleast10patients,ofwhomatleast5were eculizumab-naiveshouldbeenrolled.Nevertheless,onlydatafrom4eculizumab-naivepatientswere Patientsincluded in thestudywerebetween9 and 17years(medianage 15years),witha median bodyweight lower than30kg wasincluded in the study.Thus,ravulizumabclinical data in children SmPC isforpatients weighting at least 10kg(inline withthe authorised posologyinpaediatric above).Indeed,inordertosupporttheproposedposologyinpatientswithPNHweighting&lt;30kgthe MAHhasperformed anextrapolationexerciseofPK/PDdatafromadultpatientswithPNHand paediatric/adult patients with aHUS to paediatric patients with PNH. As noted, no dose recommendation is givenforpaediatricpatients withPNH below10kg.Therefore,the indicationwas restrictedtopatientswithabodyweightof10kgorabove,inlinewiththeaHuSindication. sm i  e d l       (i a) ll As per inclusion criteria, LDH (at screening) in patients who were eculizumab-naive should be ≥1.5 ULNand&lt;1.5ULNinpatientstreatedwitheculizumab.However,medianLDHatbaselinein a higher LDH level than therequired asperinclusion criteria when assessed atbaseline.In the subgroupofeculizumab-naivepatients,medianLDH atbaseline was565.90(range:444,2269.7). atanytimepriortoinformedconsent. protocol amendmentsweremade.Norelevantimpactonresults isexpected.WithAmendment 2 (dated 23Aug2018),administrationof a supplemental dose of ravulizumabwas allowed.According to the MAH only one patient received a supplemental dose of ravulizumab during the extension period duetoBTH.

<div style=\"page-break-after: always\"></div>

Withregardstoefficacyresults,adecreaseintheLDHlevelswasobservedineculizumab-naive patients at day 183 (mean [SD] LDH% change -47.91 [52.716]). However, there was one patient with aLDHvalueof637U/l atday183inthecomplementinhibitortreatment-naivegroupandanother patientintheeculizumab-experiencedgrouphadaLDHof6i1U/Londay183.AccordingtotheMAH states therewas onepatientwitha missingvalue atday 183.MeanLDH change(LOCF)was3.57

inbothcasesitcouldbeattributabletohaemolysisof thesample.Ineculizumab-experiencedpatients, ('tt) 5' yo u () a (as)    s s1 a   s e (41.50). remainedtransfusionsfreeatday183.Resultsappearsimilarto thatobserved instudiesinadult points,respectively,atday183.Thesedataarehowever difficulttointerpretdueto thelackof comparatorandopen-labeldesignof thestudy. Three (60%) patients in the eculizumab-naive group and 6 (75%) patients in the eculizumabdifferent from the results observed in adult patients (68% and 76%, respectively). DuringthePrimaryEvaluationPeriod,noeventsofbreakthroughhaemolysiswerereported. Results of a post-hoc analysis for LDH normalization (LDH levels ≤ 1 x ULN) have also been provided. patients had LDH normalisation. Three of these patients (eculizumab-experienced) had LDH normalisationatday1. SupportivedatafromstudiesofravulizumabinPNHadultpatientshavebeenprovidedanddiscussed. patients. 351 the mean(SD) percent reduction from baseline in LDH was-54.46%(33.456%) in the treatment-naivepatientsand7ofthe8eculizumab-experiencedpatientsremainedtransfusionfree during theExtensionPeriodthroughthedatacut-offdate;theonlyeculizumab-experiencedpatient butneverthelessremainedtransfusionfreeuntilwithdrawal.

Periodthroughthedatacut-offdate,oneeculizumab-experiencedpatienthadBTHonDay666.

## 2.4.4. Conclusions on the clinical efficacy

Ravulizumab has shown efficacy in the treatment of paediatric patients with PNH. Moreover, efficacy

However,dataare limited dueto thelownumber ofpatients,particularlyinpatientsweighting&lt;30 kg.

<div style=\"page-break-after: always\"></div>

Thefollowingmeasuresareconsiderednecessarytoaddressissuesrelated to efficacy:Registrystudy M07-oo1willcollectclinicaloutcomesforPNHpatientsofanyage treatedwithravulizumab.

## 2.5.Clinicalsafety

## Introduction

Availablesafetydatafocusesonthe26weekPrimaryEvaluationPeriodoftheStudyALXN1210-PNH304,which enrolled children from birth to&lt;12 years of age and adolescents ≥ 12 to&lt; 18 years of

Inaddition,datafrom6ravulizumabstudiesinadultpatientswithPNHoratypicalhaemolyticuremic syndrome(aHUS) andfrom7eculizumab studies inpaediatric and adultpatients withPNH or aHUS are discussedtocomplementtheoverallsafetydatapackage.Studiesincluded aredisplayedonTable1.

| ClinicalStudiesinRavulizumab   | ClinicalStudiesinRavulizumab                         | ClinicalStudiesinRavulizumab                               | Studies in PNH                                                                                | Studies in PNH                                                                                                                                        | Studies in aHUS                                                             | Studies in aHUS                                                                                                            |
|--------------------------------|------------------------------------------------------|------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Study Numb er                  | ALXN1210- PNH-103 (N = 13)                           | ALXN121 o- PNH-201 (N = 26)                                | ALXN1210- PNH-301 (N = 246)                                                                   | ALXN1 210-P NH-30 2 (N = 1 95)                                                                                                                        | ALXN121 0- aHUS-31 1 (N = 58)                                               | ALXN1210-aHUS-312 (N = 31)                                                                                                 |
| Study design                   | Phase 1b, open-label, multiple-dose, dose escalation | Phase 2, open-label uncontroll ed, multiple ascending dose | Phase 3, randomized (1:1), open-label, active-contr olled                                     | Phase 3, rando mized (1:1), open-la bel, active- controll ed                                                                                          | Phase 3, open-label uncontroll ed, single-arm                               | Phase3,open-label,uncontrolled,single-a                                                                                    |
| Populat ion                    | Complement inhibitor treatment- naive adult patients | Compleme nt inhibitor treatment- naive adult patients      | Complement inhibitor treatment- naive adult patientsa Ravulizuma b n = 125 Eculizumab n = 121 | Adult patient swho have been treated with eculizu mab (eculiz umab- experie nced) for at least the past 6 mont hsa Ravuliz umab 6 =u Eculizu mab n=98 | Adult patients with evidence ofTMA naive to compleme nt inhibitor treatment | PaediatricpatientswithevidenceofTMAeithernaiveto inhibitor treatment (Cohort 1) or eculizumab-experienc 90 days (Cohort 2) |

<div style=\"page-break-after: always\"></div>

| ClinicalStudies inEculizumab   | ClinicalStudies inEculizumab   | ClinicalStudies inEculizumab                                                                | Studies in PNH                                            | Studies in aHUS                  | Studies in aHUS                                                            | Studies in aHUS                                                               |
|--------------------------------|--------------------------------|---------------------------------------------------------------------------------------------|-----------------------------------------------------------|----------------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Study Numb er                  | M07-005 (N = 7)                | C04-001 (N = 87)                                                                            | C04-002 (6 =N)                                            | C10- 003b (N = 22)               | C08-002A/B (N = 17)                                                        | C08-003A/B (N = 20)                                                           |
| Study design                   | Open-label, single-arm         | Phase 3 double- blind, placebo- controlled                                                  | Phase 3 open-label, single-arm                            | Phase 2 open- label, single- arm | Phase 2 open-label, single-arm                                             | Phase 2 open-label, single-arm                                                |
| Populat ion                    | Paediatric patients with PNH   | Transfusion- dependent adult patients with haemolytic PNH Eculizumab n = 43, Placebo n = 44 | Transfusion- dependent adult patients with haemolytic PNH | Paedia tric patien ts with aHUS  | Adults(C08-002A)and adolescents(C08-002B) withplasma therapy-resistantaHUS | Adults(C08-003A)and adolescents (C08-003B) with plasma therapy-sensitive aHUS |

Abbreviations:aHUS=atypical haemolyticuremic syndrome;PNH=paroxysmal nocturnal;TMA=thrombotic microangiopathy

Source:Module5.3.5.3ExtrapolationReportTable3,Table 4,Table5,andTable6

Abbreviations: aHUS = atypical haemolytic uremic syndrome; PNH = paroxysmal nocturnal; TMA = thrombotic microangiopathy

Source: Module 5.3.5.3 Extrapolation Report Table 3, Table 4, Table 5, and Table 6

aPatientsinStudyALXN1210-PNH-301andStudyALXN1210-PNH-302receivedravulizumabandeculizumabduring thefirst 26weeks; all patients inboth studies either continued orswitched(from eculizumab) to ravulizumab during the Extension Period.

## Patientexposure

All patients in the paediatric Study ALXN1210-PNH-304 received infusions according to the protocolspecifiedvisit schedule during the Primary EvaluationPeriod,with no missed doses(4 infusions).The mean treatment duration up to the 52-week evaluation period was 740.8 days for all 13 patients. ExtentofexposureisdetailedonTable2.

Table 2. Study Duration, Treatment Duration, Compliance, and Exposure (Safety Set)

| Variable                                                                | Treatment Naive (N = 5)   | Eculizumab Experienced (N = 8)   | Total (N = 13)   |
|-------------------------------------------------------------------------|---------------------------|----------------------------------|------------------|
| StudyDurationfromInformed ConsenttoExtensionPeriodatData Cut-off (days) |                           |                                  |                  |
| Mean (SD)                                                               | 529.2 (100.08)            | 873.1 (238.93)                   | 740.8 (258.79)   |
| Median                                                                  | 546.0                     | 899.0                            | 753.0            |
| Min, Max                                                                | 359,618                   | 369, 1121                        | 359,1121         |
| Treatment Duration(days)                                                |                           |                                  |                  |
| Mean (SD)                                                               | 514.6 (95.91)             | 855.4 (243.30)                   | 724.3 (259.56)   |
| Median                                                                  | 529.0                     | 878.0                            | 737.0            |
| Min, Max                                                                | 351,597                   | 341,1107                         | 341,1107         |
| TotalPatient-YearsofExposure (years)                                    | 7.0                       | 18.7                             | 25.8             |
| Number ofInfusions                                                      |                           |                                  |                  |
| Mean (SD)                                                               | 8.0 (0.00)                | 7.9 (0.35)                       | 7.9 (0.28)       |

<div style=\"page-break-after: always\"></div>

| Variable                                          | Treatment Naive (N = 5)   | Eculizumab Experienced (N = 8)   | Total (N = 13)   |
|---------------------------------------------------|---------------------------|----------------------------------|------------------|
| Median                                            | 8.0                       | 8.0                              | 8.0              |
| Min, Max                                          | 8,8                       | 7,8                              | 7,8              |
| NumberofPatientswithanInfusion Interruption,n (%) | 1 (20.0)                  | 1 (12.5)                         | 2 (15.4)         |
| NumberofInfusionsInterrupted                      |                           |                                  |                  |
| Total                                             | 1                         | 1                                | 2                |
| Mean (SD)                                         | 1.0                       | 1.0                              | 1.0 (0.00)       |
| Median                                            | 1.0                       | 1.0                              | 1.0              |
| Min, Max                                          | 1, 1                      | 1, 1                             | 1, 1             |
| NumberofInfusionsInterrupteddue toAdverseEvent    |                           |                                  |                  |
| Total                                             | 0                         | 0                                | 0                |
| Mean (SD)                                         |                           |                                  |                  |
| Median                                            |                           |                                  |                  |
| Min, Max                                          |                           |                                  |                  |
| Drug Compliance,n (%)                             |                           |                                  |                  |
| ≥100%                                             | 5 (100.0)                 | 8 (100.0)                        | 13 (100.0)       |
| ≥ 80% to < 100%                                   | 0 (0.0)                   | 0 (0.0)                          | 0 (0.0)          |
| ≥ 60% to < 80%                                    | 0 (0.0)                   | 0 (0.0)                          | 0 (0.0)          |
| ≥40% to < 60%                                     | 0 (0.0)                   | 0 (0.0)                          | 0 (0.0)          |
| ≥20% to<40%                                       | 0 (0.0)                   | 0 (0.0)                          | 0 (0.0)          |
| ≥0% to<20%                                        | 0 (0.0)                   | 0 (0.0)                          | 0 (0.0)          |

Asingleinfusioninterruptionwasreportedfor1complementinhibitortreatment-naivepatientdueto technical issue and 1 eculizumab-experienced patient due to a problem with the infusion pump.

Themediandurationoftreatmentin thepooledravulizumabtreatmentgroupofPhase3studies in adult patients with PNH (Study ALXN1210-PNH-301 and Study ALXN1210-PNH-302) was 182 days. The median treatment duration for adult patientsinStudyALxN120 aHUS-311 was 262.5 days, and that in paediatric patients inStudy ALXN1210 aHUS-312was 183.0 days.

## Baseline characteristics

Table 3. Key Demographic and Baseline Characteristics for Phase 3 Study ALXN1210-PNH304inPaediatricPatientsWithPNH(Full AnalysisSet)

<div style=\"page-break-after: always\"></div>

| Variable                                      | Treatment Naive (N = 5) n (%)   | Eculizumab Experienced (N = 8) (%) u   | Total (N = 13) (%) u   |
|-----------------------------------------------|---------------------------------|----------------------------------------|------------------------|
| Sex, n (%)                                    |                                 |                                        |                        |
| Male                                          | 4 (80.0)                        | 1 (12.5)                               | 5 (38.5)               |
| Female                                        | 1 (20.0)                        | 7 (87.5)                               | 8 (61.5)               |
| Ethnicity, n (%)                              |                                 |                                        |                        |
| NotHispanic or Latino                         | 5 (100)                         | 6 (75.0)                               | 11 (84.6)              |
| Not Reported                                  | 0 (0.0)                         | 2 (25.0)                               | 2 (15.4)               |
| Hispanic or Latino                            | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Missing/Unknown                               | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Race, n (%)                                   |                                 |                                        |                        |
| White                                         | 5 (100)                         | 3 (37.5)                               | 8 (61.5)               |
| BlackorAfricanAmerican                        | 0 (0.0)                         | 2 (25.0)                               | 2 (15.4)               |
| Not Reported                                  | 0 (0.0)                         | 2 (25.0)                               | 2 (15.4)               |
| Other                                         | 0 (0.0)                         | 1 (12.5)                               | 1 (7.7)                |
| AmericanIndian or Alaska Native               | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Asian                                         | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Multiple                                      | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Native Hawaiianor OtherPacific Islander       | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Age at First Infusion (years)                 |                                 |                                        |                        |
| Mean (SD)                                     | 14.4 (2.19)                     | 14.4 (3.07)                            | 14.4 (2.66)            |
| Median                                        | 15.0                            | 15.0                                   | 15.0                   |
| Min, Max                                      | 11, 17                          | 9,17                                   | 9,17                   |
| Age at First Infusion (years) Category, n (%) |                                 |                                        |                        |
| < 12 years                                    | 1 (20.0)                        | 1 (12.5)                               | 2 (15.4)               |
| ≥ 12 years                                    | 4 (80.0)                        | 7 (87.5)                               | 11 (84.6)              |
| Baseline Weight (kg)                          |                                 |                                        |                        |
| Mean (SD)                                     | 56.26 (11.594)                  | 56.25 (12.247)                         | 56.25 (11.502)         |
| Median                                        | 55.60                           | 55.50                                  | 55.60                  |
| Min, Max                                      | 39.5, 72.0                      | 36.7, 69.0                             | 36.7, 72.0             |
| Baseline Weight (kg) Category, n (%)          |                                 |                                        |                        |
| ≥5to<10 kg                                    | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| ≥10 to < 20 kg                                | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| ≥20 to<30kg                                   | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| ≥30to<40kg                                    | 1 (20.0)                        | 1 (12.5)                               | 2 (15.4)               |
| ≥ 40 to<60kg                                  | 3 (60.0)                        | 4 (50.0)                               | 7 (53.8)               |
| ≥ 60 to <100 kg                               | 1 (20.0)                        | 3 (37.5)                               | 4 (30.8)               |
| ≥ 100 kg                                      | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Baseline Height (cm)                          |                                 |                                        |                        |
| Mean (SD)                                     | 163.40 (11.760)                 | 160.99 (9.369)                         | 161.92 (9.940)         |
| Median                                        | 168.00                          | 158.95                                 | 164.00                 |
| Min, Max                                      | 143.0, 171.0                    | 146.0, 176.2                           | 143.0, 176.2           |
| Baseline Body Mass Index (BMI) (kg/m2)        |                                 |                                        |                        |

<div style=\"page-break-after: always\"></div>

| Variable                                      | Treatment Naive (N = 5) n (%)   | Eculizumab Experienced (N = 8) (%) u   | Total (N = 13) (%) u   |
|-----------------------------------------------|---------------------------------|----------------------------------------|------------------------|
| Sex, n (%)                                    |                                 |                                        |                        |
| Male                                          | 4 (80.0)                        | 1 (12.5)                               | 5 (38.5)               |
| Female                                        | 1 (20.0)                        | 7 (87.5)                               | 8 (61.5)               |
| Ethnicity, n (%)                              |                                 |                                        |                        |
| Not Hispanic or Latino                        | 5 (100)                         | 6 (75.0)                               | 11 (84.6)              |
| Not Reported                                  | 0 (0.0)                         | 2 (25.0)                               | 2 (15.4)               |
| Hispanic or Latino                            | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Missing/Unknown                               | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Race, n (%)                                   |                                 |                                        |                        |
| White                                         | 5 (100)                         | 3 (37.5)                               | 8 (61.5)               |
| BlackorAfricanAmerican                        | 0 (0.0)                         | 2 (25.0)                               | 2 (15.4)               |
| Not Reported                                  | 0 (0.0)                         | 2 (25.0)                               | 2 (15.4)               |
| Other                                         | 0 (0.0)                         | 1 (12.5)                               | 1 (7.7)                |
| AmericanIndianorAlaska Native                 | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Asian                                         | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Multiple                                      | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Native Hawaiian or OtherPacific Islander      | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Age at First Infusion (years)                 |                                 |                                        |                        |
| Mean (SD)                                     | 14.4 (2.19)                     | 14.4 (3.07)                            | 14.4 (2.66)            |
| Median                                        | 15.0                            | 15.0                                   | 15.0                   |
| Min, Max                                      | 11, 17                          | 9,17                                   | 9,17                   |
| Age at First Infusion (years) Category, n (%) |                                 |                                        |                        |
| < 12 years                                    | 1 (20.0)                        | 1 (12.5)                               | 2 (15.4)               |
| ≥ 12 years                                    | 4 (80.0)                        | 7 (87.5)                               | 11 (84.6)              |
| Baseline Weight (kg)                          |                                 |                                        |                        |
| Mean (SD)                                     | 56.26 (11.594)                  | 56.25 (12.247)                         | 56.25 (11.502)         |
| Median                                        | 55.60                           | 55.50                                  | 55.60                  |
| Min, Max                                      | 39.5, 72.0                      | 36.7, 69.0                             | 36.7, 72.0             |
| Baseline Weight (kg) Category, n (%)          |                                 |                                        |                        |
| ≥5to<10kg                                     | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| ≥10 to < 20 kg                                | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| ≥20 to<30kg                                   | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| ≥30to<40kg                                    | 1 (20.0)                        | 1 (12.5)                               | 2 (15.4)               |
| ≥ 40 to<60kg                                  | 3 (60.0)                        | 4 (50.0)                               | 7 (53.8)               |
| ≥60to<100kg                                   | 1 (20.0)                        | 3 (37.5)                               | 4 (30.8)               |
| ≥ 100 kg                                      | 0 (0.0)                         | 0 (0.0)                                | 0 (0.0)                |
| Mean (SD)                                     | 20.92 (2.657)                   | 21.45 (2.756)                          | 21.25 (2.618)          |
| Median                                        | 20.20                           | 21.60                                  | 20.70                  |
| Min, Max                                      | 18.9, 25.5                      | 17.2, 24.8                             | 17.2, 25.5             |

Note:Percentages arebased on thetotal number ofpatientsin eachgroup,or overall.

Abbreviation:SD=standarddeviation

Source:Table 14.1.1.1.1,Response toD90 RSI

<div style=\"page-break-after: always\"></div>

Table 4.KeyPopulation Characteristics of Ravulizumab Studies in Patients with PNH and aHUS

| PatientsTreatedwithRavulizumab                       | PatientsTreatedwithRavulizumab   | PatientsTreatedwithRavulizumab   | PatientsTreatedwithRavulizumab    | PatientsTreatedwithRavulizumab   | PatientsTreatedwithRavulizumab          | PatientsTreatedwithRavulizumab          |
|------------------------------------------------------|----------------------------------|----------------------------------|-----------------------------------|----------------------------------|-----------------------------------------|-----------------------------------------|
|                                                      | AdultPatientswith PNH            | AdultPatientswith PNH            | AdultPatientswithPNH              | AdultPatientswithPNH             | Adolescent and Adult Patients with aHUS | Adolescent and Adult Patients with aHUS |
|                                                      | Study ALXN1210 PNH-103 (N = 13)  | Study ALXN1210 PNH-201 (N =26)   | Study ALXN1210- PNH-301 (N = 125) | Study ALXN1210 PNH-302 (6 = N)   | Study ALXN1210 -aHUS- 311 (N = 58)      | Study ALXN1210 -aHUS- 312 (N =31)       |
| Sex, n (%)                                           |                                  |                                  |                                   |                                  |                                         |                                         |
| Male                                                 | 6 (46.2)                         | 20 (76.9)                        | 65 (52.0)                         | 50 (51.5)                        | 19 (32.8)                               | 19 (61.3)                               |
| Female                                               | 7 (53.8)                         | 6 (23.1)                         | 60 (48.0)                         | 47 (48.5)                        | 39 (67.2)                               | 12 (38.7)                               |
| Race, n (%)                                          |                                  |                                  |                                   |                                  |                                         |                                         |
| Asian                                                | 12 (92.3)                        | 7 (26.9)                         | 72 (57.6)                         | 23 (23.7)                        | 16 (27.6)                               | 11 (35.5)                               |
| White                                                | 1 (7.7)                          | 15 (57.7)                        | 43 (34.4)                         | 50 (51.5)                        | 30 (51.7)                               | 15 (48.4)                               |
| Black or African                                     | 0                                | 0                                | 2 (1.6)                           | 5 (5.2)                          | 2 (3.4)                                 | 4 (12.9)                                |
| American                                             |                                  |                                  |                                   |                                  |                                         |                                         |
| AmericanIndian or                                    | 0                                | 0                                | 1 (0.8)                           | 0                                | 1 (1.7)                                 | 1(3.2)                                  |
| Alaska Native                                        |                                  |                                  |                                   |                                  |                                         |                                         |
| Other                                                | 0                                | 1 (3.8)                          | 4 (3.2)                           | 2 (2.1)                          | 1 (1.7)                                 | 0                                       |
| Not reported                                         | 0                                | 3 (11.5)                         | 3 (2.4)                           | 13 (13.4)                        | NA                                      | 0                                       |
| Unknown                                              | 0                                | 0                                | 0                                 | 3(3.1)                           | 8 (13.8)                                | 1 (3.2)                                 |
| Age (years) at first infusion in study               |                                  |                                  |                                   |                                  |                                         |                                         |
| Mean (SD)                                            | 42.4 (11.91)                     | 44.3 (16.33)                     | 44.8 (15.16)                      | 46.6 (14.41)                     | 43.4 (16.04)                            | 8.1 (5.17)                              |
| Median Min,max                                       | 41.5 24.5, 62.3                  | 41.0 18.8, 80.2                  | 43.0 18,83                        | 45.0 18,79                       | 41.1 19.5, 77.1                         | 8.5 0.5, 17.3                           |
| Age categories,n                                     |                                  |                                  |                                   |                                  |                                         |                                         |
| Birth to<12years                                     | 0                                | 0                                | 0                                 | 0                                | 0                                       | 22                                      |
| ≥12to<18years                                        | 0                                | 0                                | 0                                 | 0                                | 0                                       | 6                                       |
| ≥18years                                             | 13                               | 26                               | 125                               | 121                              | 58                                      | 0                                       |
| Body weight (kg) category, n (%)                     |                                  |                                  |                                   |                                  |                                         |                                         |
| ≥ 5 to <20 kg                                        | 0                                | 0                                | 0                                 | 0                                | 0                                       | 14 (45.2)                               |
| ≥20 to<40                                            | 0                                | 0                                | 0                                 | 0                                | 0                                       | 8 (25.8)                                |
| kg                                                   |                                  |                                  |                                   |                                  |                                         |                                         |
| ≥40 to<60                                            | 3 (23.1)                         | 3 (11.5)                         | 41 (32.8)                         | 27 (27.8)                        | 13 (22.4)                               | 7 (22.6)                                |
| kg                                                   |                                  | 21 (80.8)                        | 79 (63.2)                         | 62 (63.9)                        | 39 (67.2)                               | 2 (6.5)                                 |
| ≥ 60 to<100                                          | 10 (76.9)                        |                                  |                                   |                                  |                                         |                                         |
| kg ≥100kg                                            | 0                                | 2 (7.7)                          | 5 (4.0)                           | 8 (8.2)                          | 6 (10.3)                                | 0                                       |
| pRBC/whole blood transfusionspriortofirst dose,n (%) | 5 (38.5)                         | 7 (27.0)                         | 103 (82.4)                        | 13 (13.4)                        | 17 (29.3)                               | 12 (57.1)                               |

Abbreviations:aHuS=atypicalhaemolyticuremicsyndrome;LDH=lactate dehydrogenase;max=maximum; min=minimum;PNH=paroxysmalnocturnalhemoglobinuria;pRBC=packed red blood cell;SD=standard deviation

aHUS

| PatientsTreatedWithEculizumab   | PatientsTreatedWithEculizumab   | PatientsTreatedWithEculizumab   | PatientsTreatedWithEculizumab   | PatientsTreatedWithEculizumab   | PatientsTreatedWithEculizumab   | PatientsTreatedWithEculizumab   | PatientsTreatedWithEculizumab   |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                 | Pediatri c Study                | AdultPNH Studies                | AdultPNH Studies                | PediatricandAdultaHUSStudies    | PediatricandAdultaHUSStudies    | PediatricandAdultaHUSStudies    | PediatricandAdultaHUSStudies    |
| Variable                        | Study M 07-005 (N = 7)          | Study C 04-001 (N = 43          | Study C 04-002 6 = N) ）         | Study C10 -003 (N = 22)         | Study c08-00 2A/B (N = 17)      | Study c08-00 3A/B (N = 20)      | Study C10 -004 (N = 41)         |
| Sex, n (%)                      |                                 |                                 |                                 |                                 |                                 |                                 |                                 |

<div style=\"page-break-after: always\"></div>

| PatientsTreatedWithEculizumab                         | PatientsTreatedWithEculizumab   | PatientsTreatedWithEculizumab   | PatientsTreatedWithEculizumab   | PatientsTreatedWithEculizumab   | PatientsTreatedWithEculizumab   | PatientsTreatedWithEculizumab   | PatientsTreatedWithEculizumab   |
|-------------------------------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                                       | Pediatri c Study                | Adult PNH Studies               | Adult PNH Studies               | PediatricandAdultaHusStudies    | PediatricandAdultaHusStudies    | PediatricandAdultaHusStudies    | PediatricandAdultaHusStudies    |
| Variable                                              | Study M 07-005                  | Study C 04-001 (N = 43          | Study C 04-002 6 = N)           | Study C10 -003                  | Study C08-00 2A/B               | Study C08-00 3A/B               | Study C10 -004                  |
|                                                       | (N = 7)                         |                                 | ）                               | (N = 22)                        | (N = 17)                        | (N = 20)                        | (N = 41)                        |
| Male                                                  | 3(43)                           | 20 (46.5)                       | 48 (49.5)                       | 12 (54.5)                       | 5 (29.4)                        | 8 (40.0)                        | 13 (31.7)                       |
| Female                                                | 4 (57)                          | 23 (53.5)                       | 49 (50.5)                       | 10 (45.5)                       | 12 (70.6)                       | 12 (60.0)                       | 28 (68.3)                       |
| Race, n (%) Not available                             | 0                               | 1 (2.3)                         | 0                               | NA                              | NA                              | NA                              | NA                              |
| Caucasian/                                            | 5 (71.4)                        | 37 (86.0)                       | 88 (90.7)                       | 18 (81.8)                       | 15 (88.2)                       | 17 (85.0)                       | 38 (92.7)                       |
| White Blackor African American                        | 2 (28.6)                        | 4 (9.3)                         | 3 (3.1)                         | 0                               | 1 (5.9)                         | 2 (10.0)                        | 2 (4.9)                         |
| Asian Other                                           | 0 0                             | 1 (2.3) 0                       | 3 (3.1) 3 (3.1)                 | 2 (9.1) 2 (9.1)                 | 1 (5.9) 0                       | 0 1 (5.0)                       | 1 (2.4) 0                       |
| Age (years) Mean (SD)                                 | 15.0 (2.28)                     | 42.1 (15.47)                    | 41.05 (14.41)                   | 6.6 (6.06)                      | 31.8 (13.32)                    | 32.3 (14.92)                    | 40.3 (15.33)                    |
| Median (min, max)                                     | 15.6 (11.0, 17.1)               | 41.0 (20.0, 85.0)               | 41.0 (18.0, 78.0)               | 6.5 (0.0, 17.0)                 | 28 (17,68)                      | 28 (13, 63)                     | 35.0 (18.0, 80.0)               |
| Age categories, n Birth to < 12 years                 | 1                               | 0                               | 0                               | 18                              | 0                               | 0                               | 0                               |
| ≥ 12 to < 18 years ≥ 18 years                         | 6 0                             | 0 43                            | 0 97                            | 4                               | 1                               | 5 15                            | 0                               |
| Weight(kg)                                            |                                 | 74.9 (11.69)                    | 73.59                           | 0                               | 16                              |                                 | 41                              |
| Mean (SD)                                             | 59.19 (6.874)                   |                                 | (14.18)                         | 28.6 (24.16)                    | Not available                   | Not available                   | 69.2 (16.03)                    |
| pRBC/whole blood transfusions n (%) prior tofirstdose | 6 (85.7)                        | 43 (100.0)                      | 97 (100.0)                      | Not available                   | Notavailable                    | Notavailable                    | Not available                   |

## Adverse events

In theinterimanalysisofStudyALXN1210PNH304,10of12patientsexperiencedatleast1AEduring thePrimaryEvaluationPeriod(Table6).MostAEswereGrade1orGrade2inseverity.Onepatient related to study drug.

Three patients experienced 1 or more serious adverse events(SAEs)(device related sepsis, staphylococcal infection, multiple organ dysfunction syndrome, septic shock, and device related thrombosis in 1 patient; influenza A virus test positive in 1 patient; and viral upper respiratory tract infection [URTI] in 1 patient). None of the SAEs were assessed to be related to study drug. No patients had meningococcal infections.

NopatientsdiedordiscontinuedfromthestudyduetoAEsduring thePrimaryEvaluationPeriod.No patients experienced AEs leading to permanent discontinuation of study drug.

<div style=\"page-break-after: always\"></div>

Table6.OverviewofAllTreatment-EmergentAdverseEventsandSeriousAdverseEvents through 52weeks of Study ALXN1210-PNH-304(Safety Set)

|                                               | Treatment Naive (N = 5)   | Treatment Naive (N = 5)   | Eculizumab Experienced (8 = N)   | Eculizumab Experienced (8 = N)   | Total (Et = N)   | Total (Et = N)   |
|-----------------------------------------------|---------------------------|---------------------------|----------------------------------|----------------------------------|------------------|------------------|
|                                               | (%) u                     | E                         | n (%)                            | E                                | n (%)            | E                |
| TotalPatient-YearsofExposure(years)toALxN1210 |                           | 7.0                       |                                  | 18.7                             |                  | 25.8             |
| Any Adverse Event(AE)                         | 5 (100)                   | 17                        | 8 (100)                          | 71                               | 13 (100)         | 88               |
| Any Serious AE (SAE)                          | 1 (20.0)                  | 5                         | 2 (25.0)                         | 3                                | 3 (23.1)         | 8                |
| Death                                         | 0 (0.0)                   |                           | 0 (0.0)                          |                                  | 0 (0.0)          |                  |
| AEsLeadingtoWithdrawal ofStudyDrug            | 0 (0.0)                   | 0                         | 0 (0.0)                          |                                  | 0 (0.0)          | 0                |
| SAEsLeadingtoWithdrawal ofStudyDrug           | 0 (0.0)                   | 0                         | 0 (0.0)                          | 0                                | 0 (0.0)          | 0                |
| AEsbyRelationship                             |                           |                           |                                  |                                  |                  |                  |
| Relateda                                      | 1 (20.0)                  | 1                         | 5 (62.5)                         | 10                               | 6 (46.2)         | 11               |
| Definitely Related                            | 0 (0.0)                   |                           | 0 (0.0)                          |                                  | 0 (0.0)          | 0                |
| Probably Related                              | 1 (20.0)                  | 1                         | 0 (0.0)                          |                                  | 1 (7.7)          | 1                |
| Possibly Related                              | 0 (0.0)                   |                           | 5 (62.5)                         | 10                               | 5 (38.5)         | 10               |
| Not Related                                   | 5 (100)                   | 16                        | 8 (100)                          | 61                               | 13 (100)         | 77               |
| Unlikely Related                              | 1 (20.0)                  | 5                         | 5 (62.5)                         | 27                               | 6 (46.2)         | 32               |
| Not Related                                   | 5 (100)                   | 11                        | 8 (100)                          |                                  | 13 (100)         | 45               |
| AEs by Toxicity                               |                           |                           |                                  |                                  |                  |                  |
| Grade 1                                       | 4 (80.0)                  | 7                         | 8 (100)                          | 40                               | 12 (92.3)        | 47               |
| Grade 2                                       | 3 (60.0)                  | 5                         | 7 (87.5)                         | 20                               | 10 (76.9)        | 25               |
| Grade 3                                       | 1 (20.0)                  | 2                         | 2 (25.0)                         | 10                               | 3 (23.1)         | 12               |
| Grade 4                                       | 1 (20.0)                  | 3                         | 1 (12.5)                         | 1                                | 2 (15.4)         | 4                |
| Grade 5                                       | 0 (0.0)                   |                           | 0 (0.0)                          |                                  | 0 (0.0)          | 0                |
| SAEs by Relationship                          |                           |                           |                                  |                                  |                  |                  |
| Relateda                                      | 0 (0.0)                   |                           | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Definitely Related                            | 0 (0.0)                   |                           | 0 (0.0)                          | 0                                | 0 (0.0)          | 0                |
| Probably Related                              | 0 (0.0)                   |                           | 0 (0.0)                          | 0                                | 0 (0.0)          | 0                |
| Possibly Related                              | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Not Related                                   | 1 (20.0)                  | 5                         | 2 (25.0)                         | 2                                | 3 (23.1)         | 7                |
| Unlikely Related                              | 1 (20.0)                  | 5                         | 2 (25.0)                         | 2                                | 3 (23.1)         | 7                |
| Not Related                                   | 0 (0.0)                   |                           | 0 (0.0)                          | 0                                | 0 (0.0)          | 0                |
| AEs of Special Interest                       |                           |                           |                                  |                                  |                  |                  |
| MeningococcalInfections                       | 0 (0.0)                   | 0                         | 0 (0.0)                          | 0                                | 0 (0.0)          | 0                |

Percentagesarebasedonthenumberofpatientsineachcolumn,ie,%=n/Nx100.

Notes:Patients are counted in each relationship and severity category in case ofmultiple events.

Treatment-emergentAEsareAEswithastartdateonorafterfirstdosedateinthestudy.

Grade 1=mild;Grade 2=moderate;Grade 3=severe;Grade 4=life-threatening;Grade5=Fatal.

<div style=\"page-break-after: always\"></div>

The toxicity of AEs are graded usingCTCAEversion 4.03orhigher.

AEsarecodedusingMedDRA20.1.

Related AEsare defined as AEs that are possibly,probably,or definitelyrelated to study treatment.Notrelated AEs aredefinedasAEsthatareunlikelyornotrelatedtostudytreatment.

Abbreviations:AE=adverse event;CTCAE=CommonTerminologyCriteriaforAdverseEvents;E=numberof events;MedDRA=Medical DictionaryforRegulatoryActivities;SAE=serious adverse event

The analysis of AEs by SoC is presented in Table 7. The most frequently reported AEs belonged to the Infections and infestations S0C (11 patients, 84.6%) and Gastrointestinal disorders (6 patients, 46.2%).

Abdominal pain and nasopharyngitis were each experienced by 3(23.1%) patients. Most of the rest of AEs were reported by 1 patient each in Study ALXN1210-PNH-304 (Table 7).

Table 7. Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term through 52 Weeks (Safety Set)

| System Organ Class Preferred Term                    | Treatment Naive (N = 5)   | Treatment Naive (N = 5)   | Eculizumab Experienced (8 = N)   | Eculizumab Experienced (8 = N)   | Total (N = 13)   | Total (N = 13)   |
|------------------------------------------------------|---------------------------|---------------------------|----------------------------------|----------------------------------|------------------|------------------|
| System Organ Class Preferred Term                    | (%) u                     | E                         | (%) u                            | E                                | n (%)            | E                |
| TotalPatient-YearsofExposure(years)to ALXN1210       |                           | 7.0                       |                                  | 18.7                             |                  | 25.8             |
| PatientswithTreatment-EmergentAdverse Events         | 5 (100)                   | 17                        | 8 (100)                          | 71                               | 13 (100)         | 88               |
| Blood and lymphaticsystemdisorders                   | 1 (20.0)                  | 1                         | 2 (25.0)                         | 6                                | 3 (23.1)         | 7                |
| Anaemia                                              | 0 (0.0)                   | 0                         | 2 (25.0)                         | 5                                | 2 (15.4)         | 5                |
| Haemolysis                                           | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Lymphadenitis                                        | 1 (20.0)                  | 1                         | 0 (0.0)                          | 0                                | 1 (7.7)          | 1                |
| Earandlabyrinthdisorders                             | 0 (0.0)                   | 0                         | 1 (12.5)                         | 2                                | 1 (7.7)          | 2                |
| Ear pain                                             | 0 (0.0)                   | 0                         | 1 (12.5)                         | 2                                | 1 (7.7)          | 2                |
| Endocrinedisorders                                   | 1 (20.0)                  | 1                         | 0 (0.0)                          | 0                                | 1 (7.7)          | 1                |
| Cushing's syndrome                                   | 1 (20.0)                  | 1                         | 0 (0.0)                          | 0                                | 1 (7.7)          | 1                |
| Gastrointestinaldisorders                            | 0 (0.0)                   | 0                         | 6 (75.0)                         | 13                               | 6 (46.2)         | 13               |
| Abdominal pain                                       | 0 (0.0)                   | 0                         | 3 (37.5)                         | 3                                | 3 (23.1)         |                  |
| Abdominal pain upper                                 | 0 (0.0)                   | 0                         | 2 (25.0)                         | 2                                | 2 (15.4)         | 2                |
| Constipation                                         | 0 (0.0)                   | 0                         | 2 (25.0)                         | 2                                | 2 (15.4)         | 2                |
| Diarrhoea                                            | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Dysphagia                                            | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Nausea                                               | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Rectal haemorrhage                                   | 0 (0.0)                   | 0                         | 1 (12.5)                         | 2                                | 1 (7.7)          | 2                |
| Vomiting                                             | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| General disorders and administration site conditions | 1 (20.0)                  | 3                         | 4 (50.0)                         | 5                                | 5 (38.5)         | 8                |
| Pyrexia                                              | 1 (20.0)                  | 1                         | 1 (12.5)                         | 1                                | 2 (15.4)         | 2                |
| Administrationsitepain                               | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Chest pain                                           | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Devicerelatedthrombosis                              | 1 (20.0)                  | 1                         | 0 (0.0)                          | 0                                | 1 (7.7)          | 1                |
| Fatigue                                              | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Multiple organ dysfunction syndrome                  | 1 (20.0)                  | 1                         | 0 (0.0)                          | 0                                | 1 (7.7)          | 1                |
| Non-cardiac chest pain                               | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Hepatobiliarydisorders                               | 1 (20.0)                  | 1                         | 0 (0.0)                          | 0                                | 1 (7.7)          | 1                |
| Hyperbilirubinaemia                                  | 1 (20.0)                  | 1                         | 0 (0.0)                          | 0                                | 1 (7.7)          | 1                |

<div style=\"page-break-after: always\"></div>

| System Organ Class Preferred Term               | Treatment Naive (N = 5)   | Treatment Naive (N = 5)   | Eculizumab Experienced (N = 8)   | Eculizumab Experienced (N = 8)   | Total (N = 13)   | Total (N = 13)   |
|-------------------------------------------------|---------------------------|---------------------------|----------------------------------|----------------------------------|------------------|------------------|
| System Organ Class Preferred Term               | n (%)                     | E                         | (%) u                            | E                                | n (%)            | E                |
| Immune system disorders                         | 1 (20.0)                  | 1                         | 0 (0.0)                          | 0                                | 1 (7.7)          | 1                |
| Serum sickness                                  | 1 (20.0)                  | 1                         | 0 (0.0)                          | 0                                | 1 (7.7)          | 1                |
| Infections and infestations                     | 4 (80.0)                  | 7                         | 7 (87.5)                         | 17                               | 11 (84.6)        | 24               |
| Nasopharyngitis                                 | 1 (20.0)                  | 1                         | 2 (25.0)                         | 2                                | 3 (23.1)         | 3                |
| COVID-19                                        | 2 (40.0)                  | 2                         | 0 (0.0)                          | o                                | 2 (15.4)         | 2                |
| Upper respiratory tract infection               | 0 (0.0)                   | 0                         | 2 (25.0)                         | 2                                | 2 (15.4)         | 2                |
| Viral upper respiratory tract infection         | 0 (0.0)                   | 0                         | 2 (25.0)                         | 2                                | 2 (15.4)         | 2                |
| Cystitis                                        | 0 (0.0)                   | o                         | 1 (12.5)                         | 4                                | 1 (7.7)          | 4                |
| Device related sepsis                           | 1 (20.0)                  | 1                         | 0 (0.0)                          | 0                                | 1 (7.7)          | 1                |
| Hordeolum                                       | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Infected bite                                   | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Paronychia                                      | 1 (20.0)                  | 1                         | 0 (0.0)                          | o                                | 1 (7.7)          | 1                |
| Pharyngitis                                     | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Rhinitis                                        | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Septic shock                                    | 1 (20.0)                  | 1                         | 0 (0.0)                          | 0                                | 1 (7.7)          | 1                |
| Sinusitis                                       | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Staphylococcal infection                        | 1 (20.0)                  | 1                         | 0 (0.0)                          | 0                                | 1 (7.7)          | 1                |
| Urinary tract infection                         | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Viral infection                                 | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Injury,poisoning and procedural complications   | 0 (0.0)                   | 0                         | 3 (37.5)                         | 4                                | 3 (23.1)         | 4                |
| Electric shock                                  | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Sunburn                                         | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Transfusion reaction                            | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Wound                                           | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Investigations                                  | 1 (20.0)                  | 1                         | 1 (12.5)                         | 1                                | 2 (15.4)         | 2                |
| Blood pressure increased                        | 1 (20.0)                  | 1                         | 0 (0.0)                          | o                                | 1 (7.7)          | 1                |
| InfluenzaAvirus testpositive                    | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Metabolism andnutritiondisorders                | 0 (0.0)                   |                           | 2 (25.0)                         | 2                                | 2 (15.4)         | 2                |
| Decreased appetite                              | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Iron deficiency                                 | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Musculoskeletal and connective tissue disorders | 1 (20.0)                  | 1                         | 3 (37.5)                         | ¥8                               | 4 (30.8)         | ６                |
| Arthralgia                                      | 1 (20.0)                  | 1                         | 0 (0.0)                          | 0                                | 1 (7.7)          | 1                |
| Back pain                                       | 0 (0.0)                   | 0                         | 1 (12.5)                         | 2                                | 1 (7.7)          | 2                |
| Kyphosis                                        | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Musculoskeletal chest pain                      | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Neck pain                                       | 0 (0.0)                   | o                         | 1 (12.5)                         | 3                                | 1 (7.7)          | 3                |
| Pain in extremity                               | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Nervous system disorders                        | 1 (20.0)                  | 1                         | 3 (37.5)                         | 3                                | 4 (30.8)         | 4                |
| Headache                                        | 1 (20.0)                  | 1                         | 2 (25.0)                         | 2                                | 3 (23.1)         | 3                |
| Dizziness                                       | 0 (0.0)                   |                           | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Reproductive system and breast disorders        | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Dysmenorrhoea                                   | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Respiratory,thoracic and mediastinal disorders  | 0 (0.0)                   |                           | 3 (37.5)                         | 5                                | 3 (23.1)         | 5                |
| Oropharyngeal pain                              | 0 (0.0)                   | 0                         | 2 (25.0)                         | 2                                | 2 (15.4)         | 2                |

<div style=\"page-break-after: always\"></div>

| System Organ Class                 | Treatment Naive (N = 5)   | Treatment Naive (N = 5)   | Eculizumab Experienced (N = 8)   | Eculizumab Experienced (N = 8)   | Total (N = 13)   | Total (N = 13)   |
|------------------------------------|---------------------------|---------------------------|----------------------------------|----------------------------------|------------------|------------------|
| Preferred Term                     | (%) u                     | E                         | (%)u                             | E                                | (%) u            | E                |
| Cough                              | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Nasal congestion                   | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Rhinitis allergic                  | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Skinandsubcutaneoustissuedisorders | 0 (0.0)                   | 0                         | 2 (25.0)                         | 2                                | 2 (15.4)         | 2                |
| Ingrowing nail                     | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Pruritus                           | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Vasculardisorders                  | 0 (0.0)                   | 0                         | 2 (25.0)                         | 2                                | 2 (15.4)         | 2                |
| Haematoma                          | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Pallor                             | 0 (0.0)                   | 0                         | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |

Notes:% =n/Nx 100.

If a patient had more than one eventfor a particularSoc,he/she is counted only once for thatSoc.

Treatment-emergentAEsareAEswithastartdateonorafterfirstdosedatein thestudy.

If a patient had more than one eventfor a particularPT,he/she is counted only oncefor that PT.

AEsarecodedusingMedDRA20.1.

Abbreviations: AE = adverse event; CovID-19 = coronavirus disease 2019; E= number of events; Source:Table 14.3.1.3.2,Response to Rapporteur preliminary assessment report

The majorityof AEs were Grade1or Grade2inseverity.Three(23.1%)patients experienced AEs of Grade3 and 2(15.4%)patients reported any AEs of Grade 4 severity.

- Patient(complementinhibitortreatment-naive)hadGrade3SAEsofstaphylococcalinfection onDay43anddevice-relatedthrombosisonDay44.Thispatientalsohad3Grade4SAEs; device-relatedsepsisonDay43,septicshockonDay44,andmultipleorgandysfunction syndrome on Day 44.
- Patient(eculizumab-experienced)had aGrade 3nonseriousAEof anaemia(worsening anemia) on Day 71.
- Patient(eculizumab-experienced)hadaGrade3seriousAEofinfluenzaAvirustestpositiveon Day 129.

## Serious adverse event/deaths/other significant events

## Deaths

There were no deaths during the Primary Evaluation Period nor the 52-week evaluation of Study ALXN1210-PNH-304.

## Seriousadverseevents

Three patients (25.0%) experienced 1 or more SAEs (1 complement inhibitor treatment naive patient; 2 eculizumab experienced patients) (Table 8). None of the SAEs were assessed to be related to study drug. None of the SAEs led to discontinuation of study drug. All SAEs resolved during the Primary EvaluationPeriod.

- s SAEs(device-relatedsepsisandstaphylococcalinfectiononDay43,andmultipleorgan dysfunctionsyndrome,septicshock,anddevice-related thrombosisonDay44).Theeventof device-relatedthrombosisonDay44metthecriteriaofMAVE.
- virus test positive on Day 129.
- Patient(13 years old at study entry, eculizumab-experienced) was hospitalized for viral URTI on Day 77.

<div style=\"page-break-after: always\"></div>

Table 8. Treatment-Emergent Serious Adverse Events by MedDRA System Organ Class and Preferred Term through 52 Weeks (Safety Set)

|                                                        | TreatmentNaive (N = 5)   | TreatmentNaive (N = 5)   | Eculizumab Experienced (N = 8)   | Eculizumab Experienced (N = 8)   | Total (N = 13)   | Total (N = 13)   |
|--------------------------------------------------------|--------------------------|--------------------------|----------------------------------|----------------------------------|------------------|------------------|
| System Organ Class Preferred Term                      | (%) u                    | E                        | (%) u                            | E                                | (%) u            | E                |
| TotalPatient-YearsofExposure(years)to ALXN1210         |                          | 1.6                      |                                  | 4.3                              |                  | 5.9              |
| Patients with Treatment-Emergent Serious AdverseEvents | 1 (20.0)                 | 5                        | 2 (25.0)                         | 3                                | 3 (23.1)         | 8                |
| Bloodand lymphaticsystemdisorders                      | 0 (0.0)                  |                          | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Haemolysis                                             | 0 (0.0)                  | 0                        | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Generaldisordersandadministrationsite conditions       | 1 (20.0)                 | 2                        | 0 (0.0)                          | 0                                | 1 (7.7)          | 2                |
| Devicerelated thrombosis                               | 1 (20.0)                 | 1                        | 0 (0.0)                          | 0                                | 1 (7.7)          | 1                |
| Multiple organ dysfunctionsyndrome                     | 1 (20.0)                 | 1                        | 0 (0.0)                          |                                  | 1 (7.7)          | 1                |
| Infections andinfestations                             | 1 (20.0)                 | 3                        | 1 (12.5)                         | 1                                | 2 (15.4)         | 4                |
| Device related sepsis                                  | 1 (20.0)                 | 1                        | 0 (0.0)                          |                                  | 1 (7.7)          | 1                |
| Septic shock                                           | 1 (20.0)                 | 1                        | 0 (0.0)                          | 0                                | 1 (7.7)          | 1                |
| Staphylococcal infection                               | 1 (20.0)                 | 1                        | 0 (0.0)                          | 0                                | 1 (7.7)          | 1                |
| Viral upperrespiratory tract infection                 | 0 (0.0)                  |                          | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| Investigations                                         | 0 (0.0)                  | 0                        | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |
| InfluenzaAvirustestpositive                            | 0 (0.0)                  | 0                        | 1 (12.5)                         | 1                                | 1 (7.7)          | 1                |

Notes:%=n/Nx 100.

IfapatienthadmorethanoneeventforaparticularSoc,he/sheiscountedonlyonceforthatSoc.

Treatment-emergentAEs areAEswith astart date onorafterfirstdose date in thestudy.

Ifapatienthad more thanone eventforaparticularPT,he/she is counted only oncefor thatPT.

Abbreviations: AE = adverse event; E = number of events; MedDRA = Medical Dictionary for Regulatory Activities;

AEsarecodedusingMedDRA20.1.

PT=PreferredTerm;SoC=SystemOrganClass

Source:Table 14.3.1.4.2,Response toRapporteurpreliminaryassessmentreport

## Adverse events of specialinterest

The AE of special interest for this study was meningococcal infection. None of the 13 patients experienced a meningococcal infection.

## Adverse events in studies providing supplementary safety data

AdverseEventsinRavulizumabStudiesinAdultPatientswithPNH

<div style=\"page-break-after: always\"></div>

InthepooledravulizumabgroupofthePhase3studies,87.8%ofpatientsexperienced atleast 1 TEAE,withmostAEsofGrade1/2severityandmostAEs(83.3%)assessedasunrelatedtothestudy drugby theInvestigator (Table 9).

Overall,nopatientsdiedordiscontinuedfromthestudyduetoAEsthroughthe26weekPrimary EvaluationPeriod inall 4ravulizumabstudiesinPNH.InStudyALXN1210-PNH-301,2patients died duringtheExtensionPeriodthroughthe52weekdatacutoffdate,1duetopulmonarysepsisand the otherdue tolungadenocarcinoma(onsetduringPrimaryEvaluationPeriod).Twopatientshad TEAEs thatledtodiscontinuationofstudydruginStudyALxN1210PNH-301,1duetolungadenocarcinoma andtheotherduetomyelodysplasticsyndrome.

A totalof2patientswhohadmeningococcalinfectionsinStudyALXN1210-PNH-201during the interruption.

Table9.OverviewofAll Treatment-EmergentAdverseEvents andSeriousAdverseEventsin Pooled Ravulizumab GroupAcrossPhase 3 AdultPNH Studies During the Primary Evaluation Period (Phase 3 PNH Population)

| Variable                                                                                                                                                   | All Ravulizumab (N = 222)                                                           | All Ravulizumab (N = 222)   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-----------------------------|
|                                                                                                                                                            | (%) u                                                                               | E                           |
| Any TEAE Related TEAE UnrelatedTEAE Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 TEAEleading tostudydruginterruption TEAE leading to study drug discontinuation | 195 (87.8) 75 (33.8) 185 (83.3) 172 (77.5) 117 (52.7) 28 (12.6) 7 (3.2) 0 2 (0.9) 0 | 932 179 44 9 0 4 0 2        |
| Any seriousTEAE(SAE)                                                                                                                                       |                                                                                     |                             |
|                                                                                                                                                            |                                                                                     | 753                         |
|                                                                                                                                                            |                                                                                     | 651                         |
|                                                                                                                                                            |                                                                                     | 228                         |
| TEAEconsideredasaMAVE                                                                                                                                      | 2 (0.9)                                                                             |                             |
| TEAEofspecialinterest                                                                                                                                      | 27 (12.2)                                                                           | 33                          |
|                                                                                                                                                            | 15 (6.8)                                                                            | 22                          |
| RelatedSAE                                                                                                                                                 | 5 (2.3)                                                                             | 8                           |
| Unrelated SAE                                                                                                                                              | 10 (4.5)                                                                            | 14                          |
| SAEleadingtostudydruginterruption                                                                                                                          | 0                                                                                   | 0                           |
| SAEleading to studydrugdiscontinuation                                                                                                                     | 0                                                                                   | 0                           |
| SAEconsideredasaMAVE                                                                                                                                       | 1 (0.5)                                                                             | 1                           |
| TEAEleadingtodeath                                                                                                                                         | 0                                                                                   | 0                           |

Notes:PooledPhase3PNHpopulation includesStudiesALXN1210-PNH-301 and ALXN1210-PNH-302. Abbreviations:AE=adverse event;E=number of events;MAvE=major adversevascular event;N= total TEAE=treatment-emergentadverse event

Source:Module5.3.5.3ExtrapolationReportTable30

## AdverseEventsinRavulizumabStudiesinPatientswithaHuS

Intotal,98.6%ofpatientsexperiencedatleast1TEAEinbothPhase3aHUSstudies,withmostAEs of (table 10).

<div style=\"page-break-after: always\"></div>

Overall,4patientsdiedinStudyALxN1210aHUS-311duringthePrimaryEvaluationPeriod,all SAEs(2duetosepticshockand1duetointracranialhemorrhage);1patientdiedduetoa withdrawalofpatientfromthestudy:autoimmunehaemolyticanemia,immune thrombocytopenic purpura,intracranialhaemorrhage in Study ALXN1210 aHUS 311, and anemia and hypertensive crisis inStudyALXN1210aHUS-312.

Therewerenofurtherdeathsorstudydrugdiscontinuations duetoAEsinpatientswithaHuS through 52 weeks of treatment.

Nomeningococcalinfectionswerereportedthroughthe52-weekdatacut-offdate.

Table1o.OverviewofAllTreatment-EmergentAdverseEventsandSeriousAdverseEvents AcrossPhase3 aHUsStudiesDuring thePrimaryEvaluationPeriod(SafetySet)

| Variables                                 | Study ALXN1210-aHUS-311 (N =58)   | Study ALXN1210-aHUS-311 (N =58)   | StudyALXN1210-aHUS-312 (N =16)   | StudyALXN1210-aHUS-312 (N =16)   | StudyALXN1210-aHUS-312 (N =16)   | StudyALXN1210-aHUS-312 (N =16)   | Total (N =74)   | Total (N =74)   |
|-------------------------------------------|-----------------------------------|-----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|-----------------|-----------------|
|                                           | n (%)                             | E                                 | Birth to < 12 years (N = 14)     | Birth to < 12 years (N = 14)     | 12 to <18 years (N = 2)          | 12 to <18 years (N = 2)          | n(%)            | E               |
|                                           | n (%)                             | E                                 | n(%)                             | E                                | n (%)                            | E                                | n(%)            | E               |
| Any TEAE                                  | 58 (100.0)                        | 818                               | 13 (92.9)                        | 136                              | 2 (100.0)                        | 26                               | 73 (98.6)       | 980             |
| Related TEAE                              | 20 (34.5)                         | 58                                | 7 (50.0)                         | 16                               | 1 (50.0)                         | 6                                | 28 (37.8)       | 80              |
| UnrelatedTEAE                             | 58 (100.0)                        | 760                               | 13 (92.9)                        | 120                              | 2 (100.0)                        | 20                               | 73 (98.6)       | 900             |
| Grade 1                                   | 54 (93.1)                         | 454                               | 11 (78.6)                        | 104                              | 2 (100.0)                        | 16                               | 67 (90.5)       | 574             |
| Grade2                                    | 46 (79.3)                         | 223                               | 9 (64.3)                         | 23                               | 2(100.0)                         | 10                               | 57 (77.0)       | 256             |
| Grade3                                    | 31 (53.4)                         | 116                               | 3 (21.4)                         | 8                                | 0 (0.0)                          | 0                                | 34 (45.9)       | 124             |
| Grade4                                    | 14 (24.1)                         | 22                                | 1 (7.1)                          | 1                                | 0(0.0)                           | 0                                | 15 (20.3)       | 23              |
| Grade5                                    | 3 (5.2)                           | 3                                 | 0 (0.0)                          | 0                                | 0(0.0)                           | 0                                | 3 (4.1)         | 3               |
| TEAEleading to study drug interruption    | 0                                 | 0                                 | 1 (7.1)                          | 1                                | 0 (0.0)                          |                                  | 1 (1.4)         |                 |
| TEAEleading to study drug discontinuation | 3 (5.2)                           | 3                                 | 1 (7.1)                          | 2                                | 0 (0.0)                          | 0                                | 4 (5.4)         | 5               |
| Any serious TEAE (SAE)                    | 30 (51.7)                         | 71                                | 7 (50.0)                         | 12                               | 1(50.0)                          | 1                                | 38 (51.4)       | 84              |
| Related SAE                               | 2(3.4)                            | 2                                 | 3 (21.4)                         | 4                                | 0 (0.0)                          | 0                                | 5 (6.8)         | 6               |
| UnrelatedSAE                              | 29 (50.0)                         | 69                                | 7 (50.0)                         | 8                                | 1 (50.0)                         | 1                                | 37 (50.0)       | 78              |
| SAE leading to study drug interruption    | 0                                 | 0                                 | 0 (0.0)                          | 0                                | 0 (0.0)                          | 0                                | 0               | 0               |
| SAE leading to study drug discontinuation | 3 (5.2)                           | 3                                 | 1 (7.1)                          | 2                                | 0 (0.0)                          | 0                                | 4 (5.4)         | 5               |
| TEAEleading todeatha                      | 3 (5.2)                           | NA                                | 0 (0.0)                          |                                  | 0 (0.0)                          |                                  | 3 (4.1)         | NA              |

## AdverseEventsinEculizumabStudiesinPatientswithPNHandaHuS

throughthe12-weekevaluationperiod.Twopatientsreported12SAEs，with3 SAEs(anemia, thrombocytopenia,andheadache)assessedby theInvestigatoraspossiblyrelated tostudydrug.No patientsdiedorwithdrewfromthestudyduetoAEs.

Acrossthe2adultstudiesinpatientswithPNHthroughthe26-weekPrimaryEvaluationPeriod,1patient diedduetoahaemorrhagiccerebrovascularevent(cerebralherniation)inStudyC04-0o2(assessedas unrelated to eculizumab).One patient discontinued study drug due topregnancyinStudyC04-o01; therewerenoothertreatment/studydiscontinuationsduetoAEsinthe3studies.

NoneofthepaediatricoradultpatientswithPNHhadmeningococcal infectionsacrossthestudies.

Among patients with aHuS treated with eculizumab in the Primary Evaluation Period across 4 studies, 1 inStudyC08-003A/B.Inatotalof3patientsacrossthe4aHUSstudies,AEsledtopermanent StudyC10-003),renalimpairmentorworseningrenalfunction(StudyC08-002A/B)andmeningococcal infection Study C10-004). A total of 2 patients had meningococcal infection/sepsis (Study C10-004), whichledtopermanentdiscontinuationofstudydrugin1patient.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

Changes over time for all chemistry parameters have been provided, including boxplots for LDH, bilirubin, creatinine, AST, ALT and GGT. Same for haematology parameters and boxplots for haemoglobin,hematocrit,reticulocytesandfreehaemoglobin.

Shifts in laboratory parameters (between low, normal and high) from baseline to each post-baseline

IndividuallaboratoryabnormalitiesofGrade3orhighertoxicity/severitywereasfollows:

- andon Day 70). One complement inhibitor treatment-naive patient had Grade 3 increased bilirubin(onDay65);thispatienthadanongoingGrade2AEofhyperbilirubinemiathatbegan onDay45.Ofnote,PatienthadalsoexperiencedaGrade2AEofdrug-inducedliverinjury thatstarted6dayspriortothefirstinfusionofravulizumabandlastedthroughDay1ofthe Primary Evaluation Period.
- onlythelasteventwasreportedasanAE(worseninganemia)withonsetonDay71.

For the LDH level, there were two exceptions at the Day 183 observation: one eculizumab-naive and one eculizumab-experienced patient had elevated (above 6oo U/L) LDH concentrations without any haemolysis.

One new SAE of breakthrough haemolysis(BTH) occurred in an eculizumab-experienced patient on splenic andrenal infarctsand transfusionprior tostudy entry.Thepatientexperienced anaemia (haemoglobin[Hb]5.7g/dL)1 weekbefore the reportedepisode of BTH(Day659).On the dayof BTH diagnosis, the patient's haemoglobin level was 4.6 g/dL and presented with a 1-day history of receivedbloodtransfusiononthesamedayand asupplementaldose ofravulizumabthenextday (Day667).TheSAEresolvedand theinvestigatorassessedtheeventaspossiblyrelatedtothestudy drug since there was no complement activating condition for the BTH.

## Vital signs

Mean values for vital signs (temperature, heart rate, systolic BP, diastolic BP, and respiratory rate) at baselineweresimilarbetweenthecomplementinhibitortreatment-naivecohortandtheeculizumabheart rate, respiratory rate, or systolic and diastolic BP values at each post-baseline visit in either the

## Electrocardiograms

wereofclinical significance.NopatientshadQTorQTcFabnormalitiesineither thecomplement inhibitortreatment-naivecohortortheeculizumab-experiencedcohort.NoAEsofQTprolongation, syncope, or torsades de pointes were reported in any patients. Electrocardiograms by visit for each patienthavebeenprovided.

<div style=\"page-break-after: always\"></div>

## Inmunogenicity

Nopatientshad antidrug antibodies(ADA)positiveresponsethroughDay911visitofravulizumab treatment.

## Adverse Drug Reactions

The ADRs identified for ravulizumab are consistent with ADRs observed with eculizumab.Adverse drug summarized in table 10.

Table 11.Adverse Drug Reactions Reported During RavulizumabTreatment-PNH and aHUS Combined (Safety Set)

| MedDRA System Organ Class                         | Very Common (≥ 1/10)                               | Common (≥ 1/100 to < 1/10)                    | Uncommon (≥ 1/1,000 to < 1/100)               |
|---------------------------------------------------|----------------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Gastrointestinaldisorders                         | Diarrhoea,Nausea                                   | Abdominal pain, Vomiting,Dyspepsia            | NA                                            |
| Generaldisordersand administrationsite conditions | Pyrexia, Fatigue                                   | Influenza like illness, Asthenia              | Chills                                        |
| Infectionsandinfestations                         | Upper respiratory tract infection, Nasopharyngitis | NA                                            | Meningococcal infection, Meningococcal sepsis |
| Musculoskeletaland connectivetissuedisorders      | NA                                                 | Arthralgia, Back pain, Myalgia, Muscle spasms | NA                                            |
| Nervoussystemdisorders                            | Headache                                           | Dizziness                                     | NA                                            |
| Skin and subcutaneous tissuedisorders             | NA                                                 | Rash, Pruritus                                | NA                                            |

## Discontinuation due to adverse events

TherewerenoAEsleading towithdrawalofstudydrugduringthePrimaryEvaluationPeriod.NoAEs led to interruption or permanent discontinuation of study drug during the Primary EvaluationPeriod.

No AEs led to the interruption of study drug infusion during the Primary Evaluation Period.

## Post marketing experience

Overall, the estimated exposure to ravulizumab since the first Marketing Authorization (21 Dec 2018) RiskEvaluationReport[PBRER]).

Alexioncloselymonitoredthefollowingrisksfor ravulizumabinthepostmarketing setting:

<div style=\"page-break-after: always\"></div>

- Importantidentifiedrisk:Meningococcal infection
- Importantpotential risks:Serious haemolysis after drug discontinuation inPNH patients, severethromboticmicroangiopathy(TMA)complicationsinaHUSpatientsafterravulizumab discontinuation, immunogenicity, serious infections, and malignancies and hematologic abnormalitiesinPNHpatients
- Missing information:Use in pregnant and breast-feeding women

Meningococcal infection:Twopatientsreported meningococcal infectionin thepostmarketing s ravulizumab administration was confirmed in both the patients. Both patients were noncompliant with theantibioticprophylaxis.

- infectionpriorto2yearswhileoneculizumabtreatment.Thephysicianreportedthatthe
- progressive multiorgan failure,which was refractory to vasopressors and broad spectrum antibiotics.Familymembersofthepatientdecidedtoallowfornaturaldeath.Thecauseof death was reported as Neisseria meningitis septic shock, complicated by aplastic anaemia and PNH.

As of30Jun2020,thecumulativepostmarketingrateofmeningococcalinfectionwasapproximately meningococcalrateobservedwitheculizumabtreatment(0.30per1o0PY).Longtermpostmarketing eculizumab-treated patients over the past 10 years at approximately 0.3 to 0.5 per 100 PY with the meningococcal infections, similar to the proportion of fatal events in the general population (10% to 15%).

The understanding and characterization of this risk remain unchanged based on the cumulative data.

## 2.5.1. Discussion on clinical safety

Thesafetydatasetinsupportforthisnewclaimedindicationfortreatmentofpaediatricpatientswith PNHwithravulizumabismainlybasedondatafromthe26-weekprimaryevaluationperiodofStudy be followed for up to 4 years in the long-term extension period, so the MAH later provided updated safetydatauptothe52-weekevaluationperiod(DBL4-Mar-2021),includingthe13thenrolledpatient forwhomsafetydatawasnotavailableattheinitialcut-offdate.

Assupportive data,a summary ofsafetyresultsfromfour clinical studieswithravulizumab inadults withPHN(N=261)andothertwostudies,oneinadults(N=58)andoneinpaediatricpatients(N=31) withaHuS,havebeensubmitted.Therefore,atotalof 362patientshavereceived,atleast,one dose ofravulizumabwithinclinicaltrials.

<div style=\"page-break-after: always\"></div>

technicalissues,notrelatedtotreatment.Themediantreatmentdurationuptothe52-week evaluationperiodwas737(341,1107)days. Eighteculizumab-treatedpatientswereincluded,onlyoneof themwas&lt;12yearsoldandbelow40kg weight,andfourC5-inhibitortreatment-naivepatientswith,alsoonebelow12yearsand34kg. Overall,safetydata ofravulizumabforPNHtreatmentareconsideredlimited,especiallyforchildren (&lt;12).Ravulizumab treatmentis weight-based.InStudyALXN1210-PNH-304,2patientsbetween 30 and 40 kg were included, 6 patients from 40 to 60 kg and 4 patients in the range 60-100 kg. No safety dataforPNHpatientsunder30kgisavailable. DuringthePrimaryEvaluationPeriod,83.3%(10/12)ofpatientsexperiencedat least1AE(47events) infections(URTIs) during thePrimary EvaluationPeriod and tworeported abdominalpain.Three andtwoofinfections. CausalityofAEswasestablishedbytheinvestigatorandAEswereconsideredasrelatedtotreatment in four patients (33.3%). These were related to administration site conditions and device-related infectionin onepatient andtoviralinfectionsforthe other twosubjects. patientsanalysedexperienced thiseventupto theDBL.Therewerenochangesto thefrequencyof ADRs with the inclusion of the 12 paediatric patients and no immunogenicity have been observed. Supportive data,asmentioned,havebeenincluded to assessthesafetyprofileof ravulizumabin these havebeenprovided.Overall,ravulizumabsafetyprofile in childrenand adolescents isbasedon 31 paediatric patients treated with ravulizumab for aHus, 7 eculizumab treated paediatric patients for PNHand28eculizumabtreatedforaHus. ForthepooledravulizumabPNHstudies,AEsincidencesweresimilartotheonesobservedinStudy ALXN1210-PNH-304:87.8% ofpatients experienced at least1TEAE,most of themGrade 1-2 and unrelatedto treatment.Nopatientsdiedordiscontinued treatmentduring theprimary evaluation InStudyALXN1210-PNH-201,2patientshadmeningococcalinfectionsbutthetreatmentwasnot interrupted.Regardingstudieswith aHUSpatients,98.6%experienced atleastoneTEAE,most of 4 patientshad SAEs that led to discontinuation.In thepaediatric StudyALX1210-aHUS-312,one patient reported anaemia and one hypertensive crisis that led to discontinuation of treatment in the primary analysis. Hypertension was commonly reported across the aHuS studies. Due to the limited available data(N=2), characterization of ravulizumab safety profilein children(&lt;12 patientsenrolledintheaHUSstudyALXN1210-312.Inthatstudy,14patients&lt;20kgofweightwere included,aweightrangethatincludednopatientsinStudyALXN1210-PNH-304. Updated safety results from the 52-week evaluation period were provided during the procedure, these dataaccountedforamediantreatmentdurationof529daysforthetreatment-naivecohort(N=5)and 899 days for the eculizumab-experienced patients (N=8). Data from the 13th enrolled patient were included in this update, since this subject had not reached the primary evaluation period (26 weeks) at thefirstdatacut-off.Overall,norelevantchangeswereidentifiedintheravulizumabsafetyprofilein adverseevent(TEAE),with3patients(23.1%)experiencinga totalof8serious adverseevents (SAEs).Abdominalpain,nasopharyngitis and headachewere themostfrequentlyreported adverse events (AEs), each experienced by 3 (23.1%) patients in total. One new SAE of breakthrough the investigator assessed the event as possibly related to the study drug since there was no discontinued the study due to AEs. No patient had meningococcal infection through the data cut-off date.NonewADRs were identified during this period.However,theMAH was asked to update the thesedataontheassessmentreport.

<div style=\"page-break-after: always\"></div>

Nopatientshad antidrugantibodies(ADA)positiveresponse throughDay911visitofravulizumab

Treatmentandnorelevantdifferencesregardinglaboratoryparameterswereobserved.

Overall,norelevantdifferenceshavebeenfoundbetweensafetydatafromStudyALXN1210-PNH-304 and previous studies with ravulizumab or eculizumab. No new adverse reactions have been identified.

## 2.5.2.Conclusions on clinical safety

line with that reported during treatment of adults with PNH and adults and children with aHUS. The frequencyofAEswasconsistentwith thereportedinthepreviousstudies.Therewerenodeaths,no treatment discontinuations and no cases of meningococcal infections up to the primary evaluation period.Nonewsafetyconcernswereidentified.

However thereislimitedsafetydatainPNHchildrenunder12yearsandnodataforpatients&lt;30kg weight.Also,long-termsafetydatawouldallowconfirmingtheobservedeffects.

Overallevaluationofthecumulativedataregarding theimportantidentifiedrisk/potentialrisksof meningococcal infections associated with ravulizumab treatment, the benefit-risk balance of ravulizumabcontinuestobepositiveandfavourableforthechronictreatmentofpatientswith complement-mediated disordersincludingPNH and aHUSundertherecommendedconditions ofuse.

Thefollowingmeasuresareconsiderednecessarytoaddressissuesrelatedtosafety:

The observational study M07-001:Paroxysmal NocturnalHemoglobinuria(PNH)Registry as cat.3 additionalPVactivityintheRMPstudiespatientsofanyagewillcollectandevaluatefurthersafety following: meningococcal infections, infections with serious outcomes, formation of HAHA or ADA to SOLIRIS / ULTOMIRIS, malignancy, thrombotic events, pulmonary hypertension, impaired renal function, serious haemolysis, pregnancies, infusion reactions, targeted adverse events, bone marrow transplant,and mortality.In addition,all serious adverse events,regardless of causality,will be clonesites,clinical symptoms,and clinical outcomes.

## 2.5.3.PSURcycle

outinthelistofUnionreferencedates(EURDlist)provided forunderArticle107c(7)ofDirective

<div style=\"page-break-after: always\"></div>

2001/83/ECandanysubsequentupdatespublishedontheEuropeanmedicinesweb-portal.

## 2.6. Risk management plan

TheMAHsubmittedanupdatedRMPversionwiththisapplication.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 2.1 is acceptable. The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 2.1 with the following content:

## Safety concerns

Table23:Summaryofsafetyconcerns

| Importantidentifiedrisks   | Meningococcal infection                                                                                                                                                                                                       |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks  | SerioushaemolysisafterdrugdiscontinuationinPNH patients SevereTMAcomplicationsin aHUSpatients after ravulizumab discontinuation Immunogenicity Serious infections Malignancies and haematologic abnormalities in PNH patients |
| Missinginformation         | Useinpregnantandbreast-feedingwomen                                                                                                                                                                                           |

## Pharmacovigilanceplan

Table 24:

Ongoing and Planned Additional Pharmacovigilance Activities

<div style=\"page-break-after: always\"></div>

| Study/Status                                                                            | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                     | Safety Concerns Addressed                                                                                                                                                                                                  | Milestones                                              | Due Dates                                               |
|-----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
| Category3-requiredadditionalpharmacovigilanceactivities                                 | Category3-requiredadditionalpharmacovigilanceactivities                                                                                                                                                                                                                                                                                                                   | Category3-requiredadditionalpharmacovigilanceactivities                                                                                                                                                                    | Category3-requiredadditionalpharmacovigilanceactivities | Category3-requiredadditionalpharmacovigilanceactivities |
| PNH extension safety study in treatmentnaive patients ALXN1210- PNH-301 Ongoing         | Toevaluatethe safety and efficacy of ALXN1210 administered by intravenous infusion to adult patients with PNH who are naive to complement inhibitor treatment To collect and evaluate safety data specific to the uSe of ULTOMIRIS and to collect data tocharacterisethe progression of PNH as well as clinical outcomes, mortality and morbidity in treated PNH patients | Meningococcal infection Serioushaemolysis after drug discontinuation in PNH patients Immunogenicity Serious infections Malignancies and haematologic abnormalitiesinPNH patients Use in pregnant and breast-feeding women  | Final CSR                                               | Oct 2023                                                |
| PNH extension safety study in patients treated witheculizumab ALXN1210- PNH-302 Ongoing | To collect and evaluate efficacy and safety data specific to theuse ofULTOMIRISand to collect data to characterisethe progression of PNH as well as clinical outcomes, mortality and morbidity in treated PNH patients                                                                                                                                                    | Meningococcal infection Serious haemolysis after drug discontinuation in PNH patients Immunogenicity Serious infections Malignancies and haematologic abnormalitiesinPNH patients Use in pregnant and breast-feeding women | Final CSR                                               | Sep 2021                                                |
| M07-001 \"PNH REGISTRY\" Ongoing                                                          | To collect and evaluate safety data specific to the use ofSOLIRIS/ ULTOMIRIS and to collect data to characterisethe progression of PNH as well as clinical outcomes, mortality and morbidity in SOLIRIS / ULTOMIRISand non-SOLIRIS /                                                                                                                                      | Meningococcal infection Serious haemolysis after drug discontinuation in PNH patients Immunogenicity Serious infections Malignancies and haematologic abnormalitiesinPNH patients Use in pregnant and breast-feeding women | Interim data analysis                                   | Every2years interim data analysis report                |

<div style=\"page-break-after: always\"></div>

| Study/Status                                                           | Summary of Objectives                                                                                                                                                                                                                                                                                                                             | Safety Concerns Addressed                                                                                                                                                     | Milestones            | Due Dates                                |
|------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------------------------------|
|                                                                        | ULTOMIRIS treated patients.                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                               |                       |                                          |
| M11-001 \"aHUS REGISTRY\" Ongoing                                        | Tocollectand evaluate safety and effectiveness data specific to the use ofeculizumab /ravulizumabin aHUS patients To assess the long-term manifestations of TMA complications ofaHUS aswellas other clinical outcomes, including mortality and morbidity in aHUS patients receiving eculizumab / ravulizumab treatmentorother disease management. | Meningococcal infection Severe TMA complications in aHUSpatients after ravulizumab discontinuation Immunogenicity Serious infections Use in pregnant and breast-feeding women | Interim data analysis | Every2years interim data analysis report |
| aHUS safety study in adults and adolescents ALXN1210- aHUS-311 Ongoing | To assess the efficacy and long- term safety of ravulizumab in complement inhibitor treatment-naive adolescent and adult patients with aHUS toinhibit complement- mediated TMA as characterised by thrombocytopenia, haemolysis, and renal impairment                                                                                             | Meningococcal infection Severe TMA complications in aHUSpatients after ravulizumab discontinuation Immunogenicity Serious infections Use in pregnant and breast-feeding women | Final CSR             | Dec 2023                                 |

<div style=\"page-break-after: always\"></div>

## Riskminimisationmeasures

Table 25:

SummaryTableofRiskMinimisationActivitiesbySafetyConcern

| Safety Concern                                                          | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Meningococcal infection                                                 | Routine risk minimisation measures SmPCsections4.3,4.4,and 4.8 PL sections2and4 Recommendations for vaccination/antibioticprophylaxis in SmPCsection4.4andPLsection2 Signsandsymptomsofmeningococcalinfectionslistedin SmPCsection4.4andPLsection2 Restricted medical prescription Additionalriskminimisationmeasures Educational materials PNH/aHUSPhysician'sGuide PNH/aHUSPatient'sInformationBrochure PNH/aHuSParent'sInformationBrochure Patientcard Controlleddistribution |
| Serious haemolysis after drug discontinuationinPNHpatients              | Revaccinationreminder Routine riskminimisation measures SmPC section 4.4 PL section3 MonitoringofpatientswhodiscontinuedULTOMIRIS recommendedinSmPCsection4.4andPLsection3 Additionalriskminimisationmeasures Educationalmaterials PNHPhysician'sGuide PNHPatient'sInformationBrochure PNHParent'sInformationBrochure                                                                                                                                                            |
| SevereTMAcomplicationsinaHUS patients after ravulizumab discontinuation | Routine risk minimisation measures SmPCsection4.4 Additionalriskminimisationmeasures Educational materials aHUSPhysician'sGuide aHUsPatient'sInformationBrochure aHUSParent'sInformationBrochure                                                                                                                                                                                                                                                                                 |
| Immunogenicity                                                          | Routineriskminimisation measures SmPC section 4.4 Additionalriskminimisationmeasures Educationalmaterials PNH/aHUSPhysician's Guide PNH/aHUS Patient's Information Brochure PNH/aHUSParent'sInformationBrochure                                                                                                                                                                                                                                                                  |
| Serious infections                                                      | Routine riskminimisation measures SmPC sections 4.3,4.4and 4.8 PL sections2,3 and 4 Recommendationsforvaccinationofpaediatricpatients againstHaemophilusinfluenzaeandpneumococcal infections inSmPCsection4.4andPLsection2. Additionalriskminimisationmeasures Educationalmaterials PNH/aHUSPhysician's Guide PNH/aHUS Patient's Information Brochure PNH/aHUSParent'sInformationBrochure                                                                                        |
| Malignancies and haematologic abnormalitiesinPNHpatients                | Routineriskminimisationmeasures None proposed Additionalriskminimisationmeasures: PNH Physician's Guide PNHPatient'sInformationBrochure PNHParent'sInformationBrochure                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Safety Concern                           | Risk MinimisationMeasures                                                                                                                                                                                                                                            |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Use in pregnant and breast- feedingwomen | Routine risk minimisation measures SmPCsections4.6and5.3 PL section 2 Recommendations on contraception inSmPC section 4.8 and PLsection2 Additional riskminimisationmeasures Educationalmaterials 一 PNH/aHUSPhysician's Guide 二 PNH/aHuSPatient'sInformationBrochure |

Abbreviations:aHuS=atypicalhaemolyticuraemicsyndrome;PNH=paroxysmalnocturnal

## 2.7.UpdateoftheProductinformation

As a consequence of this new indication,sections 4.1,4.2,4.4,4,8,5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

Pleaserefer toAttachment 1which includes all agreed changes to theProduct Information.

## 2.7.1. User consultation

leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

- the PIL is sufficiently similar in both content and layout to the currently approved one, based on previous user consultation assessed:
- 0 Initial MAA of Ultomiris user consultation,
- Both user bridging testing carried out as part of the subsequent Type II variation to extend Ultomirisindicationtopatientswithatypicalhaemolyticuremicsyndromeand the mg/3 mL and 1,100 mg/11 mL)

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1.Disease or condition

Treatment of adult and paediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal haemoglobinuria (PNH):

- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.
- inpatientswhoareclinicallystableafterhavingbeentreatedwitheculizumabforatleastthe past 6 months (see section 5.1).

<div style=\"page-break-after: always\"></div>

## 3.1.2.Availabletherapiesandunmetmedicalneed

therapiesforpatientswithclassicalPNH.

EculizumabwasthefirstC5inhibitor tobeevaluated astreatmentoptioninpaediatricpatientswith PNH.Eculizumab(Soliris),is humanized monoclonalantibody(mAb) that specifically targetsC5of the terminal complement cascade, which was first approved in the EU in 2007. Eculizumab is the only approvedmedicinalproductforPNH in childrenintheEU.

## 3.1.3.Main clinical studies

The main study in support of this submission is study ALXN1210-PNH-304. This is a Phase 3, open-

Thestudyconsistedona4-weekscreeningperiod,a26-weekPrimaryEvaluationPeriodand an extensionperiodofupto4years.Throughthecurrentsubmission,resultsfromthePrimaryEvaluation Periodhavebeenprovided,witha datacut-offof27May2020.During theprocedure,updatedefficacy data through the Extension Period were submitted. Results presented below are from the Primary EvaluationPeriod.

The primary objective of the study was to assess PK and PD of ravulizumab in paediatric patients with PNH. Efficacy was a secondary objective in this study. Efficacy endpoints included percent change from baseline in LDH, transfusion avoidance, quality of life (using the Paediatric FACIT-Fatigue haemolysis.All analyseswereperformed throughtheendof thePrimaryEvaluationPeriod(Day183). Resultspresentedarebasedon13patients(5eculizumab-naiveand8eculizumab-experienced)inthe study.

## 3.2.Favourableeffects

Eculizumab-naivepatients

- ·
- Therewere3(60%)patientswhoremainedtransfusionsfreeatday183.
- There were 3 (60%) patients who achieved haemoglobin stabilisation.
- FreeC5levelnormalisedshortlyafterthefirstravulizumabinfusionandremainedinthenormal rangeduringthe26weeksofthestudy.

## Eculizumab-experiencedpatients

- The mean (SD) LDH percent (%) change from baseline was +4.65 (44.70).
- All patients remained transfusions free at day 183.
- ·Therewere6(75%)patientswhoachievedhaemoglobinstabilisation.

No events of breakthrough haemolysis were reported during the Primary Evaluation Period.

LessfrequentIVinfusionsin8-week-intervalsmayreducetheriskofmisseddosesandalsomaybe associatedwithimprovedtreatmentadherence.

<div style=\"page-break-after: always\"></div>

## 3.3.Uncertaintiesandlimitationsaboutfavourableeffects

One of the main limitations of this study is the lack of control arm and the limited sample size. However,duetotherarityofthediseaseinchildren,thisdesignisacknowledged.

Clinical data in children &lt;12 years are limited. Patients included in the study were between 9 and 17 onlytwoofthemwereunder12years(1eculizumab-naive and1eculizumab-experienced).

Registry study M07-o01 aims to collect and evaluate clinical outcomes and characterise the progression ofPNH inUltomiristreatedPNHpatients,includingpaediatricpatients.

## 3.4.Unfavourableeffects

Allofthe13patientsreportedatleastoneadverseevent(AE)inStudyALXN1210-PNH-304uptothe 52-weekevaluationperiod.MostAEswereGrade1or Grade2inseverity.Five(38.5%)patientshad AEs assessed by the Investigator to be related to study drug.

staphylococcal infection,multiple organ dysfunction syndrome, septic shock, and device related thrombosis in 1 patient; influenza A virus test positive in 1 patient; and viral upper respiratory tract infection[URTI] in 1patient).

Three (23.1%) patients experienced AEs of Grade 3: device-related sepsis, anaemia and influenza A virus test positive; and 2 (15.4%) patients reported any AE of a Grade 4 severity.

## 3.5.Uncertaintiesandlimitationsaboutunfavourableeffects

Safety data provided is based on the 52-week evaluationperiod of Study ALXN1210-PNH-304 and no onlytwopatientswere&lt;12years(therestwereadolescents)andnopatientswith&lt;30kgweight wereincludedinthestudysosafetyassessmentrelyondatareportedfromravulizumabstudiesin paediatricpatientswithaHUSandadultswithPNH.

Two patients had elevated LDH-level at Day 183without any signs and/or symptoms of breakthrough haemolysis.Noneofthemmetthedefinitionofbreakthroughhaemolysis(BTH)perprotocol.TableTopHaemolysiscouldnotbeassessedfor theinterimanalysissupporting theinitialsubmissionandwil be determined when conducting the analysis for final CSR.

importantriskswereidentifiedintheextensionperiodofdifferentravulizumabstudies.The observationalstudyM07-001:Paroxysmal NocturnalHemoglobinuria(PNH)Registryascat.3 additionalPVactivityintheRMPstudiespatientsofanyagewillcollectandevaluatefurthersafety data(seeRMP).

<div style=\"page-break-after: always\"></div>

## 3.6.Effects Table

Table26EffectsTablefor treatmentwithravulizumabinpaediatricpatientswithPNH(datacut-off:04 Mar 2021)

| Effect                        | Short description                                          | Unit                 | Complement inhibitor naive(n=5)   | Ecu exp (n=8)        | Uncertainties/ Strength of evidence                                                                                                                 | References                                                                                                                           |
|-------------------------------|------------------------------------------------------------|----------------------|-----------------------------------|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| Favourable effects*           | Favourable effects*                                        | Favourable effects*  | Favourable effects*               | Favourable effects*  | Favourable effects*                                                                                                                                 | Favourable effects*                                                                                                                  |
| %LDH                          | Percentage change in LDH from baseline to Day 183 (Week26) | Mean (SD)            | -47.91 (52.716)                   | +4.65 (44.70)        | Clinicaldata in children (i.e. <12 years) are limited.Patientsincluded in the study were between 9 and 17years, only two ofthemwere under 12years（1 |                                                                                                                                      |
| TA                            | Transfusion avoidance                                      |                      | n(%)3(60)                         | 8(100)               | eculizumab-naive and 1 eculizumab-experienced) Thelackofcontrolarm and the limited sample size,hinder the                                           |                                                                                                                                      |
| HGB-S                         | Haemoglobin stabilization                                  | n (%) 3 (60)         |                                   | 6(75)                | appropriate interpretation of the results. Dueto therarity of the disease in children,this design is acknowledged.                                  |                                                                                                                                      |
| Unfavourable effects          | Unfavourable effects                                       | Unfavourable effects | Unfavourable effects              | Unfavourable effects | Unfavourable effects                                                                                                                                | Unfavourable effects                                                                                                                 |
| AEs                           | Adverse events                                             | %                    | 100                               | 100                  | Safetydataprovidedisbasedonthe                                                                                                                      | Safetydataprovidedisbasedonthe                                                                                                       |
| Related AEs                   | Adverse events related to study drug                       | %                    | 20                                | 62.5                 | 52-week evaluation period ofStudy ALXN1210-PNH-304.Nolong-term safety datafortreatment ofpaediatric patientswithPNHhavebeenprovided.                | 52-week evaluation period ofStudy ALXN1210-PNH-304.Nolong-term safety datafortreatment ofpaediatric patientswithPNHhavebeenprovided. |
| Grade 3AEs                    | Adverse events of grade3                                   | %                    | 20                                | 25                   |                                                                                                                                                     |                                                                                                                                      |
| Grade 4AEs                    | Adverse events of grade 4                                  | %                    | 20                                | 12.5                 |                                                                                                                                                     |                                                                                                                                      |
| SAEs                          | Serious adverse events                                     | %                    | 20                                | 37.5                 |                                                                                                                                                     |                                                                                                                                      |
| Infectio ns and infestat ions | adverse event                                              | %                    | 80                                | 87.5                 |                                                                                                                                                     |                                                                                                                                      |

*Efficacy data presented arebased on thePrimary EvaluationPeriod(Day 183).

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Results of the study ALXN1210-PNH-304 showed a response in paediatric patients with PNH. However, dataarebasedonpatientsbetween9and17yearsandabodyweightover30kg.Therefore,there arenoclinicaldatainchildrenwithPNHandalowerweight.Inordertofurther supporttheproposed posology in patients with PNH weighting&lt; 30 kg the MAH has performed an extrapolation exercise of withPNH.

Overall,thesafetyprofileofravulizumabinpaediatricpatientswithPNHappearsconsistentwiththat

## 3.7.2.Balanceofbenefitsandrisks

patientswithPNH.However,dataarebasedonalownumberofpatientsandnoexperimentaldataare available inpatientsweighting&lt;30kg.

Complete complement C5-inhibition was developed/maintained for all of them as assessed by thefree C5level measurementsshowingthatthePDendpointof thestudywasreachedforallpatients. level wasmaintained in the eculizumab-experienced ones.Efficacy has alsobeenobserved in terms of patientsareevenmorelimited.

SafetycharacteristicsofravulizumabseemtobesimilartothatobservedinadultPNHaswellasin adultandpaediatricaHUSstudies.

LessfrequentIVinfusionsin8-week-intervalsmayreducetheriskofmisseddosesandalsomaybe associatedwithimprovedtreatmentadherence.

## 3.7.3. Additional considerations on the benefit-risk balance

N/A

## 3.8.Conclusions

The overall B/R of Ultomiris in the applied indication of treatment of paediatric PNH patients is positive.

## 4. Recommendations

## Outcome

Basedonthereviewof thesubmitteddata,theCHMPconsidersthefollowingvariationacceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

<div style=\"page-break-after: always\"></div>

| Variation accepted   | Variation accepted                                                                                              | Type    | Annexes affected   |
|----------------------|-----------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.1.6.a              | C.I.6.a-Change(s)to therapeuticindication(s)-Addition ofanewtherapeuticindicationormodificationofan approvedone | Type II | 1, II and IIIB     |

Extensionof indicationfor Ultomiristoincludetreatmentofparoxysmal nocturnal haemoglobinuria 4.2, 4.4, 4.8, 5.1, and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition,AnnexII is updated toreflect the agreed educational material(addition of a\"Parent guide\"). Version2.1oftheRMPhas alsobeensubmitted,inordertoinclude thenewindication.

The variation leads to amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP).

## Amendmentstothemarketingauthorisation

Inviewof thedatasubmittedwiththevariation,amendmentstoAnnexesI,IIandIIIBandtotheRisk ManagementPlanarerecommended.

## Conditions or restrictions with regard to the safe and effective use of the medicinalproduct

## Risk management plan (RMP)

interventionsdetailed intheagreedRMPpresentedinModule1.8.2of themarketingauthorisationand any agreed subsequent updates of the RMP.

## AnupdatedRMPshouldbesubmitted:

- At the request of the European Medicines Agency; ·
- Whenevertheriskmanagementsystemismodified,especiallyastheresultofnewinformation beingreceivedthatmayleadtoasignificantchangetothebenefit/riskprofileorastheresult of animportant(pharmacovigilance orrisk minimisation)milestone beingreached.

## Additional riskminimisationmeasures

Prior tolaunch/useofUltomirisineachMemberState theMarketingAuthorisationHolder(MAH)must agree about the content and format of the educational and controlled distribution programmes, including communicationmedia,distributionmodalities,and any otheraspects oftheprogrammes, withtheNational CompetentAuthority.

ofselectedsafetyconcernsassociatedwithUltomiris.

<div style=\"page-break-after: always\"></div>

TheMAHshallensurethatineachMemberStatewhereUltomirisismarketed,allhealthcare professionals andpatientswhoareexpectedtoprescribe,dispense or useUltomirishaveaccess to/are provided with the following educational package to be disseminated through professional bodies:

- Physician educational material
- ·Patient/parentinformationpack

## Thephysician educational material should contain:

- 0The Summary of Product Characteristics
- oGuideforhealthcareprofessionals
- ·TheGuideforhealthcareprofessionalsshallcontainthefollowingkeyelements:
- 0To address the safety concerns of meningococcal infection, serious haemolysis after drug discontinuation in PNH patients,severe TMA complications in aHUS patients after ravulizumab discontinuation,immunogenicity,seriousinfections,malignancies and haematological abnormalities in in PNH patients, use in pregnant and breast-feeding women.
- TreatmentwithravulizumabincreasestheriskofN.meningitidisinfections.
- o All patients must be monitored for signs of meningitis.
- The need for patients to be vaccinated against N. meningitidis two weeks prior to receiving ravulizumab and/or to receive antibiotic prophylaxis.
- o Theriskofdevelopingantibodiestoravulizumab.
- Noclinical data on exposedpregnanciesis available.Ravulizumab should be giventoa pregnantwomanonlyif clearlyneeded.The needforeffective contraceptioninwomen of childbearing potential during and up to eight months after treatment. Male patients should notfather a child or donate spermupto eightmonths after treatment.Breast-feeding shouldbediscontinuedduringandup toeightmonths aftertreatment.
- O Riskofserioushaemolysisfollowingravulizumabdiscontinuationandpostponementof administration, its criteria, the required post-treatment monitoring and its proposed management(PNHonly).
- RiskofsevereTMAcomplicationsfollowingravulizumabdiscontinuationandpostponement of administration, its signs, symptoms, monitoring and management (aHUS only).
- o Theneed toexplaintoand ensureunderstandingofbypatients:
- 0the risk of treatment with ravulizumab(including potential risks of malignancies and haematologic abnormalities inPNH patients and serious infections)
- o the patient's/parent's guides and their contents
- o theneedtocarrythePatientcard andtotellanyhealthcarepractitioner thathe/sheis receivingtreatmentwithravulizumab
- o
- othe enrolment in thePNH and aHUSregistries
- 0 Details of the PNH registry, aHUS registry and how to enter patients

## The patient/parent's information packshould contain:

- oPackage leaflet
- oA patient guide
- 0A parent guide
- 0A Patient card
- The patient guide shall contain thefollowingkey messages:
- 0To address the safety concerns of meningococcal infection, serious haemolysis after drug
- discontinuationinPNHpatients，severeTMAcomplicationsinaHUSpatientsafter ravulizumab discontinuation,immunogenicity,serious infections, malignancies and haematological abnormalities inPNH patients, use in pregnant and breast-feeding women.
- Treatment with ravulizumab increases the risk of N. meningitidis infections.
- care.
- antibioticprophylaxis.
- The risk of immunogenicity with ravulizumab, including anaphylaxis, and the need for clinical monitoring post-infusion.
- The need for effective contraception in women of childbearing potential during and up to eightmonthsaftertreatment,andthatbreast-feeding shouldbediscontinuedduring and spermuptoeightmonthsaftertreatment.
- Riskofseverehaemolysisfollowingdiscontinuation/postponementofravulizumab administrations，theirsignsandsymptomsandtherecommendationtoconsultthe prescriberbefore discontinuing/postponing ravulizumab administrations(PNH only).
- Risk of severeTMA complicationsfollowing discontinuation/postponement of ravulizumab prescriber before discontinuing/postponing ravulizumab administration (aHuS only)
- Potentialrisksofsevere,non-neisserial infections andmalignanciesandhaematologic abnormalitiesinPNHpatientstreatedwithravulizumab.
- oEnrolment in thePNH and aHUSregistries.
- Theparentguide(providedtogetherwithpatientguide)shallcontainthefollowingkey messages:
- 0To address the risks of meningococcal infection and serious infections in infants and children.
- ThePatientcard shallcontainthefollowingkeymessages:
- 0Signs and symptoms of meningococcal infection
- Warning to seek immediate medical care if above are present
- Statement that the patient is receiving ravulizumab
- Contactdetailswhereahealthcareprofessionalcanreceivefurtherinformation
- Patientcardshouldberetainedfor8monthsafterlastdoseofravulizumab

<div style=\"page-break-after: always\"></div>

TheMAHshall send annuallytoprescribersorpharmacistswhoprescribe/dispenseravulizumab,a isneededforhis/herpatientsonravulizumab.

TheMAHshallensure thatineachMemberStatewhereUltomirisismarketed,asystemaimed to control distributionof Ultomirisbeyond the level ofroutine riskminimisationmeasuresis inplace.The followingrequirementsneed tobefulfilledbefore theproductis dispensed:

- Submissionofwrittenconfirmationofthepatient`svaccinationagainstallavailable meningococcalinfectionserotypesN.meningitidis and/orprophylacticantibiotictreatment accordingtonationalvaccinationguideline.

<div style=\"page-break-after: always\"></div>

## Paediatricdata

PaediatricInvestigationPlanP/0399/2020andtheresultsofthesestudiesarereflectedinthe Summary of Product Characteristics(SmPC) and,as appropriate,the Package Leaflet.

## 5.EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module8\"stepsaftertheauthorisation\"willbeupdatedasfollows:

## Scope

PleaserefertotheRecommendationssectionabove.

## Summary

PleaserefertoScientificDiscussion`Ultomiris-H-C-004954-II-0010'

## Attachments

1. SmPC,Annex II, Labelling,Package Leaflet(changes highlighted) as adopted by the CHMP on 22 July 2021.